Cloning and Analysis of Thyroid Stimulating Hormone Antibodies by Qowaider, Salema
i 
 
Cloning and Analysis of Thyroid Stimulating 
Hormone Antibodies 
 
Salema R. M. Qowaider 
           
Department Of Human Metabolism 
(Academic Unit of Endocrinology) 
Faculty of Medicine Dentistry & Health 
University of Sheffield 
Thesis submitted for the degree of Doctor 
 Philosophy 
May 2014 
ii 
 
Declaration 
I hereby declare that this thesis has been composed by myself and has not been accepted 
in any previous application for a higher degree. The work reported in this thesis has 
been carried out by me and all sources of information have been specifically 
acknowledged by means of references. 
 
Salema 
May, 2014 
  
iii 
 
DEDICATION 
I would like to dedicate this thesis to: 
The loving memory of my dear father, who has always been an inspiration to me through 
his loving care, patience and loving sacrifice and who is forever in my prayers. 
My mother for her Love, Support and Encouragement 
My husband for his Love, Support and Encouragement 
My Lovely Daughters Hala and Sarah  
iv 
 
Acknowledgments 
 
I thank the Almighty God for giving me the opportunity and the 
strength to go through the course. 
I give a massive thank you to my supervisor Dr Phil Watson who have 
given me many a wise word and have truly been brilliant supervisor. 
Thank you for all your time, effort and energy. It may be your job, but 
you do it very well.  
I am indebted to my many colleagues who supported me: Jamila, 
Basma, Maha, Jehan, Najwa Muftah, Najwa, Muna and Mabrouka.  
I would like to thank Dr Bouka for her constant help and advice.  
I would like to thank Sue Justice and Janine for their help.  
Finally I would like to thank the Libyan Arabian cultural bureau in 
London for funding of this work. 
 
 
  
v 
 
Summary 
In this study we were able to synthesis a control TSAb monoclonal phage antibody 
construct and investigate binding of this and related reagents to the human TSH 
receptor. We are the first group to report stimulatory activity of a TSAb in scFv format, 
a finding that will contribute to our understanding of the mechanism of receptor 
stimulation by autoantibodies. We were able to demonstrate that the conformation of the 
native receptor rendered the target stimulatory epitope inaccessible to phage antibody 
constructs. This was an important finding that explained previous failed attempts, both 
reported and unreported, to enrich receptor antibodies by phage display. We went on to 
investigate this phenomenon at length and were finally able to resolve these difficulties 
by generating a novel cell line which expressed a receptor sub-domain (amino acids 1-
260) anchored by a GPI motif. We were able to demonstrate that this receptor construct 
was able to specifically bind TSAb monoclonal antibody in phage form, a discovery 
that will open the door to future phage enrichment studies, and may contribute to the 
isolation of further examples of TSAb monoclonals from patient samples. Finally, we 
became the first research group to generate an anti-idiotypic monoclonal antibody that 
was able to bind and negate the antigen recognition site of the M22 TSAb antibody. 
This reagent should enable an entire series of novel experiments involving isolation and 
recovery of “M22-like” antibodies and corresponding B cells from patients samples. In 
addition this anti-idiotypic reagent should offer a novel selective strategy for the 
recovery of stimulatory antibodies from recombinant antibody libraries. 
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INTRODUCTION
1 
 
1.1 Introduction to Autoimmune Thyroid Disease (AITD) 
Autoimmune thyroid disease (AITD) is the most common form of organ-specific 
autoimmunity with a frequency in the population of 1-2% (Tunbridge, Evered et al. 
1977). Historically, thyroid autoimmunity was the first human autoimmune disease to 
be characterised. Autoantibodies to thyroid specific antigens were observed in patients 
with Hashimoto’s thyroiditis and hypothyroidism (Rose and Witebsky 1956).  In the 
same year it was shown that the symptoms of Graves’ disease (autoimmune 
hyperthyroidism) were caused by a long acting thyroid stimulator (LATS) in the patient 
serum (Adams and Purves 1956) and this was subsequently shown to be autoantibodies 
directed against the thyrotropin receptor (TSHR). 
Autoimmune thyroid disease is a series of overlapping conditions including, Graves’ 
disease (GD), Hashimoto’s thyroiditis, postpartum thyroiditis (PPT), atrophic 
autoimmune hypothyroidism, and thyroid-associated ophthalmopathy. The conditions 
can be broadly classified as loss of thyroid function, hypothyroidism (the most common 
form), and excessive thyroid function, or autoimmune hyperthyroidism, also known as 
Graves’ disease. The disease may shift from one form to another other as the course of 
the autoimmune process progresses (Swain 2005). Autoimmune hypothyroidism affects 
about 5 to 10% of women in middle age and older age group. In addition, many GD 
patients develop hypothyroidism either spontaneously after treatment with antithyroid 
drugs, or following radiotherapy or surgery (Rose, Bonita et al. 2002). The main feature 
of autoimmune thyroid disease is the development of autoantibodies to thyroglobulin 
(TG), thyroid peroxidase (TPO), and the TSHR (Weetman and McGregor 1984). The 
latter class of antibodies include a subclass that possesses bioactivity, acting as agonists, 
and rarely antagonists, of the thyrotropin receptor. These thyroid stimulatory antibodies 
represent the focus of this current study. 
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Table1. 1: Presentation of the main types of autoimmune thyroid diseases 
(AITD) 
Clinical presentation Volume of 
thyroid gland 
Function of 
thyroid gland 
Characteristics 
 
Focal thyroiditis 
 
Variable 
 
Normal or 
subclinical 
hypothyroidism 
Presence of TG-Ab and 
TPO-Ab 
May progress to overt 
hypothyroidism 
P+++ 
Hashimoto’s 
thyroiditis 
 
Nontender, 
firm goitre 
 
Normal or 
hypothyroid 
Presence of TG-Ab and 
TPO-Ab 
US: hypoechoic 
P+++ 
Atrophic thyroiditis 
(primary 
myxedema) 
 
Atrophic 
 
Hypothyroid 
Presence of TG-Ab and 
TPO-Ab 
P+ 
Postpartum 
thyroiditis 
 
Small 
Transient 
hyperthyroid 
and/or 
hypothyroid 
P± 
US: hypoechoic 
Silent thyroiditis  
Small 
Transient 
hyperthyroid 
and/or 
hypothyroid 
P+++ 
US: hypoechoic 
Graves’ disease  
Variable 
 
Hyperthyroid 
Presence of TSAb 
Presence of TG-Ab and 
TPO-Ab 
Extrathyroidal manifestation 
P+++ 
P: prevalence; TG-Ab: Thyroglobulin antibody; TPO-Ab: thyroid peroxidase 
antibodies; TSAb   
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1.1.1 Autoimmune Hypothyroidism 
Autoimmune hypothyroidism includes Hashimoto’s thyroiditis (chronic autoimmune 
thyroiditis) and non-goitrous primary myxedema. The diagnosis of autoimmune 
hypothyroidism depends on both histochemical, and biochemical (thyroid hormone and 
TSH levels) abnormalities as well as the presence of high levels of circulating 
autoantibodies directed against TG, TPO and the TSHR. TPO and TG autoantibodies 
are present in the serum of more than 90% of autoimmune hypothyroidism patients. The 
most important mechanisms of thyroid damage are mediated by infiltrating lymphocytes 
and complement fixation by TPO and TG antibodies (Weetman and McGregor 1984).  
1.1.2 Graves’ Disease 
 Graves' disease is the most common cause of hyperthyroidism worldwide, with an 
incidence of 30 to 200 per 100,000. A diffuse bilateral goitre and eye signs such as 
proptosis characterise the disease. Approximately 90% of Graves’ disease patients show 
some degree of Graves’ ophthalmopathy (GO), and evidence suggests that the basis of 
this association is the presence of a cross-reactive antigen present in both sites, most 
probably the TSHR (Garrity and Bahn 2006; Franklyn and Boelaert 2012).  
TSHR antibodies can be detected in almost all untreated Graves’ disease patients. An 
important class of TSHR antibodies, thyroid stimulating antibodies (TSAb) mimic the 
action of TSH, activating the receptor, leading to thyroid hyperplasia, increased thyroid 
hormone production, and clinical thyrotoxicosis (Fig. 1.1) (Bartels 1941; Weetman and 
McGregor 1984; de Lloyd, Bursell et al. 2010). A distinct class of TSHR antibodies 
(TBAb) block binding of TSH to TSHR and can play a role in the pathophysiology of 
hypothyroidism. Assays are available for the different classes of TSHR antibodies. 
Radioligand assays based on labelled TSH measure IgG-mediated inhibition of TSH 
binding and are generally referred to as the TSH binding inhibiting immunoglobulin 
(TBII) assay. In common with other G-protein coupled receptors, TSHR stimulates the 
cAMP pathway when activated and TSAb activity is usually assayed by measurement 
of cAMP production by cultured thyrocytes or TSHR-expressing cells (Weetman and 
McGregor 1984; Ochi, Kajita et al. 2012).  
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Figure1.1 Pathogenesis of Graves’ disease 
The thyroid gland is regulated by thyroid-stimulating hormone (TSH), which is made by 
the pituitary gland, TSAb mimic the action of TSH, activating the receptor, leading to 
de-regulated thyroid hormone production leading to Graves’ disease.  
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1.1.3 Aetiology of Autoimmune Thyroid Disease 
Susceptibility to AITD is determined by a combination of genetic and non-genetic 
factors. It is generally accepted that disturbance of the immune system due to 
environmental effects combined with genetic susceptibility leads to a breakdown in self-
tolerance. 
The process of autoimmunity in autoimmune thyroid disease is influenced by several 
factors. These include: 
Cross-reacting epitopes with thyroid antigens 
The expression of inappropriate HLA-DR  
 Mutated B or T cell clones 
Failure in T cell and B cell tolerising mechanisms 
Stimulation of the thyroid by inflammatory cytokines 
Re-exposure of antigens by thyroid cell damage 
T suppressor cell malfunction 
Inheritance of HLA and other immune-response related genes 
Even though, the immune system is proposed to avoid self-reactivity, low levels of 
reactivity to self antigen are usually present, and may have some physiological function 
(DeGroot and Quintans 1989). Apparently environmental and genetic factors act 
together to enhance self immunity, from a benign level, to a level that may cause a 
disease. Several contributing factors in the aetiology of GD and other AITD have been 
recognized. TSHR mRNAs, TG and TPO are processed in the human thymus to 
immunoreactive proteins (Coles, Wing et al. 1999) and other researchers have noted the 
same (Sospedra, Ferrer-Francesch et al. 1998). This means pre-T lymphocytes might be 
taught in the thymus to identify thyroid epitopes, and hence to develop tolerance against 
these antigens. This procedure is not complete, as cells reacting with thyroid antigens 
are both in the peripheral blood of normal, and in those with AITD (Spitzweg, Joba et 
al. 1999). In a process planned to give the maximum repertoire of lymphocytes, the 
lymphocytes, which recognize weakly self antigens in the context of autologous HLA, 
may be approved to continue in the circulation. It is not known if this differs from one 
individual to another and is a predisposing factor for the initiation of GD.  
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GD immune responses include generation of antibodies to different autoantigens (Table 
1.1) and cell-mediated immune responses caused by lymphocyte reactivity, and the 
generation of circulating antigen/antibody complexes (Mariotti, Kaplan et al. 1980), at 
least for some antigens. GD is statistically linked with autoimmune diseases including 
pernicious anaemia, vitiligo (Ochi and DeGroot 1969), alopecia (Welti 1968), 
angioedema (Amoroso, Garzia et al. 1997), and myasthenia gravis (Marino, Ricciardi et 
al. 1997). There may be a weak link with systemic lupus erythematosus (White, Bass et 
al. 1961; Dalan and Leow 2012). 
 
Table1. 2: Antibodies in Graves' disease 
Antibodies in Graves' disease 
Increase TSAb, TBII, and TSBAb level 
 
Increase TPO-Ab level 
Increase TG-Ab level  
Increase iodide symporter antibodies level (NIS) 
Increase  antibodies recognizing components of fibroblasts 
Increase DNA antibodies level 
Increase parietal cells antibodies level (rarely) 
Increase platelets antibodies level 
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1.1.4 Genetic Risk Factors for AITD 
Research among twins and families shows the aetiology of AITD is multifactorial and 
involves the interplay of environmental, genetic and constitutional elements in the 
working of the immune system (Weetman 1991). Disturbances to the immune system 
from environmental effects (e.g. infection, stress, trauma, diet, drugs) combined with a 
background of genetic susceptibility lead to a loss of tolerance to thyroid antigens 
(Weetman 2003; Bogdanos, Smyk et al. 2012). 
The role of heredity in Auto immune thyroid disease is well established and there is a 
significant concordance in family members, monozygotic twins and first-degree 
relatives, (Weetman and McGregor 1994; Hasham and Tomer 2012). Genes of the HLA 
system are major determinants of the susceptibility to some autoimmune diseases and 
class II MHC alleles have been the subject of a number of studies of AITD (Tomer 
2010). The majority of studies have identified HLA-DR3 as a susceptibility gene for HT 
and GD in Caucasians, and has been shown to incur an approximately 2 fold increased 
risk. The researchers had shown that an amino acid substitution between glutamine or 
alanine and arginine at position 74 in the HLA-DR peptide is a key factor in the 
occurrence of AITD (Hasham and Tomer 2012). additionally to class II MHC genes, 
now there are few established gene loci linked to auto immune thyroid disease, 
involving immune-regulatory ( CD40, CTLA-4, PTPN22, CD25 and FOXP3) and 
thyroid-specific genes (thyroglobulin and TSHR)(Tomer 2010; Eschler, Hasham et al. 
2011; Simmonds and Gough 2011; Dalan and Leow 2012; Hasham and Tomer 2012). 
Many studies have been undertaken on the immunomodulatory molecule CTLA-4, 
which is expressed on the T cell surface and cooperates with B7 on APC to down-
regulate T cell activation. Polymorphisms of CTLA-4 have been considered as a risk 
factor for Graves’ disease and Hashimoto’thyroiditis (Yanagawa, Hidaka et al. 1995; 
Kotsa, Watson et al. 1997; Hasham and Tomer 2012). Many other groups have 
demonstrated polymorphisms in immunoregulatory cytokines IL-1α, IL-1 receptor, 
TNF,   antagonist that may also work as minor risk factors in AITD (Dinarello 1991; 
Badenhoop, Schwarz et al. 1992). Resent study shown that polymorphisms in the  IL-
17F gene increase the risk of AITD, therefore  IL-17F considered as a superior gene for 
the prediction of AITD in the population of Han Chinese (Guo, Huo et al. 2013). 
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Recently, fine mapping of the Graves’ disease locus, 14q, shown that Graves’ disease 
phenotype has association with rs2284720 and, rs12147587 markers, present in the 
genes TSHR and NRXN3, consequently. These findings of new Auto immune disease 
susceptibility genes create a new clarification of the aetiology of AITD (Tomer, 
Hasham et al. 2013). 
1.1.5 Non-Genetic Factors 
 
1.1.5.1 Infection and Molecular Mimicry  
The role of infectious agents in aetiology of AID has always been interesting theory. 
There are numerous data showed that bacteria and virus  may play a role in AITD 
(Weetman 1996). Several mechanisms have been suggested by which infectious agent 
can cause the AITD. Some bacterial and viral proteins share antigenic epitopes with 
proteins of the host. In this method they may ‘trick’ the immune system into allowing 
them access because of the protection of self-tolerance. on the other hand, an immune 
response against the epitope of the bacterial and viral agent may cross-react with the 
mimicked host protein leading to autoimmunity. An example of this idea is cross 
reactivity of Yersinia enterocolitica with TSHR autoantibodies (Arscott, Rosen et al. 
1992) (Davies 2008) . It has been found that patients with Y. enterocolitica infections 
have TSAbs and that Graves’ disease patient have antibodies to Y. enterocolitica 
(Gripenberg, Miettinen et al. 1978) It has also been demonstrated that thyroiditis can be 
induced in rats by injection of Y. enterocolitica membranes (Luo, Fan et al. 1993). This 
concept is still under review but seems unlikely to be of major importance, as most of 
the patients with Y. enterocolitica infections do not progress to GD. H. pylori infection 
of the gastric mucosa is also contributing in the development of AITD.  Eighty five 
percentage  of autoimmune atrophic thyroiditis patients have H. pylori infection, and 
this implied that H. pylori might be implicated in the pathogenesis of AITD (de Luis, 
Varela et al. 1998).  This is also suggested that staphylococcal enterotoxins are highly 
mitogenic for T-cells and work as super antigens which stimulate the expression of T 
cells to certain TCR families (McIntosh, Watson et al. 1997). Viruses have been 
implicated as cross-reacting agents showing similarity to thyroid antigens, or as immune 
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system stimulators; influenza, measles, adenovirus, Coxsackie, Epstein-Barr viruses, 
and retroviruses are some of those suggested. Even though it has been demonstrated that 
GD mononuclear cells contain retroviral sequences (Ciampolillo, Marini et al. 1989) 
and also that HIV-1 (human immune deficiency virus-1) and TSHR have 66% similarity  
which could suggest molecular mimicry. These findings have not been confirmed 
subsequently. 
An additional possible role for viral infection in autoimmune diseases is that cell 
damage caused by viruses can release hidden self-antigens leading to a breakdown in 
tolerance state or causing the development of altered self-antigens leading to an immune 
response (Tomer and Davies 1993). Moreover viral infections can stimulate IFNγ 
production, which consecutively induce HLA class expression in non-immune cells 
(e.g. thyrocytes).  
 
 Mechanisms of how infection may influence AITD. (Davies 2008)  
Molecular mimicry 
superantigens  
TLR activation by virus  
Increase HLA thyroid expression  
 
1.1.5.2 Toxins and Drugs 
It has been reported that the treatment by radiation predisposes people to AITD 
(Nagataki, Shibata et al. 1994) and as well lithium therapy can exacerbate AITD by its 
action on regulatory T cells (Weetman, Creagh et al. 1981; Lazarus 1998). Moreover, it 
was been shown that using of pro-inflammatory cytokines including IL-2, IFN-α, and 
GM-CSF, in the treatment, can aggravate existing AITD. Apparently these types of 
treatment act to increase occurrence latent immunity (Hoekman, von Blomberg-van der 
Flier et al. 1991). Novel therapeutic approaches to multiple sclerosis include 
lymphocyte depletion using T cell specific monoclonal reagents. The researchers noted 
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that the treatment with anti-CD52 monoclonal antibody may change the immune system 
from a Th1 to a Th2 type response or delete an important subset of suppressor or 
regulatory T cells leading to a breakdown in tolerance to thyroid antigens (Coles, Wing 
et al. 1999). Onset of auto immune thyroid diseases has been noted to occur after IFN-α 
treatment for hepatitis B and C (Preziati, La Rosa et al. 1995), or treatment with IFN- 
for multiple sclerosis patients (Kreisler, de Seze et al. 2003; Prummel and Laurberg 
2003). 
Recently, several studies on the influence of the environmental chemicals on disruption 
of the thyroid function have been published. In vitro studies and animal experiments 
have concentrated on clarifying the mechanism of action of some chemicals. (Boas, 
Feldt-Rasmussen et al. 2012). 
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1.1.6 Immunopathogenesis of Graves’ disease  
Autoimmune response in Graves' disease needs a thyroid specific and non thyroid 
specific signal (Fountoulakis and Tsatsoulis 2004). The antigen specific signal could be 
exogenous (e.g. viruses or bacteria in the course of molecular mimicry) or endogenous 
(e.g. dying thyrocytes going through apoptosis) (Fountoulakis and Tsatsoulis 2004). 
Apoptosis of thyrocytes can be caused by Toxins like smoking, and drugs or lead to a 
modification in TSHR structure by the receptor mutation and encourage the follicular 
cells to generate chemokines (Yamazaki, Tanigawa et al. 2010). During the early stages, 
the abnormal structural of the TSHR endure spontaneous cleavage and produce free A 
subunit acting a vital role in the initiation of Graves' disease (Chazenbalk, Jaume et al. 
1997; Nielsen, Leslie et al. 2001; Chen, Pichurin et al. 2003). Dendritic cells (antigen-
presenting cells (APC)) (Chen, Pichurin et al. 2003), and thyrocytes which can act as 
APCs MHC class II expression, even though this cannot provoke an autoimmune attack 
on its own and only serves to propagate disease once it is initiated (Kimura, Kimura et 
al. 2005). TSHR extracellular domain epitopes must associate with MHC class II 
peptide, HLA-DR. Those peptides are transferred to the surface of APCs (Ghosh, 
Amaya et al. 1995; Posch, Araujo et al. 1995). The APCs present thyroid autoantigens 
to T helper cells in the draining lymph nodes of the thyroid in the early stage but later 
lymphoid tissue develops in the thyroid forming mainly of activated T lymphocytes, and 
a small number of B lymphocytes, macrophages and dendritic cells(Iyer and Bahn 
2012). Even though the regional lymph nodes and bone marrow plasma cells are 
resources of TSHR antibodies (Weetman, McGregor et al. 1984), the thyroid is perhaps 
the major site of these autoantibody production (Rapoport and McLachlan 2001). 
 
1.1.6.1 Role of T lymphocytes 
Activation of T lymphocytes in Graves' disease through (TCR)-CD3 complex with 
CD4, TCR-CD3 complex, binds to TSHR peptides located in the binding compartment 
of MHC class II molecule on the APCs (signal 1). The T lymphocytes now need other 
co-stimulation to proliferate and produce cytokines (signal 2) (Fig. 1.2). Immature 
CD4+ T cells can differentiate into Th1, Th2, Th17 and Treg according to the cytokine. 
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In Graves' disease, Cell immunity usually mediating by Th1 CMI and humoral 
immunity mediating by Th2 (Fountoulakis and Tsatsoulis 2004).  
The immune response mediated by Th1 related to CXC chemokines production of 
which induced by gamma interferon (Antonelli, Rotondi et al. 2005) also associated 
with high levels of TSHR autoantibodies (Romagnani, Rotondi et al. 2002). Recently, 
Th17 has been correlated to autoimmune diseases, that the quantity of Th17 cells was 
more during active disease (Nanba, Watanabe et al. 2009).  Lack of T regs cells can 
induce autoimmunity, because of its suppressive roles on effector T cells. 
 
1.1.6.2 Role of B cells 
Activated T cells enhance the production of thyroid antibodies from B cells (Fig. 4). B 
cells regulation is affected in AITD due to defects of tolerance (peripheral and central).  
B cells work as Antigen presenting cells and they are essential to produce a varied T 
lymphocytes and maturity of memory T cells (Braley-Mullen and Yu 2000). 
 1.1.6.3 Regulation of apoptosis 
The regulation of apoptosis in Graves' is abnormal because Th2 cytokines able to 
upregulate anti-apoptotic factors, including Bcl-2. This unusual apoptotic regulation 
suppresses the roles of cytolytic infiltrating lymphocytes whereas letting thyroid cells to 
endure longer than usual and become hyperplastic, thus leading to hyperthyroidism.  
1.1.6.4 Current drugs targeting autoimmunity 
Blocking the effects of TSHR antibodies by using monoclonal antibodies considered as 
possible autoimmune plan. On the other hand, although the noticed effect of TBAb of  
those antibodies in vitro, their effect on patients was week (Lenzner and Morgenthaler 
2003). This is most likely because of the fact that a different types of thyroid antibodies 
are present in the Graves' disease patient sera, and the monoclonal antibodies can not 
bind to all TSAb epitopes (Lenzner and Morgenthaler 2003), Sanders, generated a 
human monoclonal antibody (5C9)  which can block TSHR to the TSHR using severe 
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hypothyroid patients ‘sera. IgG preparations of 5C9 inhibited the cAMP activities of 
M22, TSH, serum TSAbs and mouse monoclonal TSAbs (Sanders, Evans et al. 2008). 
On the other hand, the fact that this new mAb will be useful for Graves' patients is 
unclear. Those therapies which directed to B cell are hopeful for Graves' disease 
patients. Rituximab (RTX) is a chimeric monoclonal antibody against CD20 
(Hasselbalch 2003; Edwards and Cambridge 2006). Consequently, a number of reports 
were on the treatment of Graves' ophthalmopathy by RTX (Nielsen, Hegedus et al. 
2004; El Fassi, Nielsen et al. 2007).  
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Figure1.2 Immune pathogenesis of Grave’s disease. 
Due to exposure to many factors e.g. stress, drugs, infection or any environmental 
factors, thyrocyte undergo apoptosis and TSH parts release into the circulation, then 
taken in the regional lymph nodes by the dendritic cells, which deal with the antigens 
by many ways. The dendritic cells and B lymphocytes present the thyroid peptide which 
bound to class II MHC, CD4, TCR-CD3 complex, binds to the antigens located in the 
binding compartment of MHC class II molecule on the APCs (signal 1). The T 
lymphocytes with other co-stimulation proliferate and produce cytokines (signal 2). 
Immature CD4+ T cells can differentiate into Th1, Th2, Th17 and Treg according to the 
cytokine.    
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1.1.7. Antigens in Autoimmune Thyroid Disease 
There are three major thyroid autoantigens; thyroglobulin (TG), thyroid peroxidase 
(TPO), and thyroid stimulating hormone receptor (TSHR). Highly specific 
autoantibodies against these antigens are found in autoimmune thyroid disease patients. 
The main properties of these major autoantigens are summarised in Table 1.2 (Paschke, 
Van Sande et al. 1996; Tomer, Hasham et al. 2013). 
Table1. 3:  The important features of the major thyroid autoantigens  (Paschke, 
Van Sande et al. 1996). 
Feature TSHR TPO TG 
Protein type G protein binding 
receptor 
Haemoprotein Iodinated 
glycoprotein 
Chromosome 
location 
14 2 8 
Thyroid Location Basolateral 
membrane 
Apical cell surface Lumen of thyroid 
follicular 
Function Receptor for TSH Iodination and coupling 
of tyrosine 
Precursor of T3 
and T4 
Amino Acids 764 933 2748 
Molecular weight 
(kDa) 
87 105-110 660 
Glycosylation + + + 
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Other minor antibodies against the sodium/iodide symporter have been detected in the 
majority of GD sera by immunoprecipitation and immunoblotting assays, but the 
relevance of this to thyroid function is unclear (Ajjan, Findlay et al. 1998). Recent 
studies identified pendrin, a transporter mediating iodide efflux from thyroid cells into 
the follicular lumen, as an autoantigen (Yoshida, Hisatome et al. 2009). Antibodies that 
interact with thyroxine, triiodothyronine, tubulin, megalin, calmodulin, and DNA are 
also occasionally present in autoimmune thyroid disease (Weetman 2010). 
1.1.7.1 Thyroglobulin 
Historically, thyroglobulin antibodies were the first to be detected and associated with 
human thyroid disease. Thyroglobulin antibodies recognize a 670 kDa glycoprotein, 
synthesized and secreted by thyroid epithelial cells. Thyroglobulin contains 140 tyrosine 
residues, and some of these combined with iodine to form thyroid hormones, in a 
reaction catalysed by TPO. Experimental immunisation of animals has lead to the 
identification of approximately 40 distinct TG epitopes. However, patient autoantibody 
recognition is restricted to only 6 major epitopes. Thyroglobulin antibodies are found in 
30% of Graves’ disease patients and 60% of patients with autoimmune thyroiditis 
(Weetman and McGregor 1984). Although not of real pathogenic importance, they may 
contribute to inflammatory process via antibody dependent cell mediated cytotoxicity 
(ADCC) (Song, Li et al. 1996). 
1.1.7.2 Thyroid Peroxidase 
TPO is expressed on the thyroid cell surface as well as in the cytoplasm.  It is the 
primary enzyme involved in thyroid hormone synthesis. It catalyses the oxidative 
fixation of iodide during thyroid hormone synthesis. TPO autoantibodies are not known 
to play a role in GD, although they are thought to be cytotoxic and function in the 
pathology of chronic autoimmune thyroiditis, and are able to fix complement and cause 
antibody dependent cell mediated cytotoxicity (ADCC) (Song, Li et al. 1996).  
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1.1.7.3 Thyrotropin Receptor 
Thyroid stimulating hormone receptor (TSHR), also known as the thyrotropin receptor, 
is expressed on the basal surface of thyroid follicular cells and regulates thyroid growth 
and function. The landmark discovery of the long acting thyroid stimulator (LATS) in 
the circulation of Graves' patients (Adams and Purves 1956) was the first suggestion 
that the TSHR may be a target for autoimmunity, though it was not until 20 years later 
that it was conclusively shown that autoantibodies bound to solubilised preparations of 
receptor (Petersen, Dawes et al. 1977). Autoantibodies directed against the thyrotropin 
receptor are the basis of Graves' disease and as such these antibodies belong to an 
important class of bioactive autoantibodies. The nature of TSHR antibodies and the 
particular nature of the antigen itself represent a field of study with such scope and 
complexity that this topic will be considered in a separate section below. 
 
1.2 The Thyrotropin Receptor 
 
1.2.1 TSHR Structure and Function 
Evidence for a specific cell surface receptor for TSH came from studies of cAMP 
activation in cultured thyroid cells (Pastan, Roth et al. 1966; Yamashita and Field 
1970). The structural gene was cloned in 1989 (Libert, Lefort et al. 1989; Nagayama, 
Kaufman et al. 1989). TSHR is a member of G protein-coupled receptor (GPCR) 
family, also known as seven transmembrane-spanning receptors (7TMRs). In common 
with other members of the receptor family, TSHR features a transmembrane domain 
(7TM) with 7 membrane-spanning loops, and an extracellular ligand binding domain. In 
TSHR the ligand binding domain contains a leucine rich repeat motif (LRR) (Latif, 
Michalek et al. 2010; Unal, Jagannathan et al. 2012). In contrast to other glycoprotein 
receptors, that are present on the surface of cells as single polypeptide chains, TSHR 
can be subjected to intra-molecular cleavage within its ectodomain. This cleavage leads 
to the removal of a 50 residue fragment between the extracellular and transmembrane 
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domains, forming a mature receptor composed of two subunits (A and B), attached 
together by disulphide bonds (Fig. 1.3) (Rapoport and McLachlan 2001). The biological 
role of this cleavage is still unclear (Michalek, Morshed et al. 2009; Neumann, Raaka et 
al. 2009; Unal, Jagannathan et al. 2012). It has been speculated that shedding of the A 
subunit may play a role in the breakdown of tolerance to TSHR observed in Graves' 
disease, and autoimmunity to other gonadotropin receptors, that do not share this 
subunit structure, is almost unknown or very rare (Chen, Pichurin et al. 2003). The 
extracellular domain of TSHR is heavily glycosylated, approximately 35% by weight as 
sugars (Rapoport, Chazenbalk et al. 1998). It remains a matter of debate how critical 
this glycosylation is for receptor function. Evidence from expression studies (discussed 
below) suggest that unglycosylated receptor does not bind TSH or patient antibodies 
(Rapoport, Chazenbalk et al. 1998) but it is not clear whether this phenomenon is the 
result of defective cellular processing of nascent protein or truly indicates a dependence 
on glycosylation for ligand binding. Structural studies of the FSH receptor show that 
glycosylation is not present on the ligand binding surface (Fan and Hendrickson 2005).  
 
1.2.1.1 Thyrotropin 
Thyrotropin is an approximately 30 kDa glycoprotein produced by thyrotrophs in the 
anterior pituitary. It belongs to the glycoprotein hormone family, that includes follicle 
stimulating hormone (FSH), luteinising hormone (LH), and human chorionic 
gonadotropin (hCG). Glycoprotein hormones are heterodimeric cystine-knot 
glycoproteins, comprising a common -subunit and a unique -subunit that determines 
functional specificity (Szkudlinski, Fremont et al. 2002). These glycoprotein hormones 
share a common structure and the crystallisation of FSH and hCG provided useful 
insights into the three dimensional nature of these proteins (Lapthorn, Harris et al. 1994; 
Fox, Dias et al. 2001). The crystal structure of hCG shows that each subunit features a 
central cystine knot and three -hairpin loops, two on one side of the cystine knot (L1, 
L3), and a large loop (L2) on the opposite side (Fig.1.4). The so-called cystine-knot is 
formed by a series of three disulphide bridges formed by central cysteine residues, in 
which one bridge reaches through a loop formed by the remaining two bonds (Lapthorn, 
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Harris et al. 1994). This structure has also been observed in a number of growth factors, 
including PDGF, VEGF, and TGF- (Sun and Davies 1995). One particular feature of 
hCG and other glycoprotein hormones is the "seat belt" structure, in which a loop of the 
beta subunit crosses over the long L2 loop of the a-subunit and is stabilised in place by a 
disulphide bond,    
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Figure1.3 Structure of the LRR domain of the thyrotropin receptor. 
The diagram shows the 3-dimensional structure of the Leucine Rich Repeat (LRR) 
domain of the thyrotropin receptor. The side view (a) shows the concave shape of LRR 
ligand binding domain and the front view (b) shows the relatively planar surface 
presented by the arrangement of parallel beta sheets that comprise the ligand binding 
domain. The figure was produced using PYMOL and published X-ray data (Sanders, 
Chirgadze et al. 2007). 
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Figure1.4 Structure of Thyrotropin. 
The diagram shows the proposed structure of TSH based on crystallographic analysis of 
human chorionicgonadotrophin (hCG) and follicle stimulating hormone (FSH) 
(Szkudlinski, Fremont et al. 2002). The -chain is shown in blue and the -chain in 
yellow. Critical hairpin loops are indicated and the "seatbelt" structure in which a -
chain loop crosses over and encloses part of the -chain. 
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1.2.1.2 Structural Studies of TSHR 
Insights into the three dimensional structure of TSHR were provided by the 
crystallisation of the related FSH receptor extracellular domain in complex with its 
ligand (Fan and Hendrickson 2005). This study showed that the conformation of the 
LRD resembles a slightly bent tube, in common with other LRR receptors, Fig.1.4 
(Kobe and Kajava 2001). The hydrophobic leucine repeats are buried in the core of the 
structure, and the ligand binding site is provided by the almost flat concave surface of 
untwisted beta sheets. FSH is bound by the receptor with long axis of FSH 
perpendicular to FSHR tube structure (Fig. 1.5). The ligand binding site has a relatively 
large surface area (2,600 Å
2
) suggesting multiple contacts between receptor and ligand. 
The majority of contacts come interactions between the parallel beta sheets of the TSHR 
and similarly planar beta sheets of TSH- and the C-terminal 'seat belt' region of TSH-
. A key question relating to signalling is the orientation of the ligand binding domain 
with respect to the 7TM region. Fan and Hendrickson reasoned that as the L1 and L3 
loops of the  and  subunits are antibody accessible when ligand is bound to the 
receptor, but the L2 tip of the -subunit is not, then the receptor probably lies 
approximately parallel to the plasma membrane and holds FSH with the -subunit tip 
proximal to the 7TM domain (Fig. 1.6). This arrangement is most probably common to 
the other glycohormone receptors, and in the case of TSHR may be a critical factor in 
the binding of experimental mAbs and autoantibodies. 
A major recent advance saw the publication of the three dimensional structure of the 
TSHR ectodomain in complex with a monoclonal thyroid stimulating antibody 
(Sanders, Chirgadze et al. 2007). As expected the structure of the TSHR was shown to 
be very similar to that of FSHR with the same arrangement of LRR domains and overall 
geometry. This study confirmed many hypothesised features of TSAb, demonstrating 
that the antibody recognised the TSH binding site, and the molecular interactions 
between antibody variable regions and receptor mimicked those of thyrotropin. The 
features of this TSAb monoclonal and the details of its isolation will be discussed in 
more detail below. 
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Figure1. 5: Structure of the FSHR in complex with FSH. 
This diagram shows the 3-dimensional structure of the FSH receptor in complex with 
FSH. The concave face of the LRR domain (shown in red) presents a relatively flat 
surface that interacts with multiple sites on the FSH dimer (a-chain shown in blue and 
the b-chain in yellow). This figure was produced with PYMOL using published X-ray 
data (Fan and Hendrickson 2005). 
24 
 
 
Figure1.6 Diagram showing the proposed model of TSH binding to the TSHR. 
The TSHR is shown in red (the region between the LRR domain and 7TM omitted for 
clarity). TSH α-chain is shown in blue and the βchain in yellow. The TSH dimer is 
clasped by the concave face of the LRR domain, with the "seatbelt" region facing the 
binding site. The LRR domain is arranged approximately normal to the plasma 
membrane and binding of TSH brings the a-chain loops L1 and L3 into proximity with 
the 7TM alpha helices resulting in signal transduction. This model is based on data 
from structural analysis of the FSHR in complex with its ligand (Fan and Hendrickson 
2005) and TSHR complexed with TSAb monoclonal M22 (Sanders, Evans et al. 2008). 
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1.2.2 Recombinant Expression of TSHR 
Following identification of TSHR as the key autoantigen in Graves' disease it was 
anticipated that progress in understand the pathology of the disease would be rapid, and 
in particular this discovery would enable the development of relevant animal models. 
This early optimism gave way to the realisation that as an autoantigen the TSH receptor 
presented particular difficulties. The receptor is expressed at a low level on normal 
thyrocytes (approx. 2000 - 5000 receptors) and this, together with the instability of 
TSHR during purification, meant that recombinant expression of the receptor was going 
to prove essential for efficient purification of native protein (Rapoport, Chazenbalk et 
al. 1998). 
With the cloning of the human TSHR cDNA in 1989 (Libert, Lefort et al. 1989; 
Nagayama, Kaufman et al. 1989) it was hoped that all the tools of recombinant DNA 
technology could now be employed to express and fully characterise this key 
autoantigen. In the beginning many efforts were made to express recombinant TSHR in 
bacteria, and though a high level of expression of various fragments was attained, these 
purified proteins did not exhibit a native structure and more importantly were not 
recognised by the vast majority of patient sera (Takai, Desai et al. 1991; Rapoport, 
Chazenbalk et al. 1998). As antibodies recognise the extracellular domain attempts were 
made to express this region of the receptor as a soluble subunit (Rapoport, Chazenbalk 
et al. 1998). However, once again, the majority of patient sera did not recognise these 
recombinant forms of TSHR expressed in prokaryotic cells (Costagliola, Alcalde et al. 
1994). Efforts shifted to the use of baculovirus vectors and expression in eukaryotic 
insect cells (Harfst, Johnstone et al. 1992; Huang, Page et al. 1993; Seetharamaiah, 
Desai et al. 1993). Attempts to express the holoreceptor all failed and expression of the 
extracellular domain produced a good yield of protein but it was not able to bind TSH 
and was not recognised by the majority of patient sera (Rapoport, Chazenbalk et al. 
1998). Recombinant protein was retained in the endoplasmic reticulum, necessitating 
elaborate purification steps, and secondly the pattern of post-translational glycosylation 
in insect cells was inappropriate for patient antibody recognition (Rapoport, McLachlan 
et al. 1996). 
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Mammalian cells supply the most effective vehicle for generating conformationally 
native and functional TSHR. Stable expression of human TSH holoreceptor in Chinese 
hamster ovary (CHO) cells was reported by a number of groups (Harfst, Johnstone et al. 
1992; Harfst, Ross et al. 1994; McLachlan, Nagayama et al. 2005). A stable CHO cell 
line expressing full-length TSHR are responded to TSH and patient autoantibodies, and 
are used as the basis of bioassays for thyroid stimulating antibodies. Intact cells or 
membrane produced from these cells can be used in a TSH binding inhibition assay for 
TSHR autoantibodies. A typical level of TSHR expression in stably transfected cell is 
approximately 90,000 receptors per cell as in the commonly used JP09 line (Ludgate, 
Costagliola et al. 1992). Although this level of expression is far higher than which 
estimated in thyroid tissue, it is still too low to make TSHR purification practical 
(Rapoport, Chazenbalk et al. 1998). High density surface expression of the TSHR 
ectodomain was achieved through the use of a glycosylphosphatidylinositol (GPI) 
anchor (Da Costa and Johnstone 1998), and this approach provided cell lines that were 
very useful for characterising patient antibody binding through techniques such as 
FACS.  
Even though relatively high level surface expression of the TSHR extracellular domains 
was achieved by the use of a GPI anchor (approximately 300,000 copies per cell) (Da 
Costa and Johnstone 1998), this still provided too little recombinant protein to enable 
purification. Indeed, it has been estimated that approximately six confluent 10 cm 
dishes of these cells would be needed to produce 1 µg of receptor (Rapoport, 
Chazenbalk et al. 1998). 
A significant breakthrough in expression was achieved through the use of a specialised 
bicistronic vector that permitted the allowed the isolation of high producing clones by 
neomycin selection (Costagliola, Morgenthaler et al. 1999). These cell lines produced 
between 1-2 x 10
6
 copies of receptor per cell, and for the first time it became possible to 
mass produce recombinant TSHR in bioreactors (Stiens, Buntemeyer et al. 2000).  
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1.2.3 TSHR Autoantibodies - Discovery and Early Characterisation 
The discovery of the long acting thyroid stimulator (LATS) in 1956 was a landmark in 
our understanding of Graves' disease (Adams and Purves 1956), and by 1964 LATS had 
been shown to be immunoglobulin in nature, suggesting the possibility of humoral 
autoimmunity against a specific thyroid antigen as the basis of Graves' disease (Meek, 
Jones et al. 1964). The next development in the field came with the discovery of a 
specific thyrotropin receptor on the surface of thyroid cells (Pastan, Roth et al. 1966; 
Yamashita and Field 1970). Some 20 years later it was unequivocably established that 
the target of the LATS IgG was the thyrotropin receptor (Petersen, Dawes et al. 1977). 
Despite these early insights attempts to characterise these antibodies proved surprisingly 
difficult. Analysis of bulk sera from GD patients did provide yielded valuable data 
using the available technology of the period. It was shown that TSAbs are class 
restricted to IgG1 (Weetman, Byfield et al. 1990; Weetman, Yateman et al. 1990) and 
approximately one third of patients use a lambda light chain in these antibodies 
(Williams, Marshall et al. 1988). These findings suggested that a restricted number of 
B-lymphocytes are responsible for producing TSAb. Clearly the question of 
oligoclonality is central to our understanding of the origins of this autoantibody 
response, and may highlight novel therapeutic approaches, but cannot be precisely 
determined through the analysis of bulk patient sera. For these reasons great effort was 
exerted in attempts to isolate both animal and human examples of monoclonal TSAb 
and these studies, and the particular difficulties presented by the TSHR as an antigen, 
will be discussed in depth later in this chapter. 
Interestingly, measurements of circulating levels of thyroid autoantibodies in patient 
sera demonstrated that although anti-TPO and anti-TG IgG are relatively abundant in 
the circulation, TSAb are present at a very low level (de Forteza, Smith et al. 1994; 
Chazenbalk, Jaume et al. 1997), suggesting that the circulating precursor B cells would 
be correspondingly rare also. As will be discussed, this feature of TSAb was to prove a 
significant hindrance for the isolation of patient monoclonals, and is another way in 
which this class of autoantibodies clearly differ from other thyroid antibodies. 
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1.2.4 TSHR Antibody Assays 
TSH receptor autoantibodies (TRAbs) are the basis of Graves' disease and can be 
detected in the sera of almost all patients if the assay used is of sufficient sensitivity 
(Rees Smith, McLachlan et al. 1988; Rapoport, Chazenbalk et al. 1998).  
1.2.4.1 Thyroid Stimulating Activity 
Historically the first methods used to detect TSAb was the study by Purves and Adams 
in 1956, though at the time it was not known that the so-called Long Acting Thyroid 
Stimulator (LATS) detected in Graves' disease serum was immunoglobulin (Adams 
1956). In these studies the assay was based on the stimulated release of radioiodine 
from guinea pig thyroids and this in vivo approach was subsequently developed in mice 
as the eponymous "McKenzie" assay for both TSH and LATS (McKenzie 1958; 
McKenzie 1958). Useful though these assays were they were, the use of animals was 
cumbersome and not accessible for all laboratories. Accordingly, significant effort was 
invested in the development of effective in vitro bioassays of thyroid stimulating 
activity. Attention focused initially on the use of tissue slices, with output 
measurements based on the production of colloid droplets or increases in cAMP 
production (Onaya, Kotani et al. 1973), but these and other early assays suffered from 
both irreproducibility or insensitivity or both. Tissue culture of human and animal 
thyroid cells proved a more fruitful area of study and sensitive and accurate assays of 
thyroid stimulatory activity, based on measurements of cAMP, were developed using 
cultured cell monolayers (Rapoport and Adams 1978; Toccafondi, Aterini et al. 1980). 
With the cloning of the human TSHR cDNA (Libert, Lefort et al. 1989; Nagayama, 
Kaufman et al. 1989) the use of thyroid cell lines has been almost completely replaced 
by stably transfected cells, offering both higher levels of receptor expression and 
simpler tissue culture requirements (Persani, Tonacchera et al. 1993; Michelangeli, 
Munro et al. 1994). It was through the use of activity assays that another class of TRAb 
was discovered. A studies of TSAb activity in a collection of Graves' patient sera 
showed that in a few patients antibodies were present that could block the activity of 
TSH, as measured by cAMP production (Orgiazzi, Williams et al. 1976). This finding 
shed new light on the range of different TRAbs present in AITD patients and this new 
class of autoantibodies, TSH blocking antibodies (TBAb) can play a significant role in 
29 
 
some cases of autoimmune hypothyroidism (Endo, Kasagi et al. 1978; Matsuura, 
Yamada et al. 1980). The discovery of TBAb suggested that the interaction of patient 
IgG and the TSH receptor was complex, with a range of different epitopes, and 
associated effects on thyroid function. For the field to advance it was necessary to move 
beyond bioassays, and to investigate the binding of IgG to the receptor directly, and it is 
to these assays that we will now turn. 
1.2.4.2 Indirect TBI Assays 
The identification of a specific thyrotropin receptor on the surface of thryoid cells was 
the initiating point for the development of direct binding assays for TRAb. The 
demonstration that some patient TRAbs could compete with TSH for binding to the 
TSHR was ultimately developed into an assay for characterising antibody binding 
characteristics. This TSH Binding Inhibition (TBI) assay is relatively easy to perform 
and proved a useful tool to classify different classes of receptor antibodies. The assay 
originally used solubilised porcine receptor (Smith and Hall 1981) and, given the 
difficulties of expressing and purifying human TSHR (section 1.2.1.2), this material is 
still in common use at present. The assay was used to show that thyroid stimulating 
antibodies blocked the binding of TSH to the receptor, evidence that they were likely to 
recognise a similar binding site on the receptor as the natural ligand. One drawback of 
the assay is that it does not discriminate between thyroid blocking antibodies (TBAb) 
and TSAb, which limits the clinical usefulness of TBI measurements. A second problem 
with the original TBI assay, based on porcine receptor preparations and bovine TSH, 
was that it had a sensitivity of only 50-80% for the detection of TRAb from Graves' 
patient samples (Kamath, Adlan et al. 2012). This was improved with the introduction 
of so-called 'second generation' assays which used recombinant human TSHR and 
produced a 90-100% sensitivity for the detection of Graves' patient receptor antibodies 
(Costagliola, Morgenthaler et al. 1999). Interestingly, though pure recombinant human 
TSH is available, bovine TSH is still used as it has a higher binding activity than the 
human hormone (Rapoport, Chazenbalk et al. 1998). With the isolation of human 
monoclonal TSAb (Sanders, Evans et al. 2003) a 'third generation' TBI assay has been 
developed based on the ability to compete for binding to the receptor with the 
stimulating IgG, and is claimed to have even greater sensitivity (Zophel, Roggenbuck et 
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al. 2010). The use of TBI assays has allowed TRAb to be classified accordingly to their 
ability to compete with TSH. The nomenclature associated with thyroid stimulating and 
TBI activity has been subject to both confusion and variety, and a case has made for 
simplifying this terminology (McLachlan and Rapoport 2013). In the case of bioassays, 
TSAb refers to antibodies with thyroid stimulating activity, and TSH-blocking 
antibodies or TBAb, inhibit signalling by TSH. Competition assays are most commonly 
referred to as TSH binding inhibition (TBI) assays, though TSH is no longer always 
used as the ligand, this term can still refer to blocking of TSAb binding. 
1.2.4.3 Direct Binding Assays 
Detecting binding of patient TRAbs to receptor is a technically challenging task. As 
discussed, patient TSHR autoantibodies are present at a very low level in sera, typically 
in the nanogram per ml, with rare patients exhibiting microgram levels of TSAb 
(Rapoport, Chazenbalk et al. 1998). Faced with such low levels of antibody, direct 
binding assays require a significant level of purified autoantigen to provide sufficient 
sensitivity. Producing significant amounts of purified TSHR, together with the strict 
requirement for native conformation for recognition by patient antibodies, presented a 
significant hurdle for the development of direct binding assays. The use of GPI anchors 
for surface expression of TSHR ectodomain (section 1.2.2) allowed the development of 
flow cytometric assays for the detection of antibody binding (Jaume, Kakinuma et al. 
1997), though this approach lacked sensitivity and did not lend itself to high throughput 
screening. 
The isolation of cell lines expressing very high (1-2 x 10
6
 receptors per cell) levels of 
TSHR (section 1.2.2) lead to the commercial development of the first true direct binding 
assay of TSHR antibodies, the so-called "2nd generation" assay (Costagliola, 
Morgenthaler et al. 1999). This assay was based on the use of tubes coated with purified 
human TSHR captured by a monoclonal antibody and held in a stable native 
conformation. This "BRAHMS" assay offered higher sensitivity and selectivity than 
previous assays and was estimated to offer a detection level of 70-90%. 
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1.2.5 Animal Models and Isolation of TSHR Monoclonal Antibodies 
1.2.5.1 Spontaneous Models 
Many key aspects of autoimmunity have been uncovered by the use of animal models of 
autoimmune disease. These models are divided into two distinct types, spontaneous and 
induced. Spontaneous autoimmune disease models exist as a result of deliberate 
inbreeding of strains for particular characteristics including the incidence of 
autoimmune disease. In the case of AITD, there are a limited number of spontaneous 
animal models. The best known are the Buffalo Breed (BB) rat, some strains of non-
obese diabetic (NOD) mouse and the obese strain chicken. In all these models there is 
an infiltrative thyroiditis, tissue destruction, and the immune response is directed against 
the thyroid antigens TG (chicken and rat) and TPO (mouse). Interestingly none of these 
animal models exhibited the hyperthyroidism or circulating TSAb characteristic of 
human disease (McLachlan, Nagayama et al. 2005). 
1.2.5.2 Induced Models 
Since the 1950s researchers have successfully use immunisation with antigen and 
adjuvants to produce thyroiditis and autoantibody production in a range of species 
(Rose and Witebsky 1956). Immunised rabbits and mice developed serum antibodies 
that would recognise TSHR preparations in a range of assays including, ELISA, western 
blotting and immunoprecipitation (Seetharamaiah, Wagle et al. 1995). It soon became 
clear however that in no case did the animal sera contain thyroid-stimulating activity, 
and the development of an animal model of Graves’ disease was going to prove more of 
a challenge than anticipated (McLachlan, Nagayama et al. 2005).  
GD patient sera recognise conformational epitopes, thus an animal model would need to 
target these same epitopes in order to generate antibodies with thyroid stimulating 
activity. Attention turned to the expression of the native receptor. 
The first successful induction of autoimmune hyperthyroidism in animals was achieved 
using the "Shimojo" model (Shimojo, Kohno et al. 1996). In this approach expression of 
native receptor was achieved by injecting mice with autologous fibroblasts stably 
transfected with the genes for human TSHR and murine class II MHC. The features of 
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this model included lymphocytic infiltration of the thyroid gland, and more importantly, 
the induction of stimulatory TSHR antibodies. Mice were injected six times and 
approximately two weeks after the final injection about 90% of mice developed 
antibodies against the TSHR, as determined by TBI activity. Approximately 25% of 
these mice went on to exhibit hyperthyroidism, and had detectable levels of TSAb 
activity (Shimojo, Kohno et al. 1996). This approach was extended by other groups and 
used to induce hyperthyroidism in hamsters (Ando, Imaizumi et al. 2003), and repeated 
in mice using stably transfected B cells and human embryonic kidney (HEK293) cells 
(Kaithamana, Fan et al. 1999).  
An alternative approach was based on the induction of transient TSHR expression by 
naked DNA or genetic immunisation. Immunisation with DNA has shown to be an 
efficient method of generating an immune response, leading to antigen expression in 
myocytes and local antigen presenting cells (Tang, DeVit et al. 1992). It was reported 
that DNA immunisation of mice with TSHR DNA lead to the induction of TSHR 
antibodies in almost 100% of treated mice (Costagliola, Rodien et al. 1998). 
Interestingly, in this study TSAb activity could be detected in some mice, but none of 
them were thyrotoxic. Three other groups were subsequently unable to reproduce these 
results (Pichurin, Yan et al. 2001) and it became clear that the model was highly 
susceptible to the genetic background of the subject mice and sensitive to environment 
conditions such as animal housing and diet (Baker, Mazziotti et al. 2005).  
As an alternative to transient expression by DNA immunisation a number of groups 
investigated the use of replication-deficient adenovirus vectors to transfect TSHR DNA 
into animal cells. Nagayama et al (Nagayama, Kita-Furuyama et al. 2002) injected 
recombinant adenovirus intramuscularly into a number of different inbred mouse strains 
and were able to report the induction of TSHR antibodies almost all BALB/c treated 
mice, with detectable TBI activity and TSAb and thyrotoxinaemia in 50%. Interestingly 
only 25% of another strain, C57BL/6, became thyrotoxic, and some strains of mice 
undergoing the same treatment remained euthyroid (Nagayama, Kita-Furuyama et al. 
2002). However, despite this variation, the adenovirus model has been confirmed by 
two other laboratories (Chen, Pichurin et al. 2003; Gilbert, Salehi et al. 2004). 
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Through these advances it was established that immunisation with native TSHR 
receptor could lead to the production of receptor antibodies that resembled those 
observed in human disease, and, as will be discussed below, it with the use of these new 
animal models that the first TSAb monoclonal antibodies were isolated. 
 1.2.6 Cloning of TSHR Monoclonal Antibodies 
The development of methods for generating monoclonal antibodies by cell fusion 
(Kohler and Milstein 1975) enabled the characterisation of single antibodies of defined 
specificity. Theoretically it was now possible to generate monoclonal antibodies against 
antigen by immunisation with purified, often recombinant, antigen. This technique was 
soon applied to the field of autoimmunity and the generation of antibodies against 
known disease-related antigens. With the advent of recombinant DNA techniques and 
cloning of the human TSHR cDNA (Libert, Lefort et al. 1989; Nagayama, Kaufman et 
al. 1989) it was anticipated that rapid progress would be made in the generation of 
experimental antibodies by immunisation with purified recombinant protein. In the area 
of thyroid autoimmunity progress was initially rapid, and examples of anti-Tg and anti-
TPO were soon reported (Kodama, Sikorska et al. 1984; Czarnocka, Ruf et al. 1985). 
As described above, many different approaches have been taken to generate murine 
monoclonal antibodies to TSHR. Early studies used immunisation with thyroid 
membrane extracts. Antibodies from these mice failed to convincingly recognise TSHR 
in immunoassays. Subsequent studies using immunisation with different forms of 
recombinant TSHR were more successful. A series of monoclonal antibodies were 
generated, and evaluated using numerous criteria including immunoprecipitation, 
immunoblotting, and ELISA. However, with two exceptions, none of these monoclonals 
were shown to interact with native conformationally intact TSHR, and crucially, none 
possesses stimulatory activity (McLachlan, Nagayama et al. 2005). The field rapidly 
became rather confused, with a number of groups claiming TSAb activity for their 
respective monoclonals. In an effort to clarify the goal of antibody studies a set of 
criteria were described that authentic TSAb should meet  
Despite the availability of animal models, the isolation of monoclonal TSAbs remained 
an insurmountable obstacle for some time. A number of particular difficulties remained 
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to be overcome. The choice of suitable animal donor was the first obstacle, and success 
was eventually achieved using spleens from rodents with very high levels of TSAb and 
TBII activity, and evident thyrotoxinemia. The second contributing factor was the 
development of a high throughput screening technique (Costagliola, Morgenthaler et al. 
1999). In general, ELISA is the method of choice for screening of monoclonal 
antibodies as the technique lends itself to large throughput analysis necessary for the 
identification of specific antibody activity. The identification of TSAb clones required 
the use of more specific assays, such as those for TBII, or TSAb activity. Even with the 
use of an improved screening assay, few monoclonal TSAb have been isolated and 
these have been the result of tremendous effort (McLachlan, Nagayama et al. 2005).  
The development of successful animal models of GD was a crucial advance in our 
understanding of the origin of the autoimmune thyroid disease. Perhaps the most 
important aspect of this breakthrough was the impact it had on the attempts to 
characterise the TSHR autoantibody response, in particular the nature of thyroid 
stimulating antibodies that are the basis of GD. The availability of animal models was 
an important step in an attempt to isolate monoclonal TSAb.   
The experimental TSAb monoclonals described above were derived using variants of 
the well-established hybridoma procedure. In this approach, activated splenocytes from 
immunised subjects are fused with an immortal cell line such as myeloma, cultured and 
screened for the desired activity. The isolation of human monoclonal antibodies is in 
general, a much more difficult challenge, and in the case of TSHR antibodies, the 
difficulties were an order of magnitude greater still. The stable immortalisation of 
human B cells remains a technical challenge, not least due to the difficulty in 
developing suitable fusion partners (Smith 2003).  More significantly, peripheral blood, 
the most accessible source of patient lymphocytes, contains few activated B cells, and 
booster immunisation is not an option with human subjects. The successful isolation of 
human TSAb mAb thus represented a major technical triumph (Smith 2003). A critical 
factor in this success was the selection of a patient with active GD and very high levels 
of TSHR antibodies, as measured by TBII and TSAb bioassay. Some insight into the 
magnitude of the task is provided by the fact that 16,500 culture wells needed to be 
screened to isolate this single clone, some 10-20 times that required in the case of 
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animal TSAb, and this does not take into account any unreported failed attempts. The 
isolation of a human thyroid stimulating monoclonal autoantibody (M22) has been a 
key advance for the study of the thyroid autoimmunity (Smith 2003). 
The availability of monoclonal TSAb also allowed, a second major advance in the field: 
the crystallisation of the receptor-antibody complex (Sanders, Chirgadze et al. 2007). 
For the first time, structural studies could be carried out on the TSH receptor, and the 
stimulating antibody-binding site determined. It was shown that both the thyroid 
stimulating human monoclonal antibody M22 and TSH bind to the concave surface of 
the leucine rich domain (LRD) of the TSHR. It was also shown that M22 and TSH 
interact with the same or similar amino acid residues in the receptor ligand-binding 
domain (Sanders, Chirgadze et al. 2007; Nunez Miguel, Sanders et al. 2009; Guo, Huo 
et al. 2013). The light chain of M22 resembles the TSH β chain in its binding properties, 
while the heavy chain of M22 exhibits binding interactions similar to those of the TSH 
α chain (Fig. 1.7) (Sanders, Chirgadze et al. 2007; Nunez Miguel, Sanders et al. 2009; 
Sanders, Young et al. 2011). Recently two additional human monoclonal antibodies to 
the thyrotropin receptor (K1-18 with stimulating and K1-70 with blocking activity) have 
been isolated from a patient with hypothyroidism who previously presented with 
Graves’ disease (Sanders, Young et al. 2011). This provides the first experimental 
confirmation that a patient can produce both blocking and stimulating TSHR antibodies 
(Sanders, Chirgadze et al. 2007; Smith, Sanders et al. 2009; Sanders, Young et al. 
2011). Crystallographic analysis of the TSH blocking antibody, K1-70, complexed with 
the TSHR LRR domain showed that the epitope of K1-70 showed a substantial degree 
of overlap with that of the TSAb clone M22 (Sanders, Young et al. 2011) 
Although these examples of human TSHR monoclonal antibodies have provided useful 
insights into the nature of TSAb, both in terms of epitope recognition and 
immunoglobulin gene usage, it is clear that the isolation of further examples is required 
to fully understand and investigate TSAb. 
 Analysis of TSAb monoclonal and corresponding TSHR epitopes would provide novel 
therapeutic strategies and diagnostic tools as well as allowing the design of specific 
antagonists or the development of anti–idiotypic reagents. 
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Figure1.7 The TSH Receptor-M22-Fab Complex Structure 
The TSH receptor-M22 Fab complex structures are shown in differently aligned views 
related by 90˚ rotation about the vertical axis. TSH LRD is in cyan, M22 Fab light chain 
is in green, M22 heavy chain is in blue, the N-linked carbohydrates are in yellow and 
carbohydrate-bound aspargines are labelled. The amino-(N) and carboxyl-(C) termini 
are indicated. Disulphide bonds are shown in black (adapted from (Sanders, Chirgadze 
et al. 2007).  
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1.3 Antibody Structure and Function 
The molecule of Immunoglobulin (IgG) are made up of light (L) and heavy (H) 
polypeptide chains. The molecular weight of each H chain is 50-75 kDa containing 
about 445 residues. Whereas each L chain has a molecular weight of 25 kDa consisting 
of approximately 220 a.a., The antibody molecule composed of 4 polypeptide chains: 2 
H chains and 2 L chains, forming Y shape (Fig 1.8). An antibody molecule always 
consists of identical H chains and identical L chains. Each H chain is covalently linked 
with an L chain by a disulfide bond and the two heavy chains are associated to each 
other by disulfide bonds (Paul 2003). H and L chains are subdivided into variable (V) 
and constant (C) domains. Most H chains consist of one variable heavy (VH) and 3 
constant heavy (CH) domains, the constant heavy domain 1 (CH1), the constant heavy 
domain 2 (CH2), and the constant heavy domain 3 (CH3). And L chain consists of one 
variable light (VL) and one constant light (CL) regions. The main function for the 
variable domains is antigen binding, while the functions of constant regions are binding 
to cell surface receptors and complement activation. Each variable region contains three 
complementary-determining regions (CDRs) or hypervariable regions. When VH and 
VL are attached by coupling the light and heavy chains, CDRs form the antigen binding 
site (paratope), complementary in structure to epitope or the antigenic determinant and 
determine antibody specificity. The remarkable specificity of antibodies is due to these 
hypervariable regions and the immune system ability to generate high affinity 
antibodies to a huge array of antigens means that the diversity in variable regions 
encoding genes have to be very high. Two types of light chains, λ (lambda) and κ 
(kappa) chains are with a similar function. In human these are present in a κ: λ ratio of 
about 2:1, but this varies greatly between species. Both types occur in all classes of 
immunoglobulin (IgG, IgM, IgA, IgE and IgD), but any one immunoglobulin molecule 
contains only one type of L chain. The amino-terminal portion of each L chain 
participates in the antigen-binding site. H chains are distinct for each of the 
immunoglobulin classes and are designated γ (gamma), μ (mu), α (alpha), δ (delta), and 
ε (epsilon). The amino-terminal portion of each H chain participates in the antigen-
binding site; the carboxy terminal forms the Fc fragment, which has the biological 
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activities (Paul 2003). By using enzymatic cleavage property, the antibody molecule 
part of different functions can be classified. Two Fab fragments, each consisting of VH, 
CH1, VL and CL and one Fc (crystallisable fragment) fragment can be produced by 
papain treatment of antibody molecule. Pepsin cleavage releases the two fragments 
binding domains bound together, a fragment known as (Fab)2, which maintains the link 
offered by the disulphide bridge in the hinge region and thus consists of two Fab 
fragments. The antibody Fab or (Fab)2 fragment of an antibody is a unit containing the 
antigen-binding site with high affinity to their targets. Of interest is the Fv and scFv 
fragments, which considered as the smallest fragment of immunoglobulin including the 
entire antigen-binding site, consist of only VH and VL (Fig. 1.9). Through the use of 
protein engineering a range of alternative immunoglobulin domain constructs are 
possible (Janeway and Travers 1997; Paul 2003). 
1.3.1 The Variable Domains of Immunoglobulin 
The variability is not in the entire variable region, but only in certain part of the domain. 
The less variable region of the variable domain known as framework regions (FR), and 
hypervariable regions (HV) considered  as the most hypervariable regions present 
antigen epitope binding regions that are structurally complementary to their specific 
epitope, and they are known as CDR (complementary determining regions), which 
classified to CDR1, CDR2 and CDR3 (Janeway and Travers 1997; Paul 2003).  
Immunoglobulin genes can be classified into families according to the similarities of the 
DNA sequence. Seven of them which have 80% or more homology (Janeway and 
Travers 1997) and the λ chain is divided into eight families. These 8 families are not 
evenly represented in the antibody repertoire.  
The largest gene family of heavy chain is VH3, which about 50% of the collection of 
VH in peripheral B cells of the adults (Janeway and Travers 1997; Paul 2003). 
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Figure1.8 Schematic representations Structure of an immunoglobulin G (IgG) 
Antibody molecule includes two identical heavy (H) chains and two identical light (L) 
chains are connected by disulfide bonds and each chain consists of variable and 
constant region. Within the variable regions, the hypervariable (complementary 
determining) regions comprise the actual antigen-binding sites and are responsible for 
the specificity of antibody. 
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Figure1.9 Schematic representation Structures of Fab, scFv and Fv fragments. 
The Fab fragment of antibody is monovalent capable of binding to antigen and contains 
light chain associated to variable and CH1 portions of heavy chain by disulfide bond. 
The scFv fragment containing the whole antigen-binding site, consist of only VH and 
VL covalently connected by glycine-serine linker. 
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1.3.2 Immunoglobulin Diversity 
The DNA encoding the constant and variable regions of Ig chains are separated in the 
germ line. Somatic rearrangements take place during B cell development to form the 
genes that, expressed as surface bound and secreted Igs. The heavy chain variable 
domain is encoded in three different genetic elements, variable heavy (VH), diversity 
heavy (DH) and joining heavy (JH) gene segments. These regions are brought together 
to generate a functional gene by DNA rearrangement (Paul 2003; Mochizuki, Nakamura 
et al. 2011). 
All the gene segments comprising the heavy and light chains are present in several 
copies, and the extensive variation observed in immunoglobulin variable regions comes 
from the different combinations of these multiple genes (Fig 1.10)(Christoph and 
Krawinkel 1989). The joining of different parts in the recombination is inaccurate, 
which give possibility for more variability.  
The final source of variability, somatic hypermutation, takes place in secondary 
lymphoid organs after a given B cell has encountered antigen.  Under the influence of T 
cell help and specific environmental conditions found in germinal centres, this process 
may creates point mutations at a very high rate in the  rearranged V regions (Neuberger 
and Milstein 1995; Paul 2003; Mochizuki, Nakamura et al. 2011)  
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Figure1.10 Construction of V-region genes from gene segments. 
Construction of light-chain V-region genes from two segments (center panel). A joining 
(J) gene and   variable (V) gene part in the genomic DNA are joined together to form a 
light-chain V-region exon.  
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1.4 Antibody Engineering 
1.4.1 Introduction 
Antibodies are used in science and medicine as marker molecules. The specific 
properties of antibodies binding are used for the identification of antigens under study in 
the laboratory and in diagnostic tests. Antibodies are also used for purification of 
biomolecules for both therapeutic and diagnostic application in vivo (Li, Janda et al. 
1994). The low toxicity and specificity  of antibodies give a hopeful innovative plan for 
treatment of a range of diseases (Berger, Shankar et al. 2002). The production of 
antibodies was a very difficult and time consuming procedure involving immunization 
of animal and/or generation of hybridoma. Recombinant antibodies are used in a 
number of applications in medicine. For a number of reasons, antibody engineering is 
performed including minimise  immunogenicity, improving antibody generation 
through bacterial expression, improving pharmacokinetic profile and modifying for 
novel effector functions (Holliger and Bohlen 1999). A range of recombinant 
technologies have now assisted the genetic strategy of immunoglobulin. Three 
important approaches are available to the modification of antibodies for certain 
applications: humanization of antibodies, size reduction, and binding modulation 
(Hoogenboom and Winter 1992). The development of phage display vectors (Smith 
1985) and successful expression of antibody fractions in E. Coli (Better, Chang et al. 
1988) introduced the possibility of antibody engineering. The construction of phage 
display combinatorial libraries presenting human antibody fragments on the surface of 
bacteriophage as single chain Fragment variable region (scFv)(McCafferty, Griffiths et 
al. 1990) or Fab fragments (Barbas 1991; Barbas, Kang et al. 1991) permitted the direct 
selection of such libraries for antigen-binding clones. This work has stimulated interest 
in the production and modifications of recombinant antibodies as production of bivalent 
or bispecific recombinant antibody fragments, the production of antagonised antibodies 
(Zaghouani, Steinman et al. 1993). The selecting antibodies from phage libraries 
considered as the main advantages especially with the antigens that can give difficulties 
in the immunization e.g. unstable or auto antigens. The construction of antibody parts in 
E. coli has many advantages like, the possibility of labelling the antibody fragment for 
structural studies. Size reduction also has several advantages as can be seen in the 
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structure of the antibody molecule. The recombinant phage antibody system has been 
adapted to clone different fragments of antibody (e.g. scFv and Fab) and to express and 
detect functional antibodies.  
 
1.4.2 Combinatorial Antibody Library Technology  
With the improvement of molecular biological methods efforts were made to develop 
the value of monoclonal antibody reagents by the expression of modified antibody 
molecules in recombinant forms. In the beginning, antibody genes which obtained from 
hybridomas were expressed in mammalian cells as whole antibodies (Neuberger 1983) 
or in bacteria  as antibody fragments (Cabilly, Riggs et al. 1984). A number of other 
systems including insect cells (Hasemann and Capra 1990),  yeast (Wood, Boss et al. 
1985), Chinese hamster ovary cells ,(Wood, Dorner et al. 1990), transgenic plants 
(Hiatt, Cafferkey et al. 1989) and lymphoid cells (Shu, Qi et al. 1993). Each one of 
those expression systems has advantages and disadvantages. Bacterial systems generally 
well for the expression of Fv and Fab fragments but poor in the expression of whole 
antibodies.  
At first, the combinatorial immunoglobulin technique began by using a lambda (λ) 
phage vector for cloning and expression of H-chain and L-chain genes. Then this library 
binding a target antigen tested by plaque lift for clones (Burton and Barbas 1994). This 
method evolved from two key developments. Firstly, it was demonstrated that the Fv 
antigen binding fragments could be expressed and functionally assembled in E. coli 
(Skerra and Pluckthun 1988). Secondly, the development of the polymerase chain 
reaction (PCR) allowed for the rapid cloning of antibody genes from hybridomas 
(Orlandi, Gussow et al. 1989)  and mixed populations of antibody-producing cells, even 
in the case of limiting cell numbers. Initially libraries were expressed in λ phage, a lytic 
phage that releases the periplasmically sequestered Fab into the plaque of lysed host 
bacteria (Huse, Sastry et al. 1989). These libraries were screened by transfer of 
recombinant Fab onto nitrocellulose filters, which were then probed with I
125
- labelled 
antigen. Subsequently (Persson, Caothien et al. 1991)used human peripheral blood 
lymphocytes from an individual recently boosted with tetanus toxoid to construct an 
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IgG1K library in a lambda vector. The antibodies generated in this case showed 
considerable sequence diversities and affinities in the range of 10
-7
-10
-9
 nM. Recent 
boosting proved important, as it was not possible to isolate antigen-specific Fabs from 
an individual with a high anti-tetanus toxoid titre who had not been boosted. This was 
probably related to the frequency of antigen-specific plasma cells, with their high 
concentration of specific mRNA, in boosted subjects (Lum, Burns et al. 1990). A 
significant limitation to the lambda phage screening procedure was the size of the 
library antibodies would require an examination of a minimum of 10,000 filter lifts 
(assuming 50,000 plaques per plate). It is also important to remember that the VH and 
VL chain permutations are randomised in the cloned library and a particular 
combination may be present at only a low frequency. This problem is particularly 
exacerbated in the absence of booster immunisation. Furthermore, the screening 
procedure places restrictions on the antigens which are being examined in that the 
native antigen must be available in significant quantities, sufficiently pure, and be 
amenable to labelling with I
125
 or conjugation to enzymes. 
1.4.3 Phage Display antibody Techniques 
In general the selection is a more efficient than screening, and the next advance in the 
field of recombinant antibody library technology was to develop a system analogous to 
the B cell selection and maturation process observed in the native immune system. This 
was achieved by the coupling of antigen recognition and B cell selection and 
proliferation, or more simply, the linkage of phenotype to genotype. 
 
It was shown in 1985, that they could incorporate short peptides  into the f1 filamentous 
phage genome, and expressed on the phage without interference with the it’s life cycle 
(Smith 1985) . In the beginning it was applied for mapping immunoglobulin epitopes by 
expression of 10
7
-10
8 
clones (large libraries) of random peptides (Parmley and Smith 
1988; Scott and Smith 1990). Consequently it was established that the antibody 
fragments can be expressed successfully in the filamentous phage system and maintain 
their binding properties to the antigens (McCafferty, Griffiths et al. 1990; Barbas 1991). 
Unlike the  lytic phage system, the filamentous phage life cycle allowed the use of the 
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biopanning technique of very large highly diverse libraries to enrich specific antibody 
clones.  
The finding of the possibility of the expression of functional antibody fragments on the 
surface of filamentous phage was an important advance in recombinant antibody 
engineering. Derivatives such as the “single chain fragments variable" (scFv), the 
"fragment variable" (Fv), and the "fragment antigen binding" (Fab), can be expressed 
and then secreted into the bacterial periplasm of the bacteria in the oxidative 
environment , where they can processed in a way that be similar to the process taking 
place in the endoplasmic reticulum, mainly in terms of disulfide bond formation(Skerra 
and Pluckthun 1988). Recombinant antibody technology developments enable fast, easy 
and efficient modification and expression of the antibodies. 
The Fv fragment is the smallest and heterodimers part which containing the antigen 
binding site, and composed of the variable domains of the light and variable chain (VL 
and VH, respectively). Variable domain is made up of a conserved β-sheet framework. 
The binding site is composed of the CDR regions, six in total, and three to each domain. 
In opposite to Fabs in which interchain disulfide bonds held and stabilized the 
heterodimers  together and, the Fv is unstable because the VL and VH domains are non-
covalently connected (Webber, Reiter et al. 1995). VL and VH domains in synthetic 
single-chain fragments (scFv) are covalently bonded by a peptide linker (Webber, Reiter 
et al. 1995), which fuse either the N-terminus of VL and C-terminus of VH or vice 
versa.  
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1.4.4 Structure and Genetics of Filamentous Phage 
The M13, f1 and fd filamentous bacteriophages having similar genomic structure (Fig 
1.11). They can infect E.coli by a specific interaction among the phage and the bacterial 
pilus. In general the phage have a ssDNA genome, which about 6.4 kb, and its shape are 
cylindrical with a length which can differ with the size of the enclosed genome and  a 
diameter of 650 nm (Simons, Konings et al. 1981). The coat is composed of around 
2,700 copies of protein VIII which forms a shell around the genome (Simons, Konings 
et al. 1981). pVII ,pIX, pIII and pIV present only at 3 to 5 copies per virion, (Simons, 
Konings et al. 1981). Coat protein III (cpIII) has two domains, a carboxyl-terminal 
domain that integrates into the phage structure and an amino-terminal domain which 
important for phage infectivity. Unlike λ phage, in which the first repertoire cloning 
experiments were performed, Fd phage are not assembled in the cytoplasm and are not 
released by cell lysis. They are instead extruded through the outer membrane leaving the 
cell intact. Bacteriophages are extruded as they are assembled in the bacterial 
membrane. Since both pIII and pVIII are secreted and anchored in the periplasmic space 
of E. coli and are assembled to form the surface of the phage, they are ideal targets for 
fusion with antibody domains. Several systems have now been produced for the surface 
expression of Fab or Fv fragments on the surface of filamentous phage. The majority of 
these use pIII fusions (McCafferty, Griffiths et al. 1990; Barbas, Kang et al. 1991), 
although pVIII fusion vectors, giving polyvalent antibody display, have also been 
constructed (Kang, Burton et al. 1991). 
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Figure1.11 The structure of filamentous phage. 
A single stranded circular genome is surrounded by ~2700 copies of the major coat 
protein 8, and 4 or 5 copies of each of four types of minor coat proteins, including pIII.  
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1.4.5 Biopanning technique 
Biopanning is the process by which phage expressing desired specificities and binding 
characteristics are enriched from a library of phage displaying a diverse pool of 
biomolecules. This process usually involves a progressive reduction in diversity of 
phage library over repeated round of panning (Cortese, Monaci et al. 1995).The panning 
process generally involves immobilizing a target molecule onto a solid surface, 
exposing the immobilized target molecule on the phage library and eluting phage that 
bind (Fig 1.12). The eluted phage are usually amplified by infecting E. coli and again 
panned on the immobilized molecule, to enable further enrichment of specifically-
binding phage.  
1.4.6 Applications of Antibody Phage Display  
These systems have provided the opportunity for production of human antibodies 
directly from libraries, with the possibility of mutating and then selecting for antibodies 
with desired properties (Winter and Milstein 1991; Burton 1993). In human organ-
specific diseases, the phage display technique has been used to identify disease-
associated autoantibodies in primary biliary cirrhosis, myasthenia gravis and insulin-
dependent diabetes mellitus. In systemic autoimmune disease, this approach has been 
used successfully to clone autoantibodies against Ul RNA-associated A protein in SLE 
by using semi-synthetic as well as patient-derived combinatorial libraries (de Wildt, 
Finnern et al. 1996) 
1.4.7 Phage Display in the Analysis of Autoimmune Thyroid Disease 
Initially, a λ library approach was used to probe the TPO autoantibody repertoire in GD. 
Using mRNA from thyroid-infiltrating lymphocytes, an IgG1 library was constructed in 
λ phage and screened to identify Fabs with high affinities (around 0.1 nM) for TPO 
(Portolano, Seto et al. 1991; Portolano, Chazenbalk et al. 1992). These Fabs were able 
to inhibit a high proportion (36-72%) of serum TPO Abs from 11 patients with AITD, 
implying that the epitope recognised was of major significance. At the same time, 
(Hexham, Persson et al. 1991; Hexham, Furmaniak et al. 1992) utilised the same 
approach to construct an IgG library from the thyroid tissue of a HT patient and isolate 
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a high affinity TPO antibody. All the above studies were carried out using the λ phage 
system and screening with radiolabeled purified human TPO. 
The introduction of the filamentous phage display methodology has had wide 
application in the analysis of human autoimmunity. In contrast to the λ phage system, in 
which the recombinant Fab is released into solution and not physically attached to the 
viral particle, highly diverse patient antibody repertoires can be readily enriched on a 
range of antigen preparations, including pure antigen, peptides, and even cell surfaces. 
Using the pComb3 phage display system three Fabs with high affinities for TPO were 
derived from a thyroidal library of a HT patient (Hexham, Partridge et al. 1994). 
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Figure1.12 Phage display cycle. 
The isolation of a specific phage for its binding to a target guides to the isolation of the 
corresponding gene, while the unbounded clones are removed from the selection. Five 
rounds of selection can be made, the end result of the enrichment, production of 
phages that are represented in low numbers in the original library. 
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1.5 Hypothesis 
Phage display is a powerful technique for the isolation of further examples of 
monoclonal antibodies to thyrotropin receptors.  
1.6 Aims 
 Clone the recombinant human M22 scFv into a phage vector and verify that we 
had synthesised the correct scFv by characterising the binding and thyroid 
stimulatory activities of the construct 
 Investigate the binding of the M22 scFv phage construct to TSHR (BRAHMS 
tubes), and use the data obtained to design panning protocols to recover TSHR 
antibodies from phage antibody libraries. 
  Clone the recombinant human M22 Fab into pComb and verify that we had 
synthesised the correct scFv by characterising the binding and thyroid 
stimulatory activities of the construct. 
 Investigate the binding of the M22 Fab phage construct to TSHR (BRAHMS 
tubes) 
 Investigate the use of different TSHR expression systems to optimise binding of 
phage antibodies. Finally we will use the results obtained to attempt the isolation 
of novel examples of TSHR antibodies and analyse the properties of these 
reagents. 
 construct a novel cell line in which a smaller region of the TSHR. 
 Production of Anti-Idiotypic Antibodies Targeted Against the M22 s Chain.  
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Plasmids, Bacterial Strains, and Phage 
Plasmid Source 
 
pAK100 
 
Prof. A Pluckthun, University of Zurich, 
Institute of Biochemistry 
 
pAK400 
 
Prof. A Pluckthun, University of Zurich, 
Institute of Biochemistry 
 
pComb3 
 
Prof CF Barbas, Scripps Research Institute,  
La Jolla, CA, USA 
 
pET-21a(+) 
 
Novagen 
 
pcDNA3 
 
Invitrogen 
2.1.2.1 pCOMB3 
The vector pComb3 was used in this study to clone and express Fab antibodies for 
phage display (Barbas, Kang et al. 1991). The plasmid expresses immunoglobulin 
heavy and light Fab chains from two separate lacZ promoters. Each chain is preceded 
by a pelB secretion leader which directs the expressed chains to the bacterial periplasm, 
where the redox environment favours disulphide bond formation and assembly of Fab 
fragments. The heavy chain is inserted upstream of the coding region for phage coat 
protein cpIII and is expressed as a N-terminal cpIII fusion, leading to incorporation of 
functional Fab onto the phage surface, Fig. 2.1. 
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Figure2.1 Cloning sites of phage display vector pComb3. 
Immunoglobulin heavy chains are cloned into the Xho I and Spe I sites and expressed 
as amino terminal fusions with phage protein cpIII. Light chains are cloned into Sac I 
and Xba I sites. Expression of both chains is driven by a lacZ promoter and secretion 
into the periplasm is directed by a pelB secretion leader. 
 
  
56 
 
2.1.2.2 pAK100 
This vector was designed to allow the expression of scFv on the surface of filamentous 
phage (Knappik and Pluckthun 1994).Single chain Fv fragments are expressed from a 
lacZ promoter as N-terminal fusions with a segment of the cpIII gene of filamentous 
phage. Fusion proteins are expressed into the periplasm via a pelB secretion leader and 
incorporated into nascent virions. Antibodies are cloned into two Sfi I restriction sites 
with non-complementary overhangs (Fig. 2.2). The vector features a 2 kb tetracycline 
resistance stuffer fragment which is inserted into the Sfi I sites and is replaced by cloned 
scFv genes. 
2.1.2.3 pET21a  
High level expression of recombinant proteins was achieved using the T7 expression 
vector pET21a (Novagen). The essential features of the vector are shown in Fig. 2.3.  
2.1.2.4 pcDNA 3.1  
Mammalian expression vector with a selectable resistance marker to ampicillin, and 
contains promoters for T7 and SP6 polymerases flanking a diverse multiple cloning site 
(Fig.  2.4). 
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The tetracycline-resistance cassette is used as a stuffer fragment (approximately 2000 
bp) that is replaced by cloned scFv genes. In pAK100 scFv genes are expressed as 
fused to the coding region of phage minor coat protein cpIII. The myc tag is expressed 
as a carboxy-fusion and facilitates the detection and purification of expressed scFv 
fragments. Between the myc tag and cpIII there is an amber stop codon and this allows 
expression of myc-tagged soluble scFv protein in a non-suppressive host. The inset 
shows the key differences between pAK100 and pAK400. In pAK400 the phage coat 
protein coding region is absent as is the myc tag. These are replaced with a carboxy-
terminal 6-histidine tag for protein purification.  
 
  
Figure2.2 Map of pAK100 vector. 
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Figure2.3 Cloning regions of the pET21a T7 expression vector. 
Coding sequences are cloned into the multiple cloning sites downstream of the T7 
promoter. The vector features an optional T7-tag and a [His]6 purification tag at the 
carboxy terminus. Expression is achieved by transformation into an appropriate host 
expressing T7 RNA polymerase. 
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Figure2.4 Mammalian expression vector pcDNA3. 
Mammalian expression vector contains CMV promoter and allows high level transient 
and stable expression in mammalian cells 
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2.1.3 Bacterial Strains and Helper Phage 
 
 
 
  
  
Genotype 
 
Source 
 
XL1-Blue  
 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1  
lac[F’ proAB lacIqZ ΔM15 Tn10(Tetr)] 
 
Stratagene, La Jolla, CA, USA 
 
VCSM13 
helper phage 
 
Kan
r 
 
Stratagene, La Jolla, CA, USA 
 
BL-21(DE3)-
pLysS 
 
F-,ompT, hsdSB (rB-,-mB-
)dcm,gal,λ(DE3),pLys, Cm
.
 
 
Promega 
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2.1.4 Media 
Bacterial growth media, which we used, are shown in the following table: 
 
Media 
 
Content 
 
SOC medium 
 
0.5% (w:v) yeast extract 
2% (w:v) tryptone 
1mM MgSO4·7H2O 
10mM NaCl 
1mM MgCl2·6H2O 
2.5mM KCl 
2mM glucose 
 
Luria-Bertani (LB) medium 
 
1% (w:v) tryptone,  
85.6mM NaCl,  
0.5% (w:v) yeast extract 
 
Luria-Bertani (LB) agar plates 
 
0.5% (w:v) yeast extract 
85.6mM NaCl 
5% (w:v) agar 
1% (w:v) Tryptone 
Selective antibiotic 
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2.1.5 Antibiotics 
All antibiotics were prepared as 1000x stocks, sterilised by filtration (Millipore) and 
used in medium at the final concentrations shown below. All antibiotics were obtained 
from Sigma Aldrich. 
 
Antibiotic 
 
Diluent 
 
Final Concentration 
 
Source 
 
Ampicillin 
 
H2O 
 
100 µg/ml  
 
Sigma-Aldrich 
 
Tetracycline 
Hydrochloride 
 
50% ethanol/ H2O 
(v:v) 
 
20 µg/ml 
 
Sigma-Aldrich 
 
Kanamycin 
 
H2O 
 
30 µg/ml 
 
Sigma-Aldrich 
 
Chloramphenicol 
 
50% ethanol/ H2O 
(v:v) 
 
30 µg/ml 
 
Sigma-Aldrich 
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2.1.6 List of the cell lines and materials used in the tissue culture 
 
 
Material 
 
Source 
 
Chinese hamster ovary cells(CHO-K1) 
 
European Collection of Animal Cell 
Culture (ECACC), Porton Down, UK. 
 
JP09 
 
Prof. G Vassart, Institut de Recherche  
Interdisciplinaire en Biologie  
Humaine et Moléculaire, Faculté de 
Médecine,  
Université Libre de Bruxelles, Belgium 
 
GPI-95 
 
Dr. P Watson (school of medicine, 
University of Sheffield) 
Mouse hybridoma A9 and A10  
Dr. JP Banga, Guys, King’s, and St 
Thomas’ School of Medicine, London 
Sterile Dulbecco’s minimal essential 
medium (DMEM) and foetal calf 
serum (FCS).  
 
Gibco BRL, Paisley, UK. 
 
 
Cell dissociation solution  
  
Gibco (Invitrogen Corp.) 
 
Sterile trypsin (0.25%) Ethylene Di-
amino Tetra Acetic acid (EDTA 
solution, Cat. 0180). 
 
Sigma-Aldrich Company, Irvine, Ayrshire, 
UK.  
T25 and T75 tissue culture flasks (Cat. 
Nu. 156367 and156499 respectively). 
 
Nunc™, Roskild, Denmark. 
Tissue culture sterile 6, 12, 24 and 96 
well plates.  
 
COSTAR®, Corning, USA. 
 
Tissue culture Petri dishes (100mm, 
Cat. Nu. 150350).  
Nunc™ (Thermo Scientific), Roskild, Denmark. 
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2.1.7 Western blotting materials 
 
Material 
 
Source 
PVDF membrane (GE Healthcare, 
Amersham Hybond-P PVDF 
membrane optimized for protein 
transfer, pack nu. RPN1416F). 
 
GE Health care. 
 
TEMED 
 
BDH, Poole, England (4430833) 
 
Sodium dodecyl sulphate (cat. Nu. 
444464T)  
 
BDH, Poole, England. 
 
Tris (hydroxymethyl) methylamine 
AnalaR® (cat Nu.  
 
BDH, Poole, England. 
 
Tris/glycine/SDS running buffer 10X 
(Cat. Nu. 161-0732).  
 
BIO-RAD laboratories, München. 
 
SDS-PAGE Transfer Buffer 10X 
 
BIO-RAD laboratories, München. 
 
Acrylamide/Bisacrylamide 
 
BioRad 
Ammonium persulphate 
2% (v: w) ammonium persulphate was made 
in sterile deionised H2O 
 
BDH, Poole, England (443073E) 
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 Constituents of Polyacrylamide Resolving and Stacking Gel  
Running (Resolving) gel 
 
Stacking gel 1.5% 
 10% 12% 
 
15% 
 
 
1 x 
(10 ml) 
 
2 x 
(20 ml) 
10ml 20ml 10ml 20ml 10ml 20ml 
Sterile H20 3.3 ml 6.6 ml 4.3 ml 8.6 ml 3.55 ml 7.1 ml 2.22 ml 4.45 ml 
Acrylamide 40% 
w:v 
2.3 ml 4.6 ml 3.0 ml 6.0 ml 3.75 ml 7.5 ml 375 l 750 l 
1.5 M Tris, pH 
8.8 
2.5 ml 5.0 ml 2.5 ml 5.0 ml 2.5 ml 5.0 ml 0 l 0 µl 
1 mM Tris, pH 
6.8 
0 ml 0 ml 0 ml 0 ml 0 ml 0 ml 380 l 760 l 
SDS - 10% 
 
100 l 200 l 100 l 200 l 100 l 200 l 30 l 60 l 
APS - 10% 
 
100 l 200 l 100 l 200 l 100 l 200 l 30 l 60 l 
TEMED  4.0 l 8.0 l 4.0 l 8.0 l 4.0 l 8.0 l 3 l 6 l 
APS = Ammonium per-sulphate (Freshly prepared), TEMED = N, N, N’, N’-
tetramethylethylenediamine, SDS = Sodium dodecyl sulphate.  
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Secondary Antibodies 
Anti-human IgG, (Fab specific)   Amersham Pharmacia Biotech 
F (ab)2 rabbit anti-mouse IgG-Biotin  Serotec 
Rabbit anti-mouse IgG-HRP   Amersham Pharmacia Biotech 
 
2.1.8 General Laboratory Solutions and Reagents 
  
Content 
 
Elution Buffer 
 
 
Glycine  3.755 g  
H2O   500ml 
pH   adjusted to 2.7  
 
Phage 
precipitation 
solutions 
40% PEG  
 
 
5M NaCl  
 
 
 
 
 
PEG 8000 200 g 
 H2O   500ml 
 
NaCl  146.1g 
H2O   500ml 
 
Coating Buffer 
 
 
Na2HCO3 2.93 g  
Na2CO3 1.59g 
NaN3  0.2 g 
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H2O   1 L  
pH   adjusted to 9.2 
 
 
Neutralizing  
Buffer 
 
 
Tris Base 2.42 g 
H2O  10 ml 
 
Tris-HCl 
 
 
Tris-HCl  60.55 g  
H2O  500 ml 
pH   adjusted to 8.0  
 
PBS (10x) 
 
 
NaCl   80 g 
KH2PO4  2.4 g 
Na2 HPO4  14.4 g  
KCl  2 g 
H2O   1 L 
 
50 X TAE buffer 
 
 
EDTA  50 ml 
Tris base  121g 
Acetic acid  28.6ml 
H2O   500 ml  
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2.2 Methods 
2.2.1 RNA Extraction 
Total RNA was extracted from cells using Trizol. Prior to the experiment, all pipettes to 
be used were incubated under a UV light for 10 min to minimize the DNA 
contamination. Cells were homogenized by the addition of 1 ml of Trizol and incubated 
at 37°C for 5 min. This was followed by the addition of 400 µl of chloroform, and 
centrifugation for 10 min at 8,000 g to separate the upper phase and RNA precipitated 
with isopropanol and pelleted by centrifugation at 13,000 g for 10 min. The supernatant 
was disregarded, while the pellet washed with 1 ml of 70% ethanol and centrifuged 
for10 min at 8,000 g. The pellet was finally resuspended in 40 µl of DEPC-treated 
distilled water.  
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2.2.2 Synthesis of cDNA 
Total RNA was used to synthesize cDNA using Moloney murine leukemia virus reverse 
transcriptase (MMLV-RT) (Promega) in a 60 µl reaction containing: 
RNA (approx 1 µg)      5 µl  
dNTPs (100mM)     6 µl 
Reverse transcriptase  (200 U/µl)    6 µl 
Reverse transcriptase buffer (5X)    12 µl 
Random oligonucleotide hexamers (0.5 µg/µl)  1 µl 
DEPC-H2O        30 µl 
The mixture were incubated at 37˚C for 5 min and then incubated at 40˚C for 1 h, 
followed by 75˚C for 10 min incubation, cooled down to 4˚C. 
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2.2.3 Polymerase Chain Reaction (PCR) 
PCR performed on many templates depending on the DNA to amplify. Prior to the 
experiment, all pipettes to be used were incubated under a UV light for 10 min to 
minimize the DNA contamination  
Each reaction contained the following (Promega): 
Mg
2+
 buffer (25 mM)         5 µl 
Promega reaction buffer (10X)               10 µl 
dNTPs (10 µM)         1 µl 
Primer mixture (1 µm each) 0.02 µM                                      2 µl 
Sterile distilled H2O                  34 µl 
Tag polymerase (5 U/µl)              0.25 µl  
The standard PCR parameters (unless stated in the results text) were as follows: 
Event Temperature Time Cycles 
Initial Denaturation 95°C 5 min 1 cycle 
Denaturation 95°C 30 s 
n cycles Primer annealing x°C 30 s 
DNA extension 72°C 1-2 min 
Final extension 72°C 10 min 1 cycle 
Final hold 4°C As required 1 cycle 
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2.2.4 Agarose Gel Electrophoresis 
Gel electrophoresis was used qualitatively to check the DNA preparations. Agarose gels 
(1%) was dissolved in TAE buffer and melted for 1 minute in a microwave oven. The 
molten agarose was cooled and ethidium bromide added. The molten agarose was 
poured into the casting deck, combs inserted and the agarose left to set. Once it set, the 
combs removed and covered with TAE buffer and 5 µl of PCR reaction was loaded into 
each well. A molecular weight marker lane was included; a voltage of 60-100 V was 
applied for 15-60 min. The agarose gel was visualized on a UV transilluminator and 
photographed. 
2.2.5 Purification of DNA fragments and PCR Products 
PCR products were extracted using the PCR Prep kit (QIAquick kit) according to the 
manufacturer’s instructions (Qiagen). In brief, gel slices or PCR reactions were mixed 
with 700µl membrane binding buffer and incubated at 50˚C until complete dissolving. 
The dissolved gel slices were passed through a column then washed with 700 µl and 
250 µl of washing buffer respectively. The excess wash solution was removed by 
centrifugation at 8,000 g for 2 min and eluted with 60 µl of TE.  
2.2.6 Phenol-Chloroform Extraction of DNA 
The DNA solution was made up to 200 µl in TE buffer and 200 µl of phenol: 
chloroform (1:1 v:v) (Fisher scientific) was added, mixed well and centrifuged for 10 
min at 13,000 g. The top layer was removed, avoiding the interface, transferred to a 
fresh tube and an equal volume of chloroform was added. The mixture was vortexed 
and then centrifuged at 8,000 g for 10 min and the top aqueous layer recovered. Purified 
DNA was precipitated with 2 volumes of ethanol and centrifuged at 8,000 g for 20 min. 
The supernatant was removed and the pellet dried and resuspended in TE buffer. 
2.2.7 Restriction Digest of DNA 
A typical digestion reaction is shown below: 
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Component Volume 
DNA 500 ng-1 µg 
Restriction enzyme buffer (10x)(Promega) 2 µl 
Restriction enzyme (10u/µ1) (Promega) 
1 µl 
Sterile water to a final volume of 100 µl 
 
For double digestion, the compatibility is checked according the manufactures’ charts. 
If two enzymes were known to have 100-75% activity in the same buffer, then double 
digestion of the DNA was carried out in a single reaction. Digestion reactions were 
incubated according to the manufacturer's instructions. To ensure correct digestion of 
each reaction a sample of known volume was mixed with the appropriate volume of 6X 
DNA agarose gel loading buffer and analysed by agarose gel electrophoresis. 
2.2.8 Ligation of DNA 
 A typical ligation reaction as follows: 
Component Volume 
Insert 60 ng 
Vector 100 ng 
 
DNA ligase 
 
0.5-1 µl 
 
Ligase buffer  
2 µl 
Sterile water to a final volume of 20µl 
  
Reaction was incubated at room temperature for 3 h. 
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2.2.9 Heat Shock Transformation 
50 µl aliquot of one shot E. coli was thawed on ice, 3 µl of cloning reaction was 
added to the vial and mixed gently, incubated on ice for 5 min, then transferred 
the tube to a preheated water bath at 42˚C for 30 s without shaking. Rapidly the 
vial was placed on ice and allowed to chill for 2 min. 250 µl of S.O.C media was 
added to the contents of the tube. The culture was incubated at 37˚C with 
shaking for1 hour. The transformed cells ware plated out onto LB agar plate 
containing appropriate selective antibiotic and incubated overnight at 37˚C. 
Random colonies were picked from the plate and sub cultured into 10ml 
medium containing appropriate antibiotics and incubated at 37˚C in shaking 
incubator. DNA was extracted by miniprep and tested by sequencing analysis. 
2.2.10 Electroporation of XL-1 Blue 
Aliquot of electrocompetent XL1- Blue cells were thawed on ice and placed in 0.1 cm 
cuvette. 5-10 µl of DNA or the ligation reaction to be transformed was added to the 
cells and mixed gently, and the cuvette placed into the electroporation machine (E. coli 
Pulser, BioRad) and a pulse of 1700 V applied. The cuvette was washed out with 1ml 
SOC medium (GIBCO), and transferred to a universal container, then incubate it for one 
hour in a 37˚C with shaking. The cells were placed on selective agar media and 
incubated for 18 h at 37˚C. 
2.2.11 Preparation of Plasmid DNA (Miniprep Purification of DNA) 
A single colony was picked from freshly streaked agar plate containing appropriate 
antibiotics. The culture was grown at 37˚C with shaking over night. Then the 10 ml 
cultures centrifuged at 2000 g for 10 min and the pellet resuspended in 250 µl of cell 
resuspension solution and transferred to microcentrifuge tube. A further addition of 250 
µl cell lysis buffer and the samples gently mixed prior to incubation at room 
temperature for 5 min and neutralised by addition of 350 µl neutralisation buffer. The 
mixture was centrifuged for 5 min at 13,000 g; the supernatant was passed through a 
mini column then washed with 700 µl and 250 µl of washing buffer respectively. DNA 
eluted with 100 µl of nuclease free water. 
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2.2.12 Isolation of Plasmid DNA by Midiprep Procedure 
The Wizard midiprep kit (Promega) was used according to the manufacturer’s 
instructions, to purify 10 µg-200 µg of plasmid. Briefly 100 ml cultures were 
centrifuged at 13,000 g for 1 min and the pellet suspended in 3 ml of cell resuspension 
solution (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 100 µg/m1 RNase A) the cells were 
lysed by addition of 3 ml cell lysis solution (0.2 M NaOH, 1% SDS) and then 
neutralized by addition of 3 ml neutralization solution (1.32 M potassium acetate, pH 
4.8) the solution was mixed gently and centrifuged at 13,000 g for 15 min, the 
supernatant was mixed with 10 ml Wizard midiprep DNA purification resin and loaded 
onto a Wizard midi column and washed two times with 15 ml column wash solution (80 
mM potassium acetate, 8.3 mM Tris-HCl pH 7.5, 40 µM EDTA, 55% ethanol). Wizard 
midi column was centrifuged for 2 min at 13,000 g to remove excess column wash 
solution and resuspended in 400 µl of sterile H2O. 
2.2.13 Chemically Competent Cell Preparation 
The chemically competent E. coli strain XL1-Blue cells were used to transform 
different plasmids and they were prepared according to the following protocol. About 
10 µl of the XL1-Blue glycerol stock was streaked on a fresh LB/Tet agar plate and 
incubated at 37°C for overnight. Next day, one well-isolated colony was picked up from 
the plate and grown in 2 ml of selective LB/Tet broth media for 6 h at 37°C in an orbital 
shaker. The cells then seeded with 0.5ml of the bacterial culture into 50 ml LB/Tet 
media and returned to the 37°C shaker for overnight. Next day, 30 ml of the overnight 
culture were transferred into 400 ml of a pre-warmed LB/Amp media and grow until 
OD600 = 0.9. The cells centrifuged at 4000 rpm for 20 min at 4°C in H6000 rotor. The 
pellet was resuspended in 100 ml of sterile and ice cold 0.1 M MgCl2 solution and re-
centrifuged again. The pellet resuspend in 100 ml of a sterile and ice cold 0.1 M CaCl2 
and left on ice for 1 hour before another spin. The pellet was finally resuspended in 25 
ml of 85 mM CaCl2 plus 15% glycerol and aliquoted into chilled 1.5 ml eppendorf tubes 
(400 µl/tube) and frozen immediately in liquid nitrogen. Cells were then stored at -
80°C. 
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2.2.14 Preparation of Bacterial Glycerol Stocks 
Glycerol stocks were prepared by mixing 1 volume of culture with 1 volume of 50% 
glycerol and stored at -80˚C.  
2.2.15 Rescue of Library Displaying Phage 
Library rescue describes the process by which phage libraries are converted into phage 
particles prior to enrichment. 10 ml LB media contain an appropriate antibiotic 
inoculated with 10 µl of glycerol stock of cells that contain cloned antibody fragments 
(scFv or Fab) and grown at 37˚C. After the culture becomes turbid, 15 µl VCMS13 
helper phage (10
11
 plaque forming units (pfu)/ml) (Stratagene) was added and incubated 
at 37˚C for 15 min. The culture was then transferred to 100 ml LB medium containing 
appropriate selective antibiotics and grown at 37˚C overnight. The culture was 
centrifuged for 15 min at 2000 g. Supernatants were transferred into a 100 ml glass 
measuring cylinder containing 10 ml of 5 M NaCl and10 ml of 40% PEG 4000, mixed 
and incubated on ice for 2 h to precipitate the phages. The mixture was centrifuged for 
30 min at 2000 g to harvest the phages and the pellet resuspended in 1 ml of 
PBS/Tween. Stocks with titres of 10
10
- 10
11
 colony forming units (cfu)/ml typically 
were obtained in this way. 
2.2.16 Preparation of Host Cells 
10 µl of commercial XL1-Blue glycerol stock added to 10 ml LB medium containing 
appropriate antibiotics. The culture was incubatedat 37˚C with shaking until become 
turbid (4-6 h).  
2.2.17 Titration of Phage Library 
The phage library was diluted serial dilution and 5 µl of 10
-4 
phage were used to infect 1 
ml of fresh host cells at 25˚C for 20 min. 10 µl of infected host cells were plated on agar 
plates containing appropriate selective antibiotics, and incubated at 37˚C over night. 
The colonies were counted and phage titre (cfu/ml) calculated.  
2.2.19 General Enrichment Procedure for Phage Display Libraries 
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The phage enrichment (biopanning) procedure is based on affinity selection. In general 
this involves the capture of phage particles that have specific ligands on their surface 
using a solid surface coated with a specific target. In this case library screening was 
carried out by immobilized antigen on ELISA wells. The ELISA well was coated 
overnight at 4ºC of coating buffer containing 5 µg of selective ligand (immobilised IgG) 
or antigen. The following day the well was washed 3 times with 400 µl of PBS/Tween 
(0.1% v:v) and blocked for 1 h with 400 µl of 3% BSA (w: v) in PBS/Tween 1 h at 
room temperature. After blocking the wells were washed 3 times with PBS/Tween and 
100 µl of phage library was added. The well was incubated for 1 h at room temperature 
the unbound phage removed by washing 6 to 8 times with 400 µl PBS/Tween. In this 
step particles showing low affinity for immobilized target are washed away, leaving the 
strongly bound particles attached to the target. The enriched population, remaining 
bound to the target after the stringent washing, was then eluted with acidified glycine 
(0.2 M, pH 2.2). The eluted phage were used to infect host and generate an enriched 
library. The process was assessed by monitoring the number of phage being eluted each 
round and in a typical enrichment procedure the elution rate increased some 50,000 fold 
over 3 to 4 rounds of selection (Fig 2.5). 
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Figure2.5 Schematic Diagram for Panning Process. 
The phage display antibody enriched by affinity selection using immobilized TSH 
receptor. The non-bound phage washed out and the captured phage eluted and used 
to re-infect the host and to generate enriched library. This enrichment process was 
repeated 4-5 times to isolate a high affinity TSAb.  
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2.2.18 High Level Expression of Recombinant Protein from pET21a 
2.2.18.1 Pilot Scale Expression 
Transformation of recombinant proteins was achieved by using Novagen Competent 
Cells (BL21 (DE3) pLysS) according to manufacturer’s instruction, to express plasmid 
of interest from 10 ml cultures. Briefly, 50 μl of competent cells were transformed with 
1 μl of the pET-21a construct and plated onto LB agar plates containing the selective 
antibiotics (100 µg/ml ampicillin, 34 µg/ml chloramphenicol, 1% glucose (w: v)), and 
incubated overnight at 37°C. A single colony was picked from freshly agar plate were 
used to seed 3 ml of fresh LB medium containing 100 µg/ml ampicillin, 34 µg/ml 
chloramphenicol, and 1% glucose.The culture was grown over 5 h in a 37ºC shaking 
incubator set at 200 rpm. Then 10 µl of the grown culture was transferred into 10 ml of 
fresh LB medium, leave it grown overnight in a 37ºC shaking incubator set at 200 
rpm.Next day about 0.5 ml of the grown cells was transferred into 10 ml of fresh LB 
medium. The cells were grown at 37ºC, 200 rpm until OD600nm ~ 0.4 and expression was 
induced with 1 mM final concentration of IPTG (isopropyl β-D-1-
thiogalactopyranoside). Cells were incubated at 37ºC for 3 s post induction, and 
harvested by centrifugation at 4000 rpm for 10 min; the pellets were stored at -20ºC. 
The pellets were resuspended in 250 µl of PBS with complete proteases inhibitors 
cocktail. Cells were then lysed with sodium deoxycholate (Sigma) final concentration of 
25 mg/ml and sonicated four times for 10 s each time placed on ice. The cell lysate were 
then centrifuged at 13,000 rpm for 10 min and the supernatant saved as soluble fraction 
protein (SFP). The pellet then washed and resuspended in 250 µl of H2O as an insoluble 
fraction protein (IFP). The protein fractions were then analyzed by SDS-PAGE and 
western blotting.  
2.2.18.2 Subcellular Fraction Solubilisation Test 
The pellets above resuspended 1: 10 w:v in lysis buffer 1 (25 mM Tris, 200 mM NaCl, 
20 mM imidazolepH 8.0 with two mini-tablet protease inhibitor cocktail free EDTA in 
50 ml), and mixture incubated on ice for 30 min. The mixture was sonicated on ice (4 X 
30 sec cycles), then centrifugation at 40,000 g for 30 min and the supernatant saved as 
soluble protein fraction (SPF1). The pellet was resuspended 1:5 w:v in lysis buffer 2 (10 
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mM Tris-HCl, 10 mM DTT pH 8.0 with two mini-tablet protease inhibitor cocktail free 
EDTA in 50 ml), and sonicated on ice (1 x 30 s). Lysozyme was added to a final 
concentration of 500 µg/ml and mixture incubated on ice for 30 min. The mixture was 
sonicated on ice (4 x 30 s cycles), and inclusion bodies pelleted by centrifugation at 
40,000 g for 30 min. The supernatant saved as soluble protein fraction (SPF 2). The 
pellet was resuspended in 25 ml wash buffer (10 mM Tris, 10 mM DTT, pH 8.0 with 
1% Triton X100 (v:v)), and sonicated on ice (2 x 60 s cycles). Inclusion bodies were 
pelleted by centrifugation at 40,000 g for 30 min and wash step repeated 4 more times. 
An additional one washing step using H2O instead of wash buffer were included to 
remove excess washing buffer. After the final centrifugation step the pellet was 
resuspended in 5 ml H2O. The protein fractions and washes were analyzed by SDS-
PAGE with 15% (v:v) polyacrylamide concentration. 
 
2.2.18.3 Large Scale Expression of Recombinant Proteins 
A single colony carrying the selected plasmid construct was picked from a fresh agar 
plate and used to seed 10 ml of fresh LB medium containing 100 µg/ml ampicillin, 34 
µg/ml chloramphenicol and 1% glucose. The culture was grown over 5 h in a 37ºC 
shaking incubator set at 200 rpm. Then 100 µl of the grown culture was transferred into 
100 ml of fresh LB medium, leave it grown overnight in a 37°C shaking incubator set at 
200 rpm. The next day the cultures of 100 ml were centrifuged at 4000 rpm for 3 min 
and the pellet was transferred in 1 L of TB media in 2.5 L flasks. The cells were grown 
at 37ºC, 200 rpm until OD600nm was approximately 0.4 and the recombinant protein was 
induced with 1 mM final concentration of IPTG (isopropyl β-D-1-
thiogalactopyranoside) for 3 h. Cells were incubated at 37ºC for 3 h post induction and 
harvested by centrifugation at 4000 g for 30 min; the pellets were stored at -80ºC.  
2.2.19 Solubilisation, Refolding and Purification of Inclusion Body Material 
2.2.19.1 Inclusion Body Preparation 
Inclusion bodies were prepared by enzymatic lysis: The pellet from 1 L original culture 
was resuspended in 100 ml ice cold breakage buffer (10 mM Tris-HCl, 10 mM EDTA, 
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pH 8.0), lysozyme was added to a final concentration of 250 µg/ml and mixture 
incubated on ice for 30 min.sodium deoxycholate was added to a final concentration of 
500 µg/ml and incubated on ice for 30 min. The mixture was sonicated on ice (5 x 10 
second cycles) and inclusion bodies pelleted by centrifugation at 13,000 g for 30 min. 
The pellet was resuspended in 10 ml wash buffer (10 mM Tris, 10 mM EDTA, 2% 
sodium deoxycholate, pH 8.0) and sonicated on ice (2 x 10 s cycles). Inclusion bodies 
were pelleted by centrifugation at 13,000 g for 30 min and wash step repeated two more 
times, the final wash used H2O instead of wash buffer. Inclusion bodies were pelleted 
by centrifugation at 13,000 g for 30 min and the final inclusion body prep resuspended 
in 10 ml H2O. Inclusion bodies were analysed by 12% SDS-PAGE, following the 
protocol of Laemmli (Laemmli 1970). 
 
2.2.19.2 Solubilisation and Refolding of Inclusion Body Material 
Inclusion bodies were solubilised in 100 ml ice cold solubilisation buffer (40 mM Tris, 
4.5 M urea, 10 mM cysteine, pH 11.5) and stirred at 4ºC overnight. The next day the 
solution was diluted in an equal volume of arginine buffer (40 mM Tris, 500 mM L-
arginine, 10 mM cysteine, pH 11.5) to give a final arginine concentration of 250 mM. 
The solution was stirred at 4
˚
C for overnight; the next day the cleared solution dialysed 
against 30 L of dialysis buffer (10 mM Tris, pH 9.0) at 4ºC, with 5 buffer changes over 
a 48 h period. The success of refolding was assessed at this stage (pre-purification) by 
the monomeric content of the refolded protein; as determined by Coomassie stained, 
non-reduced 12% SDS-PAGE (Laemmli 1970). 
2.2.20 Preparation of bacterial cell extracts by using osmotic shock method 
Periplasmic fractions were prepared by centrifugation of the induced culture at 2000 g 
for 10 min, the supernatant was retained for further analysis, and the bacterial pellet was 
used for periplasmic extraction, using osmotic shock method. The bacterial pellet was 
washed twice with 20 ml of ice cold 10 mM Tris-HCl pH 8, and resuspended in 30 ml 
of 30 mM Tris-HCl pH 8, 20% sucrose and 60 µl 0.5 M EDTA pH 8. The suspension 
was stirred slowly for 15 min at room temperature then centrifuged at 13,000 g for 10 
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min at 4ºC. The supernatant was discarded and the pellet was resuspended in 30 ml of 
ice cold 5 mM MgSO4 and stirred slowly on ice for 10 min. During this step, the 
periplasmic proteins are released into the buffer. The mixture was then centrifuged at 
13,000 g for 10 min at 4ºC, to pellet the shocked cells; the supernatant containing the 
periplasmic fraction was collected and used for further analysis. The total cell protein 
was prepared by centrifugation of the culture at 2000 g for 10 min, the supernatant was 
removed for further analysis and the bacterial pellet resuspended in 0.1 culture volume 
of PBS containing protease inhibitors (Roche Diagnostic). Cells were disrupted by three 
freeze and thaw cycles (using liquid nitrogen and 37ºC water bath) and between each 
freezing and thawing the cells sonicated for 8-10 bursts to lyse the cells. The 
membranes were pelleted by centrifugation at 2000 g for 10 min at room temperature. 
Supernatant containing soluble protein was retained and stored at -20ºC.  
All the samples fractions were concentrated under nitrogen pressure in a micro-
concentrator (Amicon) and the protein content was estimated by Bradford assay and by 
measurement of the OD280. All samples were stored at –20ºC until required for further 
purification and analysis.  
 
2.2.21 Protein purification 
 2.2.21.1 Purification of His-Tagged Recombinant Proteins by IMAC 
Recombinant proteins were purified by one-step affinity chromatography using a Ni-
MAC column (1 ml bed volume and binding up to 30 mg His-Tag fusion protein), 
equilibrated with 5 column volumes of 1x MAC binding buffer (300 mM NaCl, 50 mM 
Na phosphate, 10 mM imidazole, pH 8.0). Refolded sample was loaded onto the Ni-
MAC column at a flow rate of 1 ml/min and the flow through was collected as FT 
fraction and stored at -80˚C. The column was washed with 10 column volumes of 1 x 
MAC binding buffer. Then the column was washed with 6 column volumes of 1 x MAC 
washing buffer (300 mM NaCl, 50 mM Na phosphate, 20 mM imidazole, pH 8.0); 
collect the binding and washing buffer fractions as W1, W2 and stored at -80ºC. 
Refolded proteins was eluted in a stepwise manner with 1 x MAC elusion buffer (300 
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mM NaCl, 50 mM Na phosphate, 0.25 mM imidazole, pH 8.0), at a flow rate of 1 
ml/min, collecting 0.5 ml fractions. Fractions were stored at -80ºC. The monomeric and 
dimeric content of peak fractions was determined by Coomassie stained, non-reduced 
15% SDS-PAGE (Laemmli 1970). The cleared purified protein dialyzed again against 2 
L of dialysis buffer (300 mM NaCl, 10 mM Tris pH 8.0) at 4ºC, with two buffer 
changes over a 24 h period and then the pure protein concentration was determined by 
Bradford assay according to manufacturer’s instruction and OD600nm recorded. 
 
3.2.21.2 Purification of IgG using Protein G columns 
IgG were purified from culture by using a protein G Sepharose column (GE Healthcare 
Life Sciences). Before applying the sample, the resin was equilibrated with 10 mM 
sodium phosphate buffer (10 column volumes). After the centrifugation of sample at 
15,000g for 10 min or filtration by a 0.22 µm filter. Sample was loaded to the column at 
an optimised1 ml/min flow rate. The sample passing throughout the column was 
collected and labelled. The column was then washed with phosphate buffer (10 column 
volumes) until the UV trace come again to baseline level. The IgG was eluted by adding 
6 ml of 0.1 M glycine, pH 2.7 (elution buffer) at a flow rate of 0.5ml/min. The eluted 
fractions were collected and neutralised with 1 M Tris/HCl pH 8 to prevent IgG 
denaturation. The protein content of the eluted fractions were then measured by 
Bradford assay and dialysed by using dialysis tubing of 8000 M.wt cut off in 5 L of 1 x 
Tris, with three buffer changes each 12 hours. The column re-equilibrated with 
phosphate buffer (5 column volumes) and after that the protein G column washed with 
phosphate buffer (10 column volumes) and stored in 20% ethanol. All purified proteins 
were stored at -80 ºC. 
2.2.22 Protein Content Estimation (Bradford assay) 
A rapid estimation of the protein content was performed using the Bradford assay. The 
method employed was adapted from (Bradford 1976) and utilizes the principle of 
protein-dye binding to measure microgram quantities of protein. A standard curve was 
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set up with bovine serum albumin (BSA) as follows. A solution of 10 mg/ml BSA was 
prepared in double distilled water and diluted 100 µg/ml.  
 
Volume of stock H2O (ml) BSA Conc. (µg/ml) 
2.0 ml of 100 µg/ml 6 25 
2.5 ml of 25 µg/ml 2.5 12.5 
2.5 ml of 12.5 µg/ml 2.5 6.25 
2.0 ml of 6.25 µg/ml 3 2.5 
2.0 ml of 2.5µg/ml 2 1.25 
 
From each sample above, 800 µl were mixed with 200 µl of the Bradford reagent in 
plastic 0.1 cm cuvette and incubated for 5 min at room temperature. The readings were 
taken for all samples at OD595nm and plotted graphically as the protein standard curve 
for the assay. Every sample to be measured was mixed with 200 µl Bradford reagent 
plus the necessary amount of distilled water in order to make up a sample volume of 1 
ml in a plastic 0.1 cm cuvette. The reading values were taken as mentioned and they 
were plotted against the BSA standard curve of measurements. The protein 
concentration in each sample was calculated by direct comparison of the OD595nm 
against the standard curve values (Sambrook et.al, 1989). 
2.2.23 SDS-PAGE 
The samples were fractioned by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The apparatus used for SDS-PAGE analysis was the 
protean II and miniprotean II (Bio-Rad). The composition of all solution and reagents is 
given in Appendix I. Plates were washed and assembled with 1mm spacers for the 
miniprotean II and 18mm spacers for the protean II. 10% polyacrylamide resolving gel 
mixture was prepared and poured between the plates. After polymerization, the 4% 
stacking gel was prepared, poured onto the resolving gel and a comb inserted. After 
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polymerization, the gel was covered in Laemmli buffer and samples, mixed with sample 
buffer (1:1) and heated at 85ºC for 5 min and loaded along with 5 µl Pre-stained SDS-
PAGE standards low range markers (Bio-Rad). The gel was run at a current of 35 mA 
until the dye front had reached the bottom of the resolving gel. The gel was visualized 
by covering with Coomassie blue stain overnight, and destaining with several changes 
of Coomassie blue destain until the bands were clearly visible. Subsequently the gel was 
dried at 65ºC for 1-2 h on a Bio-Rad model 583-slab gel drier.  
 
2.2.24 Western Blotting 
Proteins were separated by SDS-PAGE (2.2.20). The gel and 0.45µm nitrocellulose 
membrane (Bio-Rad) were placed in transfer buffer for 30 min to equilibrate. The 
transferred unit consisted of 9 sheets of wetted 3MM paper (Whatman) followed by a 
sheet of nitrocellulose, the gel and 9 more sheets of wetted 3 MM paper, and was set up 
on a semi-dry electrophoresis apparatus (Genetic Research Instrumentation) at 4C and 
proteins were transferred at 25mA overnight. After transfer the nitrocellulose membrane 
was stained with amido black for 5 min and subsequently destained with amido black 
destain. The membrane was then cut into strips and stored in foil at –20C or used 
immediately. The nitrocellulose strips were blocked for 1 h at room temperature with 
5% skimmed milk PBS/0.05% Tween. After blocking, strips were incubated with 
appropriate primary antibody at appropriate dilution in 1% skimmed milk PBS/0.05% 
Tween for 2 h at room temperature. The membrane was then washed 4 times with 
PBS/0.05% Tween and incubated with appropriate dilution of HRP conjugated 
secondary antibody diluted in 1% skimmed milk PBS/0.05% Tween for 1-2 h at room 
temperature. After this incubation washed 4 times with PBS/Tween and immersed in 
ECL substrate solution (Roche Diagnostic) according to manufacturer’s instructions for 
1 min. Then the nitrocellulose membrane strips were placed on an acetate sheet and 
covered with Saran wrap. The acetate was exposed to X-ray film (Fujifilm) for a period 
1-10, and up to 30 min, and then the film was developed and fixed.  
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2.2.25 Transfection of Mammalian Cells Using Lipofectamine 
Cells to be transfected were seeded at a density of 5 x 10
4
 cells/ml and plated out 
according to the size of the plate as; 1ml/well was added into 12-well plates and 2 
ml/well into 6-well plates and 10 ml/dish when 100 mm culture dishes were used. Cells 
were then grown in their respective culture media without antibiotics until they reached 
90-95% confluence. The Lipofectamine transfection was carried out at 1:2.5 DNA 
(µg):Lipofectamine (µl) ratios as per manufacturer’s instructions. In separate tubes, the 
DNA and the Lipofecatime reagent were diluted in OptiMEM medium depending on 
the type of the plate used according to the following table: 
Culture vessel DNA in dilution 
media 
Lipofectamine in 
dilution media 
12-well 1.6µg in 100µl 4µl in 100µl 
6-well 4µg in 250µl 10µl in 250µl 
100mm 24µg in 1.5ml 60µl in 1.5ml 
Tubes were then incubated at room temperature for 5 min. The DNA and the 
Lipofectamine tubes then mixed together and incubated for further 25 min at room 
temperature. The DNA-Lipofectamine complexes then added to the well containing 
cells and medium. Cells incubated at 37°C in a CO2 incubator for 24-48 h until they 
were ready to be tested for the transgene expression. 
 
2.2.26 Development of Stably Transfected Mammalian Cell Lines 
To select stable transfected cells at the end of incubation period, the cultures were re-
plated in 100 mm dish at 1:20, 1:200 and 1:500 dilutions in culture medium containing 
400 µg/ml 600 µg/ml, 800 µg/ml and 1000 µg/ml G418. The cells were incubated at 
37ºC in a 5% CO2 incubator for appropriate length of time around 3 weeks before 
analysis, with changing of media every 2-3 days. When complete cell death had 
occurred in untransfected CHO-K cells in control dishes, the clumps of transfected cells 
remaining were removed from dish and transferred to 24 well plates and grown in media 
containing G-418 at 400 µg/ml, 600 µg/ml, 800 µg/ml and 1000 µg/ml. Cells were 
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grown until confluent and split between two 24 well plates. When cells were confluent, 
one 24 well plate was used to analyse the clones for expression of protein by cells 
ELISA and FACS, and any clones that were positive were grown and maintained in 
media containing appropriate concentration of G418. 
2.2.27 Flow Cytometry (FACS) 
FACS analysis was carried out on a Becton Dickinson FACScan flow cytometry using 
Cell Quest date acquisition and analysis software. Briefly, the cells were grown in 
appropriate media until confluence in T75 tissue culture flask. The cells were gently 
washed with PBS, detached from culture flasks using 3 ml cell dissociation solution 
(Sigma), and incubate for 3 min. After the cells dissociated, the cells were washed with 
5 ml of appropriate media using a syringe and needle, centrifuged at 1000 g for 3 min, 
and resuspended in 1 ml of media. Cells were counted, resuspended at the density of 1 x 
10
7
 cells/ml and 100 µl aliquoted into LP4 tubes (Becton Dickinson Labware). The 
appropriate monoclonal antibody, diluted to manufacturer’s instructions, or samples was 
added to the cells, thoroughly mixed and the reaction incubated for 20 min on ice. After 
washing twice with 2 ml PBS centrifuged at 1000 g for 3 min and resuspended in 
appropriate diluted FITC-conjugated antibody and incubated on ice for 20 min. After a 
final wash, cells were analysed using a fluorescence activated cell sorter (FACScan, 
Becton Dickinson). 
 
2.2.28 Enzyme-linked Immunosorbent Assay (ELISA) 
The general ELISA protocol utilised is outlined below and specific modifications are 
detailed in the appropriate section. The protein required to coat the plate was diluted to 
the desired concentration in coating buffer and 100 µl aliquoted into each well of a 96 
well flat bottom ELISA plate (Costar), the plate was covered with parafilm and 
incubated overnight at 4ºC. After three times washing with PBS/0.05% Tween, 300 µl 
of blocking solution (3% BSA in PBS/0.05% Tween) was added to each well and 
incubated at 37ºC for 1 h. After once washing with PBS/0.05% Tween, 100 µl of the 
sample or antibody (diluted as detailed in manufacturer's instructions) was added to 
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each well and incubated at room temperature for 2 h. Each well was washed three times 
with PBS/0.05% Tween and 100 µl of the appropriate dilution of alkaline phosphatase 
conjugated anti-IgG added to each well. After incubation at room temperature for 1 h, 
each well was washed three times with PBS/0.05% Tween and 100 µl of freshly 
prepared phosphatase substrate solution (Sigma Fast p-nitrophenyl phosphate) was 
added to each well. The plate was incubated at room temperature for 15-30 min until 
colour development occurred and 100 µl of stopping solution was added and the 
OD405nm was measured in the platereader. All samples were tested in duplicate and 
results were presented graphically as the mean of absorbance of each sample verses the 
sample. Known positive or negative controls if available were used in each plate 
  
2.2.29Cell ELISA 
GPI95 and CHO-K1 cell lines media were removed, and the cells were washed in 1 x 
PBS before incubation with Trypsin-EDTA for 3 min at 37°C. The then cells dislodged 
by gently tapping the side of the flask and resuspended in 10 ml of the complete 
medium. Cells then centrifuged at 1000 rpm in a 25 ml universal centrifuge tubes for 5 
min. The cell pellets were resuspended in the appropriate medium and cells were 
counted in a haemocytometer before plating out 75,000 cells per ml, 200 ul in each well 
of a Poly-D-Lysine 96-well ELISA plate (15,000 cells per well). the plate was incubated 
overnight at 37°C in a CO2 incubator. After three times washing with PBS, 300 µl of 
blocking solution (FCS in cells media) was added to each well and incubated at 37ºC 
for 1 h. After once washing with PBS, 100 µl of the sample or antibody (diluted as 
detailed in manufacturer's instructions) was added to each well and incubated at room 
temperature for 1 h. Each well was washed three times with PBS and 100 µl of the 
appropriate dilution of HRP- conjugated anti-IgG added to each well. After incubation 
at room temperature for 1 h, each well was washed three times with PBS and 100 µl of 
freshly prepared substrate solution was added to each well. The plate was incubated at 
room temperature for 15-30 min until colour development occurred and 100 µl of 
stopping solution was added and the OD450nm was measured in the platereader. All 
samples were tested in duplicate and results were presented graphically as the mean of 
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absorbance of each sample verses the sample. Known positive or negative controls if 
available were used in each plate 
 
2.2.30 Preparation of Mammalian Cell Extracts  
Following incubation for 48-60 h transfected cells were washed 3 times with 5 ml of ice 
cold PBS and finally scraped off the well in 2 ml of ice cold PBS and transferred to a 
universal. The cells were pelleted by centrifugation at 3000 rpm for approximately 3 
min at 4ºC, the supernatant removed, and the cells resuspended in 1 ml of PBS and 
transferred to an eppendorf. The cells were pelleted by centrifugation at 13,000 rpm for 
30 s and a lysate prepared by re-suspending the pellet into 200 µl of 1% SDS denaturing 
lysis buffer (pre-heated to 90ºC and allowed to cool slightly). The resultant solution was 
passed through a 23G needle 20 times to shear genomic DNA and reduce viscosity, 
centrifuged at 13,000 rpm for 1 minute to remove any insoluble material and the 
resulting supernatant stored at -80ºC. The cell lysate then concentrated 25 times by 
using a micro-concentrator (Amicon) and the protein content determined by Bradford 
assay. Untransfected HEK293 cells as a negative control as well as a positive control 
cells were subjected to the same protocol. 
 
2.2.31 Triton X-114 Phase Partitioning of GPI-linked Proteins 
Triton X-114 phase partition is one of the preferred methods for separation of the GPI-
anchored proteins from crude cellular homogenates. This is because these proteins carry 
a hydrophilic lipid moiety (glycosylphosphatidylinisitol) attached to them.Therefore, 
under temperature-induced phase separation of Triton X-114/water, membrane and GPI-
anchored proteins partitioned into the detergent enriched phase. We applied this method 
to show that our GPI-anchored proteins are able to separate into the detergent phase and 
thus show evidence of the presence of the lipid moiety. Briefly, The GPI construct 
transfected cells (1x10
6
) were washed in PBS and lysed in 250 µl of lysis buffer (20mM 
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 2% Triton X-114, 0.1 mM PMSF, protease 
inhibitor cocktail tablets (1 tablet/10 ml) and 0.0005% bromophenol blue) in an 
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eppendorf tube. Cells were then left on ice with frequent stirring for 20 min. The 
resulting lysate was centrifuged at 13,000 x g for 5 min at 0ºC to remove cellular debris. 
The coloured supernatant was then collected into a fresh tube and incubated at 30ºC for 
5 min for phase separation. Tubes were then centrifuged briefly at 4,000 x g for 3 min at 
room temperature to separate the clear aqueous phase from the detergent phase 
containing bromophenol blue. The two phases were collected gently and analysed by 
western blotting for the target proteins. 
2.2.32 TSHR Stimulation Bioassay 
The cAMP stimulatory activity of the recombinant scFv or Fab antibody fragments 
were assessed by determining the amount of cAMP produced from CHO-K1 cells 
transfected with full length of TSHR (JP09 cells) (2.1.3). In brief, the JP09 cells were 
seeded at 10
5
cells/ml in 24 well plates 48 h before the cAMP assay. These cells were 
maintained under 5% CO2 at 37ºC and cultured in nutrient mixture F-12 (HAM) 
medium supplemented with 10% foetal calf serum, 1% 200 mM glutamine, 1% 10 
mg/ml penicillin/streptomycin and 400 µg/ml G-418. After the culture medium was 
removed, cells were pre-incubated with 500 µl of hypotonic Hanks’ balanced salt 
solution (HBSS) containing 1.5% BSA and 0.5 mM 3-isobutyl-1-methylxanthine 
(IBMX) for 20 min at 37ºC. The samples or controls (positive and negative) were then 
added into each corresponding well, mixed with the 500 µl of HBSS and incubated at 
37ºC for 2 h. The cell culture supernatant was collected and the amount of extracellular 
cAMP was determined with a commercial cAMP immunoassay kit (R&D Systems) 
according to manufacturer’s instructions. Briefly, 100 µl of the calibrator diluent was 
added to the first two wells as the zero standard wells. 100 µl of standards 
concentrations and unknown samples then added to the corresponding wells in 
duplicates; 200, 100, 50, 25, 12.5, 6.25 and 3.125 pmol/ml. 50µl of the primary 
antibody solution was then added to each well followed by 50µl of the cAMP conjugate. 
The plate was covered with adhesive strip and incubated for 3 h at room temperature on 
a horizontal orbital microplate shaker set at 500±50 rpm. Each well then aspirated and 
washed three times with 400 µl of the wash buffer. After the last wash, the remaining 
wash buffer was removed by inverting the plate and blotting it against clean paper 
towels. 200 µl of the substrate solution was then added to each well and the plate was 
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incubated for 30 min at room temperature on a benchtop. The reaction was stopped with 
50 µl of the stop solution and the optical density (OD450nm) of all samples was 
determined within 30 min, using a microplate reader. Standard absorbance values were 
subtracted from the average value of the zero standards and plotted graphically against 
their corresponding concentrations using four parameter log curve-fit generated by 
Graphpad prism software. The unknown concentrations were determined by direct 
interpolation using the same software. 
 
2.3.33 Immunisation     
Four mice BALB/c were immunised subcutaneously with 300 µg (75 µg/ mouse) of 
M22 scFv in 150 µl/mouse of Gerbu adjuvant. A second subcutaneous injection of the 
same concentration of the purified M22 scFv protein (no adjuvant) was given day 14 
after the firstl injection.  Ten days after, 100 µl of boost immune bleed from each mouse 
was collected and tested at different dilutions for plasma reactivity to the M22 scFv by 
ELISA.  At day 28, mice were injected intraperitoneally with 30 µg/mouse of antigen 
(no adjuvant) as a booster dose before killing, and the spleens are collected.           
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CHAPTER 3 
 
 
 
CLONING AND CHARACTERISATION OF TSAB 
MONOCLONAL M22 
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3. Cloning of synthetic human monoclonal M22-scFv into 
phage display vector pAK100 
3.1 Introduction 
TSHR autoantibodies are the basis of Graves’ disease. TSAb mimic the action of TSH 
and stimulate thyroid cells, leading to increased thyroid hormone synthesis and goiter. 
The therapeutic options for Graves’ disease are still limited. Understanding of the 
autoantibody response would provide novel therapeutic strategies and diagnostic tools. 
Analysis of TSAb monoclonal and corresponding TSHR epitopes would allow the 
design of specific peptide antagonists or the development of anti-idiotypic reagents. 
However, attempts to isolate anti-TSHR antibodies from patients by conventional 
methods have proven technically very challenging due to the inherent limitations of 
human B cell cloning, relatively low number of specific B cells in GD patients, and with 
difficulties in obtaining purified TSHR capable of interacting with patient antibodies. 
So far only two human TSAb monoclonals has been reported (Smith, Sanders et al. 
2009). Phage display techniques have been used to investigate the autoimmune 
repertoire in a number of diseases, and offer the potential to recover more examples of 
TSHR autoantibodies. However, the only published attempt to recover TSH receptor 
antibodies using phage display was unsuccessful (Van Der Heijden, De Bruin et al. 
1999). The reasons for this failure are not clear and before embarking on phage 
selection experiments in this study it was decided to first produce an appropriate control 
to optimise the conditions for binding and enrichment. Using the public domain patent 
document describing the properties of mAb M22 we chemically synthesised the 
appropriate immunoglobulin heavy and light chain Fv DNA sequences and cloned these 
as scFv fragments into a phage display vector. The aim of this part of the study was to 
clone the recombinant human M22 scFv into a phage vector and verify that we had 
synthesised the correct antibody by characterising the binding and thyroid stimulatory 
activities of the construct. Based on the patent description we will synthesise the 
corresponding VH and VL sequences. By using overlap PCR we will assemble the M22 
scFv DNA and clone it into phage display and expression vectors. Recombinant protein 
will be produced and identity confirmed by analysis of TSHR binding and TSAb 
activity.  
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3.2 Methods and Results 
3.2.1 Gene Synthesis of M22 VH and VL Genes 
The DNA sequence of human monoclonal TSAb M22 was published in patent 
application WO2004/050708A2 (Sanders, Smith et al. 2004). This information was used 
to extract the sequences of M22 variable heavy and variable light chain genes. These 
sequences were synthesised commercially by Eurofins GmBH. One advantage of DNA 
synthesis is that the codon usage could be adjusted to match that of the projected E. coli 
expression hosts and this optimise protein expression. The VH and VL plasmids 
provided by the manufacturer were sequenced, and the identity confirmed by 
comparison to published sequences (Sanders, Smith et al. 2004). DNA sequences were 
analysed using the VBASE2 web tool which aligns antibody sequences with all known 
immunoglobulin gene sequences and identifies CDR regions (Retter, Althaus et al. 
2005). The heavy chain used was of the IgG1 subclass and used the VH32 germline 
gene, a member of the comparatively rarely used human VH5 gene family, the D region 
gene was D6-13, and the J region gene was JH5. The light chain was of the lambda 
class and used the VL1-11 germline gene and the J region gene JL3b (Fig. 3.1 and Fig. 
3.1).The protein sequence was confirmed as identical to that of the published M22 
mAb.  
3.2.2 PCR Amplification of Heavy and Light Chain Genes 
The synthetic VH and VL chain plasmids were diluted 1:1000 in TE to produce 
template suitable for PCR amplification. The M22 heavy and light Fv coding regions 
were amplified in separate PCR reactions using 2 µl of the corresponding template and 
the TSAB-VH-S, TSAB-VH-AS, TSAB-VL-S, TSAB-VL-AS primers (Table 3.1) 
(2.2.3). A negative control containing no template was included to make sure there was 
no contamination of the PCR reagents. Amplifications were carried out using the 
following conditions; initial denaturation 94°C 1 min; 30 cycles of 92°C for 1 min, 
55°C for 1 min, 72°C for 1 min. A 10 min final extension at 72°C was carried out and 
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the reactions cooled to 4°C. PCR products were resolved by gel electrophoresis on 1% 
agarose minigels (2.2.4). The agarose gel visualized on a UV illuminator and 
photographed, and product sizes verified by comparison to a 100 bp ladder. The results 
showed the amplification of products with the appopriate size, and these were used to 
assemble the final scFv construct (Fig. 3.3). PCR products were excised and purified 
from agarose using the QIAquick PCR prep kit (2.2.5).  
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Figure3.1 Sequence of Synthetic M22-VH Construct. 
Complementarities determining regions are shown highlighted. 
  
96 
 
 
 
Figure3.2 Sequence of Synthetic M22-VLConstruct. 
Construct. Complementarity determining regions are shown highlighted. 
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Table 3.1 Primers used for the amplification and cloning of M22-scFv fragments 
into pAK100.  
 
 
TSAB-VH-S   
 
5' GGC GGC GGC GGC TCC GGT GGT GGT GGA TCC CAG 
GTA CAG CTG GTC CAG AGT GGT GCT 3' 
 
TSAB-VH-AS   
 
5' G GAA TTC GGC CCC CGA GGC CGC GCT TGA CAC 
TGT CAC TAA CGT ACC TTG 3' 
 
TSAB-VL-S   
 
5' GCC ATG GCG GAC TAC AAA GAC CTT ACG GTT CTG 
ACC CAA CCA CCC TCT 3' 
 
TSAB-VL-AS  
 
5' GGA GCC GCC GCC GCC AGA ACC ACC ACC ACC AGA 
ACC ACC ACC ACC CAG AAC CGT CAA GCG TGT ACC 
ACC GCC AAA CAG CTG GCT ATC '3 
 
SC-back  
 
5'CTA CAG CAG GCC CAG CCG GCC ATG GCG GAC TAC 
AAA G 
 
SC-for 
 
5'CGG AGT CAG GCC CCC GAG 
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Figure3.3 PCR products of M22 VH and VL Regions and their Overlap Assembly. 
(a) Amplified VH and VL DNAs appeared on the 1% agarose gel as sharp bands at 400 
bp. Lane 1: 100bp ladder. Lane 2: PCR product of M22 VH-chain (400bp). Lane 3: 
PCR product of M22 VL-chain (400bp). (b) Lane 1:  100bp ladder; Lane 2-3: The yield 
of the assembly reaction of VH and VL (800bp). The assembled PCR products 
(complete M22 scFv) digested and recovered from agarose gel slices prior to ligation 
into pAK100.  
 
 
 
  
99 
 
3.2.3 Assembly PCR and Cloning into PAK100 and PAK400 
Approximately 30 ng of purified VH and VL PCR products was combined by SOE-
PCR (splicing by overlap extension). Complementary regions in the linker sequence 
annealed to the 3’ and 5’ end respectively of the VL and VH PCR products, four 
assembly SOE-PCR reactions
 
were performed using the SC-BACK and SC-FOR 
primers (Table 3.1) which joined VL and VH products, adding the coding sequence for 
a flexible G4S linker between them and Sfi I site at the 5’ and 3' ends of the overlap 
product. A negative control containing no template was included to ensure there was no 
contamination of the PCR reagents. Amplification was performed 3 cycles of 1 min. at 
92°C, 30 sec. at 63°C, 50 sec. at 58°C and 1 min. at 72°C, followed by 25 cycles of 1 
min. at 92°C, 30 sec at 63°C, and 1 min at 72°C, and a 10 min final extension at 72°C 
was carried out before the samples were cooled to 4°C. PCR products were resolved by 
gel electrophoresis on 1% agarose minigels. PCR products were excised and purified 
from agarose using the QIAquick
 
PCR prep kit (2.2.5). The purified scFv products were 
dissolved in 40 µl of H2O and 5 µl of buffer 4 (NEB), and digested with 10 units of Sfi I 
restriction enzyme for 2 h at 50°C. At the same time 5 µg of pAK100 vector DNA was 
cut in a 100 µl reaction containing 10 µl of Buffer 4 and 10 units of Sfi I (NEB). The 
digested scFv DNA and pAK400 were slot gel purified and extracted with the Wizard 
DNA Cleanup kit. Approximately 200 ng of digested pAK100 and 100 ng of digested 
M22-scFv were mixed together in a 20 µl ligation reaction containing 2 µl of ligation 
buffer and 1 unit of T4 DNA ligase (Promega). The reaction was incubated overnight at 
15°C. The scheme for cloning M22-scFv into pAK100 is shown in Fig. 3.4. 
The pAK100 expresses scFv as fusions to phage coat protein cpIII to enable phage 
display and selection. In order to increase the functional yield of antibody fragments the 
M22 scFv gene was sub-cloned into vector pAK400. This construct enabled the 
increased expression of scFv and added a 6 His tag at the carboxy terminus to allow 
rapid purification by metal affinity chromatography. A single M22-pAK100 clone was 
verified by sequencing and after confirmation was grown as a midiprep to provide 
sufficient DNA for subcloning. Briefly 5 µg of pAK100-scFv plasmid prepared from 
glycerol stock of a single M22-PAK100 clone was digested with Sfi I enzyme as  
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Figure3.4 Schematic Diagram of Synthesis of M22-scFv Construct. 
 Immunoglobulin heavy and light chain variable regions were amplified from synthetic 
M22 template using primers TSAB-VL-S, TSAB-VL-AS, TSAB-VH-S, and TSAB-VH-AS 
(Table 3.1). Amplicons were gel purified and joined by overlap extension PCR using 
primers SC-FOR and SC-BACK (Table 3.1) to produce an scFv coding fragment which 
was cloned into the Sfi I sites of phage vector pAK100 (Krebber, Bornhauser et al. 
1997). 
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described (2.2.7) and the resulting DNA fragments resolved using an agarose slot gel 
(2.2.4) (Fig. 3.5). 
Approximately 800 bp scFv antibody fragment was excised from the gel and purified 
using the Wizard DNA Cleanup kit (2.2.5). Two µg of pAK400 vector was also 
restricted with Sfi I enzyme and purified, following agarose gel electrophoresis. The 
purified digested M22-scFv fragment was ligated into Sfi I sites of the pAK400 to create 
M22-pAK400 (Fig. 3.6). The ligation reaction was purified by ethanol precipitation and 
resuspended in 20 µl TE. 5 µl of ligated mixture was electroporated into 60 µl of a non-
suppressor E.coli BL21 (2.2.10), 2 µl was plated out onto an agar plate containing 30 
µg/ml chloramphenicol and incubated at 37ºC overnight. Positive clones were 
confirmed by restriction digest and glycerol stocks prepared and stored at -80ºC to be 
used for expression and purification of M22 scFv protein. 
3.2.4 Expression of M22-scFv  
The induction procedure of scFv expression was carried out as described in 2.2.20. 
Briefly, 10 ml of LB medium containing, 10 µl of 30 µg/ml chloramphenicol was 
inoculated with 10 µl of glycerol stock of M22-pAK400 and grown overnight in a 
shaking incubator at 37ºC. This culture was used to inoculate 1L of LB (30 µg/ml 
chloramphenicol) and grown at 25ºC with shaking until the OD600nm reached 0.6. At 
this point gene expression was induced by the addition of IPTG to a final concentration 
of 1 mM, and the culture was grown overnight in a shaking incubator at 25ºC. The 
following day the induced culture was centrifuged at 2,000 g for 10 min, the supernatant 
was removed for further analysis, and the bacterial pellet was used for periplasmic 
extraction, using osmotic shock method as previously described (2.2.20). The 
periplasmic extract and the supernatant were then concentrated ten-fold using a micro-
concentrator (Amicon). The protein content was estimated by Bradford assay (2.2.22) or 
by measurement the OD280 and analysed by SDS-PAGE (2.2.23).  
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3.2.5 SDS-PAGE and Western Blot Analysis of Bacterial Extracts 
SDS-PAGE and western blotting were performed essentially as previously described 
(2.2.23 and 2.2.24). Extracts of pAK100 approximately 20 µg of supernatants and 
periplasmic extracts were analysed by SDS-PAGE (Fig. 3.7), stained with Coomassie 
Blue staining as described in 2.2.23, and following transfer western blotted using a 
1:1000 dilution of anti-his in 1% skimmed milk PBS/0.05% Tween for 2 h at room 
temperature.  
After washing 4 times with PBS/0.05% Tween, 1:5000 goat anti-mouse IgG-HRP 
conjugate (Southern Biotech) in 1% skimmed milk PBS/0.05% was added and 
incubated for 1 h at room temperature. The blot was then visualised using an enhanced 
chemiluminescent (ECL) system (Roche Diagnostics) according to manufacturer’s 
instructions (Fig. 3.8). 
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Figure3.5 Restriction digest screening of M22-scFv-pAK100. 
 Approximately 5 µg of midiprep DNA from the M22-pAK100 was digested with Sfi 
I restriction enzyme and run on a 0.8% agarose gel. Lane1: 100bp DNA ladder, 
lane 2: λ Hind III ladder, lane 3: and 4: digested plasmid from mini-prep1 and 2. 
Inserts were recovered for cloning into pAK400. 
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Figure3.6 Purification of digested pAK400 and M22 scFv.  
Recovery of digested pAK400 and M22-scFv, samples (4 µl) of each purified DNA were 
analysed by gel electrophoresis prior to ligation. 
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Figure3.7 SDS-PAGE analyses of unpurified M22 scFv periplasmic 
extracts. 
 A 15% (w/v) reducing SDS-PAGE gel was used with to visualise expressed proteins 
by staining with Coomassie blue. The gels, shows E.coli expression of M22 scFv. Lane 
M: molecular weight marker; precision plus protein marker (Bio-Rad, UK), bands 
starting at the bottom: 10, 15, 20, 25, 37, 50, 75, 100, 150, and 250 kDa. Lane 1:- Non-
induced total cell extract (T0). Lane 2:- IPTG induced total cell extract (T4) after 4 
hours, distinct bands at 25 kDa (arrow), corresponding to M22 scFv observed upon 
induction with 1mM IPTG.  
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Figure3.8 Western blot analysis of His-tagged purified M2 scFv periplasmic extracts.  
 Lane 1: Molecular weight marker; precision plus protein marker (Bio-Rad, UK), bands 
starting at the bottom: 10, 15, 20, 25, 37, 50, 75, 100, 150, and 250 kDa, lane 2: 
sample of eluted M22-scFv fragments were stained with anti-His mAb and detected by 
ECL, lane 3: negative control, lane 4: His-tagged TG2 as a positive control. 
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3.2.6 Purification of Histidine Tagged M22-scFv from Bacterial Periplasmic Extracts  
The purification of histidine tagged proteins was achieved by metal chelate resin using 
TALON Metal Affinity Resins (BD Biosciences) according manufacturer’s instructions 
(2.2.21). Protein loading, washing, and elution were monitored using a UV absorbance 
detector (Fig. 3.9). The eluted fractions were then collected, neutralized, dialysed 
against PBS and concentrated ten-fold using a micro-concentrator (Amicon), the protein 
content were assessed by Bradford assay (2.2.22). 
3.2.7 FACS Analysis of M22-scFv 
To investigate the binding and specificity of purified M22-scFv to TSHR, the purified 
antibody was analysed by flow cytometry analysis using GPI-95 cells (2.1.6). GPI-95 
cells were derived by stable transfection of CHO-K1 cells with human TSHR cDNA, 
and express approximately 300,000 copies of TSHR per cell (Metcalfe, Jordan et al. 
2002). The flow cytometry analysis was performed as described in section 2.2.27. 
Conventional secondary antibodies are not suitable for detecting scFv, and an aliquot of 
M22-scFv was biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Scientific, 
Rockford, IL, USA). Cells were counted, resuspended at the density of 1x10
7
 cells/ml 
and 100 µl aliquoted into LP4 tubes (Becton Dickinson). Two µg/ml of biotinylated 
M22-scFv as well as 2 µg/ml (1:50) of mouse anti-human TSHR monoclonal antibody 
2C11 (Serotec) and A10 monoclonal antibody (gift from Prof JP Banga) as positive 
controls or 2 µg/ml (1:50) of irrelevant biotinylated scFv (anti-TG2 antibody) were 
added to the cells, thoroughly mixed and the reaction incubated for 20 min on ice. After 
washing twice with 2 ml of PBS, cells were centrifuged at 1,000 g for 3 min and 
resuspended in 1:100 (2 µg/ml) Extravidin -FITC (Serotec) and incubated on ice for 20 
min. After a final wash, cells were analysed using a fluorescence activated cell sorter 
(FACScan, Becton Dickinson) (Fig.3.9 (a-d)). 
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Figure3.9 Elution of purified M22-scFv protein from Ni- column.  
Bacterial extract was loaded onto a nickel affinity column and washed with 5 column 
volumes of Wash Buffer. Pure scFv was eluted with Elution Buffer containing 300 mM 
imidazole. Protein loading, washing, and elution were monitored using a UV 
absorbance detector fitted in series with the affinity column.  
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Figure3.10.a:  FACS of the binding of 2c11 to CHO-K and GPI-95 cells. 
Histograms of fluorescence intensity are showing inability of 2c11 (commercial anti 
TSH receptor antibody) (Serotec) to bind untransfected CHO-K cells as a negative 
control versus to significant binding of 2c11 to GPI-95 (CHO-K transfected with TSH 
receptor ectodomain) as a positive control. 
 
 
 
110 
 
 
 
 
Figure3.10.b: FACS of the binding of A10 IgG to CHO-K and GPI-95 cells. 
Histograms of fluorescence intensity are showing inability of A10 (mouse anti TSH 
receptor antibody) to bind untransfected CHO-K cells as a negative control versus to 
significant binding of A10 ((mouse anti TSH receptor antibody) to GPI-95 (CHO-K 
transfected with TSH receptor ectodomain) as a positive control. 
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Figure3.10.c: FACS of the binding of Fab 8 to CHO-K and GPI-95 cells.  
 Histograms of fluorescence intensity are showing inability of Fab 8{TG2 antibody) as a 
negative control to bind untransfected CHO-K cells and GPI95 (CHO-K transfected with 
TSH receptor ectodomain). 
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Figure 3.10.d FACS of the binding of Biotinylated M22-scFv to CHO-K and GPI-95 
cells.  
Histograms of fluorescence intensity showing significant binding of Biotinylated M22-
scFv to GPI-95(CHO-K transfected with TSH receptor ectodomain) versus to 
inability of Biotinylated M22-scFv to bind untransfected CHO-K cells.  
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3.2.8 Stimulation of cAMP Production by M22 scFv 
TSHR agonist activity was assessed by measurements of cAMP induction using the 
CHO-K1 cell line JP09 (Persani, Tonacchera et al. 1993). This cell line expresses 
approximately 20,000 copies of TSHR per cell and responds to TSH and TSAb by 
producing cAMP. Purified M22 scFv was tested in the JP09 bioassay using a range of 
dilutions. JP09 cells were grown to confluence in 24-well plates and 20 µl of each 
sample were added to the standard assay mix (500 µl of Hanks BSS) (2.2.32) and 
incubated for 2 h. TSH and PBS were added as positive and negative controls 
respectively (Fig. 3.11). Cell extracts were produced by lysis and cAMP concentrations 
determined by ELISA using a commercial kit (cAMP Parameter Assay Kit, R and D 
Systems, Oxford UK). 
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Figure3.101 JP09 Bioassay of TSHR Stimulation by Recombinant M22 scFv.  
Stimulation of cyclic AMP to JP09 cells (Chinese hamster ovary cells (CHO-K) cells 
transfected with thyrotropin receptor (TSHR) by M22 scFv (10 pmol/L, 100 pmol/L, 500 
pmol/L), non-stimulatory mAb A10 (500 pmol/L), bovine thyrotropin (bTSH) 500 pmol/L, 
and pooled normal human sera (20 µg/ml). Results shown are mean ± standard 
deviation (n=3). Basal cAMP production was determined in the presence of assay 
buffer only. Controls were mAb A10 was a non-stimulatory TSHR antibody (Nicholson, 
Vlase et al. 1996), bovine TSH, and pooled normal human sera. M22 scFv at 500 
pmol/L increased cAMP production approximately 42-fold over basal, and bTSH at 500 
pmol/L increased cAMP production approximately 50-fold. Negative controls showed 
no significant increase of cAMP production compared to basal levels. The overall F-test 
gave a p-value of 0.006; Results shown are the mean of at least two independent 
experiments. 
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3.3 Discussion 
In this stage of the project we were able to successfully synthesise and clone the 
immunoglobulin gene sequences of the human monoclonal thyroid stimulating antibody 
M22. The antibody was successfully expressed and characterised. We were able to 
express useful quantities of the scFv antibody and confirm its binding and stimulating 
properties. The recombinant antibody bound to the TSHR in FACS, and more 
importantly it possessed agonist activity against the receptor. We were able to induce 
cAMP production in the JP09 bioassay at ng/ml concentrations - evidence of a true 
TSAb. Thyroid stimulating activity has been previously described for Fab fragments of 
M22 (Sanders, Evans et al. 2003), but this was the first time that stimulating activity has 
been documented for an scFv fragment. This was an important step for our project as 
examples of true TSAb monoclonals are very difficult to obtain, and are still considered 
commercially sensitive reagents. 
The only reported attempt to use phage display to recover TSHR antibodies was 
unsuccessful, for reasons that were unclear (Van Der Heijden, De Bruin et al. 1999). To 
date there has been no published account of how potential TSAb antibodies behave 
when expressed on the surface of phage particles. Phage display has been sucessfully 
used to isolate patient autoantibodies in autoimmune thyroid disease (Hexham, 
Partridge et al. 1994; McIntosh, Tandon et al. 1994; McIntosh, Asghar et al. 1996; 
McIntosh, Asghar et al. 1997; McIntosh and Weetman 1997) and if this technique could 
be applied to the TSHR it would offer the potential to recover more examples of TSAb 
monoclonals from Graves' patient antibody phage libraries.  
Construction of the M22-scFv phage provided for the first time a representative 
example of a TSAb in a phage display format, and could be used to investigate the 
binding properties of these antibodies, thus enabling the development of enrichment 
strategies that could be applied to recovery of other TSHR phage antibodies. The next 
stage of the project involved an investigation of this reagent, and attempts to 
demonstrate specific binding of M22 phage to different preparations of recombinant 
TSH receptor. 
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CHAPTER 4 
 
 
SELECTIVE ENRICHMENT OF M22 PHAGE ON 
THE THYROTROPIN RECEPTOR 
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4.1 Introduction 
In the previous section we described the construction of a phage antibody positive 
control based on the published human monoclonal TSAb M22 (Sanders, Evans et al. 
2003). The identity of the antibody was confirmed by sequence analysis, and 
characterisation of its receptor binding properties, and ability to stimulate cAMP 
production in TSHR transfected CHO-K1 cells. The next stage of the project involved 
an investigation of the ability of this phage construct, and other variants, to recognise 
and bind preparations of the TSH receptor. The power of the phage display technique 
resides in the ability to select specific antibodies from diverse libraries through an 
iterative of enrichment on antigen, in which irrelevant antibodies are discarded to leave 
a population of specific recombinant monoclonal. The key to this process is the 
availability of pure or relatively pure antigen and an appropriate selective enrichment 
procedure. The phage antibody approach has been shown to be highly effective in 
autoimmune thyroid disease, and a range of monoclonal antibodies have been cloned in 
this way using other thyroid antigens such as thyroid peroxidase (TPO) and 
thyroglobulin (TG) (Hexham, Partridge et al. 1994; McIntosh, Asghar et al. 1996; 
McIntosh, Asghar et al. 1997). A stumbling block for attempts to isolate TSHR 
antibodies using this approach has been the lack of sources of pure TSH receptor. This 
protein is difficult to purify in native form (1.2.2), and binding of TSHR antibodies are 
exquisitely dependent on protein conformation (Rapoport, Chazenbalk et al. 1998). 
Recent advances in the field have seen the development of novel forms of TSH receptor 
expression, and have set the scene for renewed attempts to isolate TSHR monoclonals 
using recombinant antibody approaches. 
The development of the BRAHMS TRAK assay for TSHR antibodies (Costagliola, 
Morgenthaler et al. 1999) was the result of advances in the recombinant expression of 
the TSH receptor. New cell lines were developed that expressed approximately 2 
million copies of receptor per cell, and this breakthrough enabled the production of 
receptor on an industrial scale in bioreactors (Stiens, Buntemeyer et al. 2000). Attaching 
the recombinant receptor to solid support in plastic tubes provided the basis of the first 
commercial assay for direct binding of antibodies to the thyrotropin receptor and was 
marketed as the BRAHMS TRAb TRAK assay (BRAHMS GmbH, Hennigsdorf, 
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Germany). The BRAHMS kit provided a useful alternative source of native receptor to 
investigate binding of antibody phage constructs. 
Alternative sources of high density cell surface expression of TSH receptor were 
produced by exploitation of glycosyl-phosphatidylinositol (GPI) anchors (Da Costa and 
Johnstone 1998; Metcalfe, Jordan et al. 2002). GPI anchors are found in a number of 
natural proteins, and comprise a glycolipid moiety that is attached to the carboxyl 
terminus during post-translational processing (Low 1989). This glycolipid structure 
intercalates between the lipids of the outer membrane and anchors the protein to the cell 
surface. Expression of the TSHR extracellular domain (TSHRecd) via a GPI anchor 
leads to high levels of protein expression and in the GPI-95 cell line produced in our 
laboratory this yields approximately  300,000 copies of the TSHRecd per cell, 
providing a useful reagent for the analysis of receptor binding (Metcalfe, Jordan et al. 
2002). Another useful feature of GPI-linked proteins is that they can be extracted by 
partioning with detergents such as Triton X-114, enabling the preparation of semi-pure 
protein extracts (Patton, Dhanak et al. 1989) 
In this section of the project we will investigate the binding of the M22 antibody phage 
construct to different preparations of the TSHR. We will use this control reagent to 
attempt to develop an enrichment strategy for the recovery of TSHR antibodies using 
phage display techniques. In addition, in line with the aims of the project, we will 
attempt the enrichment of TSHR antibodies from a phage antibody library that was 
previously synthesised in our laboratory using B lymphocytes extracted from the 
thyroid gland of a Graves' patient (McIntosh and Weetman 1997). Lymphocytic 
infiltration of the thryoid gland is a feature of AITD patients and intra-thyroidal 
lymphocytes are known to be a rich source of autoantibody producing B cells (Dalan 
and Leow 2012). Phage antibody libraries made from this source represent the most 
promising starting material for attempts to recover specific receptor antibodies. 
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4.2 Initial Phage Binding Experiments 
4.2.1 Investigation of M22-scFv Phage  
4.2.1.1 Methods 
Phage displaying M22 scFv antibody was produced by phage rescue using the method 
described in section 2.2.16. In brief, a glycerol stock of M22-pAK100 was inoculated 
into 10 ml of LB medium, and after a period growth in which the turbidity 
approximately doubled it was superinfected with VCSM13 helper phage (Stratagene) 
and grown overnight with high aeration (2.2.16). Phage particles were precipitated by 
the addition of PEG 6000 and 5 M NaCl, followed by centrifugation at 2,500 g for 30 
min. Precipitated phage were resuspended in PBS/Tween (0.1% v:v) and titered 
(2.2.18). Phage particles were re-suspended to a density of approximately 10
11
 plaque 
forming units (pfu) per ml. TSHR-coated immunotubes, hereafter referred to as 
BRAHMS tubes, were obtained from a commercial anti-TSHR antibody assay kit 
(BRAHMS, GmbH, Hennigsdorf, Germany). BRAHMS tubes are coated with native 
recombinant TSHR protein which is captured and stabilised on the assay tube using a 
mouse mAb which is pre-coated onto the tube surface (Costagliola, Morgenthaler et al. 
1999). This monoclonal (BA8) was carefully selected not to interfere with the assay 
process, and does not interfere with the blocking or stimulatory epitopes of the TSH 
receptor. The tubes were blocked with 400 µl of PBS/BSA 3% (w:v) for 1 hour at 37°C. 
The blocking solution taken out and 100 µl of phage library was added (typically 10
10 
pfu) and incubated for 1 hour at room temperature. Unbound phage were removed, and 
the tubes washed eight times with 2 ml PBS/Tween (0.1% v: v) at room temperature. 
Adherent phage were eluted by the addition of 100 µl of glycine buffer and incubation 
at room temperature for 10 min. Eluted phage were, and neutralised with 6 µl of 2 M of 
Tris. Eluted phage were used to infect 1 ml of log phase culture of fresh   XL1-Blue 
host for 20 min at 37°C. The pAK100 vector is a phagemid and after infecting host 
bacteria it produces a conventional plasmid which carries antibiotic resistance and will 
give rise to a conventional colony, in contrast to other bacteriophage such lambda, 
which is limited to plaque formation. Exploiting this this feature, the number of eluted 
phage were monitored by plating 10 µl samples of infected host onto LB agar plates 
containing (30 µg/ml chloramphenicol 10 µg/ml tetracycline), followed by overnight 
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incubation at 37°C to allow colony growth. The resulting colonies were used to 
calculate the number of eluted phage. To provide a suitable negative control irrelevant 
antibody phage were prepared from an anti-tissue transglutaminase antibody (TG2-8). A 
positive control phage construct was produced using TSHR mAb A10. This antibody 
recognises a linear TSHR epitope remote from the key binding sites for TSHR 
autoantibodies, and does not require native protein conformation for recognition 
(Nicholson, Vlase et al. 1996). Both TG2-8 and A10 immunoglobulin genes were 
cloned into pAK100 and used to generate phage particles (data not shown). As an 
additional control identical uncoated immunotubes, lacking TSH receptor, were also 
used in binding-elution experiments. 
4.2.1.2 Results 
The results of the binding-elution experiments are shown in Fig. 4.1. Surprisingly, there 
was no significant difference between the binding and elution of the M22-scFv phage 
and both positive and negative control phage. Approximately 8-10 x 10
4
 phage were 
eluted in each case. In this one-step elution experiment no difference in phage binding 
to TSH receptor was observed. 
 
4.2.2 Enrichment of Graves' Patient Antibody Library on BRAHMS Tubes 
4.2.2.1 Methods 
The experiment described in the previous section was a one-step elution design, in 
which phage were simply bound to antigen coated tubes, washed to remove unbound 
phage and then eluted. This methodology is appropriate when dealing with single 
defined phage clones with specificity for the antigen target. More commonly phage 
antibody libraries are highly diverse and repeated rounds of enrichment, or panning, are 
used to select single monoclonal reagents from a non-specific background. A 
conventional phage enrichment protocol sees an increase in the number of eluted phage 
at each round of selection, typically leading to an increase of the order of 10,000 fold 
between the first and last round. In this stage of the project the library used, HT127 was 
derived from intrathyroidal lymphocytes was highly diverse, comprising approximately 
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2 x 10
6
 individual clones (McIntosh, Asghar et al. 1996). The aim of this experiment 
was to take advantage of the pure TSH receptor protein provided by the BRAHMS 
tubes to attempt the enrichment of the HT127 library by sequential rounds of panning, 
and to recover receptor specific monoclonal antibodies. 
BRAHMS tubes were blocked with 400 µl of 3% BSA in PBS/Tween for 1 hour at 
37°C. The tubes were washed five times with 2 ml (approximately 0.5 tube volumes) of 
PBS/Tween and 100 µl of HT127 phage library (10
10
 phage particles) was added and 
incubated for 1 hour at room temperature. The phage library was removed, and the tube 
washed ten times with 2 ml of PBS/Tween to remove unbound particles. Adherent 
phage were eluted by the addition of 100 µl of Glycine Buffer and incubation at room 
temperature for 10 min. was added and the tube incubated on ice for 10 min. The eluted 
phage were neutralized with 6 µl of 2 M Tris and used to infect 1 ml of log phase 
culture of fresh XL1-Blue host. Aliquots of infected host were plated onto selective 
medium and following overnight the resulting colonies were used to calculate the 
number of phage eluted from the coated tubes at each round. The remaining infected 
host was added to 100 ml of LB medium (30 µg/ml chloramphenicol, 20 µg/ml 
tetracycline) and grown for 1 hour in a 37°C shaking incubator. The culture was 
superinfected with 50 µl of helper phage VCSM13 (10
11
 pfu/ml), adjusted to 30 µg/ml 
kanamycin, and grown overnight in a 37°C shaking incubator. The rescued phage 
libraries were recovered as described (2.2.16), titered and used for the next round of 
enrichment.  
4.2.2.2 Results 
The HT127 phage library was enriched for 5 rounds on the BRAHMS tubes and on 
control uncoated tubes. As a negative control TG2-8 phage were also subjected to 
enrichment to probe the effects of any non-specific binding. The results for TSHR 
coated tubes are shown in Fig. 4.2. Both the HT127 library and negative control 
libraries showed only a moderate, approximately 3 fold increase in the number of 
eluting phage over 5 rounds of enrichment. There no apparent evidence of selective 
binding or enrichment for either Graves' patient or negative control phage antibodies. 
Similar data were obtained for the non-coated tubes (Fig. 4.3). Overall the number of 
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eluting phage was slightly less than seen with the TSH receptor coated tubes, but 
suggested that there was no specific binding to the TSH receptor. 
 
 
Figure4.1  Binding of M22-scFv to TSHR-coated BRAHMS tubes. 
The number of phage eluted from TSHR-coated and non-coated tubes. The number 
was estimated by plating of aliquots of infected host cells. Binding was determined for 
phage displaying M22 scFv, positive control phage displaying an anti-TSHR antibody 
A10, and irrelevant phage displaying an anti-transglutaminase antibody TG2-8. Data 
are the mean ± SD (n=3), results shown are the mean of at least three independent 
experiments.  
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Figure4.2:- Enrichment of 127-scFv library to TSHR-coated BRAHMS 
tubes. 
The number of phage eluted from TSHR coated tubes following binding of HT127-scFv 
and TG2-8 (negative control) libraries. A moderate increase in the number of bound 
phage was observed with both HT127 and TG2-8( anti-transglutaminase antibody) 
phage over 5 rounds of selection. There was no evidence of selective enrichment of 
the HT127 Graves' patient antibody library. The number was estimated by plating of 
aliquots of infected host cells. Data are the mean ± SD (n=3), results shown are the 
mean of at least three independent experiments. 
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Figure4.3:- Enrichment of 127-scFv library to non-coated tubes. 
 The number of phage eluted from non-coated tube from HT127 and TG2-8(anti-
transglutaminase antibody as negative control) libraries. The number was estimated by 
plating of aliquots of infected host cells. Data are the mean ± SD (n=3), results shown 
are the mean of at least three independent experiments. 
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4.2.3 Results Summary 
The binding and elution results obtained for the positive control M22-scFv phage 
showed no evidence for specific binding to BRAHMS tubes coated with purified TSH 
receptor. Both positive control A10 and negative control TG2-8 phage eluted with 
approximately similar numbers indicating a level of non-specific binding of all phage 
constructs. The M22 scFv antibody was previously shown to be specific for the TSH 
receptor and possessed the predicted agonist activity as determined by the induction of 
cAMP production in a TSHR transfected cell line. Monoclonal A10 is also specific for 
the TSHR and recognises a distinct linear epitope distal to the disease-related blocking 
or stimulatory antibody binding sites (Nicholson, Vlase et al. 1996). The eluted phage 
from M22 and A10 may have bound to the receptor in this experiment but the non-
specific background binding of negative control TG2-8 phage indicated that it would 
not be possible to select receptor targeting phage antibodies using this approach. The 
attempted enrichment of the Graves' patient antibody library HT127 seemed to support 
this conclusion. There was no evidence of selective enrichment of this library when 
compared to irrelevant control phage. This result contrasted strongly with previous 
experiments carried out in our laboratory using the HT127 library, in which selective 
enrichment on two other thyroid antigens, thyroid peroxidase and thyroglobulin, lead to 
an increase in elution frequency of approximately 100,000 fold over 5 rounds of 
panning, and the recovery of high affinity antibody clones (McIntosh and Weetman 
1997). 
A number of possible reasons could account for the results obtained and these were 
considered under two main headings: 
TSHR as an antigen 
Potential differences between the M22 antibody and M22 phage fusion 
Firstly, the receptor coated tubes may not have contained sufficient receptor to provide 
an efficient binding surface. The exact coating density of the BRAHMS tubes is 
proprietary information to which we did not have access. However, communicatios with 
a representative of the company suggested that the TSHR coating was of the order of 
micrograms, and well within the range necessary for phage enrichment. Indeed, the 
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coating density is such that the tubes can be used in a conventional ELISA format (Dr. 
Andreas Bergmann, BRAHMS GmbH, personal communication). A second 
consideration was the fact that the TSHR extracellular domain is heavily glycosylated, 
approximately 40% by weight (Rapoport, Chazenbalk et al. 1998). Heavy glycosylation 
around antigenic sites can sterically disrupt antibody binding, and this phenomenon of 
"glycan shielding" is well established in the field of viral immunology (Wanzeck, Boyd 
et al. 2011). In this case the M22 scFv antibody has already been shown to recognise the 
receptor, and possible interference with binding in this case seems to be a problem only 
when the antibody is used as a phage construct. An important consideration is that 
phage antibodies are really quite different in physical terms from their corresponding 
phage fusions. A typical IgG class antibody has a molecular weight of approximately 
150 kDa, in Fab form this becomes 50 kDa, and scFv antibodies are approximately 25 
kDa. M13 filamentous phage has a molecular weight of approximately 55 MDa, or 
more than 2,000 times bigger than an scFv antibody. A typical Fab fragment is 
approximately 8 nm in length, and an scFv antibody around 3-4 nm. In phage display 
either Fab or scFv are fused to the minor coat protein cpIII, which is approximately 4 
nm in length. M13 phage is essentially a long cylinder, capped at one end with cpIII (or 
cpIII fusions). The phage capsid is 6 nm in diameter and 900 nm long (Fig. 4.4). It 
possible that in some cases the physical form of antibody phage may sterically hinder 
access to the corresponding target epitope.  
Based on the initial results of phage panning it was decided to investigate the possible 
effects of both glycosylation and the phage antibody structure in a series of 
experiments. TSHR glycosyl groups were enzymically removed, and panning 
experiments repeated to investigate any effect on binding. In a second series of 
experiments different antibody phage constructs were made to modify the arrangement 
of antibody and capsid. Fab fragments are approximately double the size of scFv 
constructs, and a Fab version of M22 was synthesised and investigated. Finally, a long 
flexible linker was inserted between the antibody and cpIII coding regions to further 
extend the distance of the antigen binding domains from the virus capsid. 
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Figure 4.4 Schematic diagram showing the components of phage antibody structures.  
Relative sizes of antibody fragments, phage coat protein cpIII, and the M13 viral 
capsid. 
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4.3 M22 Fab Binding Experiments 
Phage binding experiments with the M22-scFv construct failed to give any results for 
specific binding of M22 scFv to tubes coated with TSH receptor while the soluble form 
of M22 scFv was shown the ability to bind to the TSH receptor in FACS analysis, and 
stimulated cAMP production. The possible reason for this may be the involvement of 
some steric factor. The structure of phage may be the cause that prevents the binding. 
 
In this part of experiments, different antibody phage constructs were made to modify 
the arrangement of antibody and phage and solve the binding problem between the 
phage expressing M22 and TSH receptors. 
  
Linking of Fab fragments to phage surfaces has been reported by a number of groups. In 
the pComb3 vector system, immunoglobulin heavy chain Fab fragments are expressed 
as fusion proteins covalently linked to the minor phage coat protein III (cpIII). 
Immunoglobulin light chain Fab fragments are expressed from a second promoter in the 
same plasmid. Secretion leader sequences direct both chains to the periplasmic space 
where the redox conditions enable the formation of disulfide bonds and generation of 
cpIII-Fab fusion protein (Fig. 4.5) (Barbas 1991).  
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Figure 4. 5 Cloning sites of phage display vector pComb3.  
Immunoglobulin heavy chains were cloned into the Xho I and Spe I sites of pComb3 
and expressed as amino terminal fusions with minor phage protein cpIII. Light chains 
were cloned into the Sac I and Xba I sites.  Expression of both chains is driven by a 
separate lacZ promoter and secretion into the periplasm is directed by a pelB secretion 
leader upstream of the 5' cloning site.  
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4.3.1 Methods 
4.3.1.1 Cloning of M22 Immunoglobulin Chains into pComb3 
The synthetic M22 heavy and light chains (section x.x.x) were diluted 1:1000 in H2O and 
used for template for PCR amplification. The M22 VH chain was amplified (25 cycles) 
using the primers RS-VH1 and RS-VH2 containing Xho I and Spe I restriction sites for 
cloning into the pComb3 heavy chain site (Table 4.1), and the M22 VL chain was 
amplified (25 cycles) using the primers RS-VL1 and RS-VL2 (Table 4.1) containing Sac 
I and Xba I restriction sites for cloning into the pComb3 light chain site. M22 VH Fab 
PCR products were purified using Wizard DNA Cleanup kit. Purified VH PCR product 
was digested with 10 units of Spe I and Xho I and 10 µl of 10 x restriction buffer (Buffer 
B), in 100 µl
 
reaction mixture at 37°C for 3 hours.  
5 µg of pComb3 was digested with 10 units of Spe I and Xho I and 10 µl of 10 x 
restriction buffer (buffer B), in 100 µl
  
reaction mixture at 37°C for 3 hours, and the cut 
vector gel purified by the Wizard DNA Cleanupkit. 60 ng of digested VH PCR products 
were ligated to 100 ng of pComb3 plasmid at 15°C overnight in a 20 µl ligation reaction 
containing 2 µl of ligation buffer and 5 units of T4 ligase (Promega). The next day the 
ligation mixture was transformed into XL1-Blue and plated out onto LB agar plates (100 
µg/ml ampicillin). Colonies were picked and the construct confirmed by sequencing and 
identified as pCOMB3-VH. 
DNA was prepared from pComb3-VH and digested for 3 hours at 37°C with Sac I and 
Xba I in a 100 µl reaction containing 10 µl of Multicore Buffer and 10 units of each 
enzyme (Promega). The recombinant pComb3-VH band was purified by slot gel 
electrophoresis and used for cloning of M22 light chains. 
Purified M22 VL PCR products were digested with Xba I and Sac I restriction in a 100 µl 
reaction containing 10 µl of Multicore Buffer and 10 units of each enzyme (Promega). 
Digested VL products were gel purified by the Wizard DNA Cleanup kit. M22 VL PCR 
products (approximately 100 ng) were ligated to 200 ng of digested pComb3+VH in a 20 
µl ligation reaction containing 2 µl of ligation buffer and 5 units of T4 ligase (Promega) 
(2.2.9). The ligation mixture was incubated overnight at 15°C, transformed into XL1-
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Blue (2.2.210), and plated out onto LB agar plates (100 µg/ml ampicillin). Random 
colonies were selected for confirmation by restriction digest and sequencing. 
 
4.3.1.2 Expression and Purification of M22 Fab 
To verify the cAMP stimulatory activity of the recombinant M22 Fab it was necessary 
to express and purify soluble Fab from the M22-pComb3 construct. The original 
pComb3 plasmid was modified by insertion of a histidine tag to facilitate Fab 
purification. A pair of phosphorylated complementary oligonucleotides were designed 
to encode a 6 histidine tag, a stop codon and included cohesive ends compatible with 
the Spe I and Nhe I sites of pComb3. These oligonucleotides, His-1 (5’- CT AGT CAT 
CAT CAT CAT CAT CAT TAA GCT AGC -3’) and His-2 (5’-C TAG GCT AGC TTA 
ATG ATG ATG ATG ATG ATG A -3’), were combined in TE buffer at a 
concentration of 10 pmol/µl and heated to 90°C for 1 minute and cooled over a period 
of 20 mins to 0°C to allow annealing. Annealed oligonucleotides were diluted 1:100 to a 
final concentration of 0.1 pmol/µl in. M22-pComb3 DNA (2 µg) was restricted for 3 
hours at 37°C with 10 units each of Spe I and Nhe I in a 100 µl reaction contained 10 µl 
of Buffer B (Promega)(2.2.7). The digested DNA was purified by slot gel 
electrophoresis and the Wizard DNA Cleanup kit (2.2.5). Annealed oligonucleotides (40 
pmole) were ligated overnight with 200 ng of digested M22-pComb3 plasmid in a 20 µl 
ligation reaction. Ligated DNA was electroporated into XL1-Blue and transformed cells 
plated onto LB agar plates (100 µg/ml of ampicillin (2.2.10). 
The induction procedure of M22 Fab expression was carried out as described in 2.2.22. 
Briefly, 10 ml of LB medium (60 µg/ml ampicillin) was inoculated with 10 µl of 
glycerol stock of M22-pComb3His and grown overnight in 37°C shaking incubator. 
This culture was used to inoculate 1L of LB (60 µg/ml ampicillin) and grown in 
presence of 1 mM IPTG for overnight in a 25°C shaking incubator. 
The induced culture was centrifuged at 2000 g for 10 min, the supernatant was removed 
for further analysis and the bacterial pellet was used for periplasmic extraction, using 
osmotic shock method as previously described (2.2.22). The periplasmic extract and the 
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supernatant were then concentrated ten-fold using a micro-concentrator (Amicon). The 
protein content was estimated by Bradford assay (2.2.22) or by measurement the OD280 
and used for SDS-PAGE, western blotting analysis and purification. The M22 Fab 
content was estimated by ELISA to be approximately 200 µg/ml. 
Periplasmic extracts were loaded onto the TALON IMAC column (2.2.23.1) and washed 
with 3 times with Equilibration/Wash buffer. His-tagged M22 Fab was eluted with 100 µl 
aliquots of elution buffer containing increasing concentrations of imidazole (50 mM, 100 
mM, 200 mM, and 500 mM). Small aliquots (10 µl) of eluted fractions were mixed 
directly with 100 µl of Bradford reagent and protein elution monitored directly by visual 
inspection. Positive fractions were pooled, dialyzed overnight against PBS and 
resuspended at approximately 50 µg/ml. Purified M22 Fab was analyzed by SDS-PAGE 
and Coomassie staining (2.2.25).  
 
4.3.1.3 FACS Analysis of M22 Fab 
To investigate the binding and specificity of purified M22 Fab to TSHR, the purified 
M22 Fab was analysed by flow cytometry analysis using GPI-95 cells (2.1.6). The flow 
cytometry analysis was performed as described in section 2.2.27 After cells were 
counted, resuspended at the density of 1x10
7
 cells/ml and 100 µl aliquoted into LP4 
tubes (Becton Dickinson). Mouse anti-human TSHR monoclonal antibody 2C11 
(Serotec) was used as a positive control, and irrelevant transglutaminase antibody TG2-
8 was used a negative control. Antibody was added to the cells, thoroughly mixed and 
the reaction incubated for 20 min on ice. After washing twice with 2 ml PBS cells were 
centrifuged at 1,000 g for 3 min, and resuspended in 1:100 (2 µg/ml) goat-anti-human 
immunoglobulin FITC conjugate (Serotec) for M22 Fab, and 1:100 (2 µg/ml) goat-anti-
mouse immunoglobulin FITC conjugate (Serotec) for the 2C11 and TG2-8 controls. 
Samples were incubated on ice for 20 min. After a final wash, cells were analysed using 
a fluorescence activated cell sorter. 
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4.3.1.4 cAMP Bioassay of M22 Fab 
To confirm the identity of the purified M22 Fab samples were tested in the JP09 
bioassay (2.2.32). Three samples of each, 10 µl, 20 µl, and 50 µl were added to the 
standard assay mix (500 µl of Hanks BSS) (2.2.24) and incubated for 2 h. TSH and PBS 
were added as positive and negative control respectively. 
 
4.3.1.5 Rescue of M22 Fab Phage and Binding Experiments 
To perform phage binding experiments the M22-pComb3 plasmid was used to produce 
phage particles by superinfection with VCSM13 helper phage (2.2.15). Briefly, a log 
phase 10 ml culture of M22-pComb3 was infected with 50 µl of VCSM13 helper phage 
and incubated at 37°C for 15 min. Then infected culture was put in 100 ml LB media 
(100 µg/ml of ampicillin, 20 µg/ml of kanamycin, and 20 µg/ml of tetracycline) and 
incubated overnight at 37°C with shaking. The culture was then centrifuged at 2,000 g 
for 15 min to remove all bacterial cells. 40% PEG 800 (5 ml) and 5 M NaCl (5 ml) were 
added to the resulting supernatant and incubated at 4°C overnight to precipitate phage 
particles. These were centrifuged at 2,000 g for 30 min and the pellet resuspended in 1 
ml of PBS. The phage suspension was tittered (2.2.18) and suspended at a density of 
approximately 10
11
 pfu/ml. 
4.3.1.6 Panning of M22 Fab Phage 
BRAHMS tubes were blocked by 400 µl of 3% (w: v) BSA for 1 hour at 37°C. The 
blocking solution taken out, and 100 µl of M22 Fab phage was added (10
10 
pfu) and 
incubated for 1 hour at room temperature. Unbound phage were removed, and the tube 
washed eight times with 2 ml PBS/Tween at room temperature. The adherent phage 
were eluted by the addition of 100 µl of glycine buffer and incubation on ice for 10 min, 
and neutralised with 6 µl of 2 M of Tris. Eluted phage were used to infect 1 ml of a log 
phase culture of XL1-Blue host for 15 min at room temperature to allow infection take 
place. The number of eluted phage were monitored by plating 10 µl of infected host 
onto LB agar plates (100 µg/ml ampicillin 10 µg/ml tetracycline) and growing overnight 
at 37°C. The resulting colonies were used to calculate the number of bound phage. 
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4.3.2 Results 
4.3.2.1 M22 cloning into pComb3 
Synthetic M22 VH and VL genes were used as template for PCR amplification of heavy 
and light chain Fab fragments. PCR products were analysed by agarose gel 
electrophoresis. Figure 4.6 shows the yield of VH and VL from the amplification . Both 
products were clean with no evidence of side bands and the negative control did not 
contain any products. 
M22 VH products were digested with Xho I and Spe I and ligated  into pComb3 to give 
pComb3-VH. This construct was linearised by Spe I digestion and compared to the 
original pComb3 vector by gel electrophoresis. Figure 4.7 shows that pComb3-VH 
contained the M22 VH chain and was approximately 800 bp larger then pComb3. M22 
VL chains were digested with Sac I and Xba I and ligated into pComb3-VH to give the 
final construct M22-pComb3. Samples of M22-pComb3 were linearised by Spe I 
digestion and compared to pComb3 and pComb3-VH (Fig. 4.7). The results showed the 
expected size of the final construct and sequencing confirmed the presence of M22 VH 
and VL chains. 
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Figure 4.6 PCR products of VL and VH M22 Fab. 
 Lane 1: 100bp ladder. Lane 2: The yield of M22 VL (approx. 700bp). Lane 3: The yield 
of variable M22 VH (approx. 800bp). The PCR products purified digested and ligated to 
pComb3. Lane 4:  Negative control. 
 
Figure 4.7 Cloning of M22 VH and VL genes into pComb3. 
 Comparison between Size of pComb3, pComb3-VH, and M22-pComb3. DNA samples 
were linearised by Spe I digestion and analysed by agarose gel electrophoresis. Lane 
M: λ HindIII ladder, Lane 1: pComb3 (4023 bp), Lane 2: pComb3-VH (4023+800 bp), 
Lane 3-6: M22-pComb3 (4023+800+700 bp). 
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4.3.2.2 Expression and Purification of M22 Fab 
To enable the production and purification of M22 Fab the M22-pComb3 construct was 
digested with Spe I and Nhe I to remove the cpIII coding region. Approximately 5 µg of 
M22-pComb3 was digested and purified by slot gel electrophoresis. Figure 4.8 shows 
the separation of the parent vector, containing M22 VH and VL genes, and the cpIII 
region. The vector was extracted from the gel using the Wizard DNA Cleanup kit. To 
produce soluble Fab a histidine tag and stop codon was introduced at the C-terminal 
coding region of the M22 heavy chain. Complementary oligonucleotides (His-1 and 
His-2) were annealed and ligated into the digested M22-pComb3 vector to produce 
M22-pComb3-His. The ligation was transformed and five random colonies were picked 
and grown in 10 ml LB (100 µg/ml ampicillin), and plasmid DNA purified by miniprep. 
The clones were screened for recombinance by sequencing using primer pc-prim2, and 
Figure 4.9 shows a partial sequence of the verified clone. The M22 heavy chain was 
placed in-frame with a 6 histidine coding sequence, followed by a stop codon.  
A 1 L culture of XL1-Blue containing the M22-pComb3-His construct was grown at 
37°C until the turbidity reached approximately 0.4 OD600nm.. At this point gene 
expression was induced by the addition of IPTG to 1 mM and the culture was continued 
for a further 12 hours. 10 ml samples of the culture were taken immediately before the 
addition of IPTG (T0) and following the 12 hour induction (T12), these were used to 
produced cell extracts and analysed by non-reducing SDS-PAGE to monitor gene 
expression. Figure 4.10 shows the gel analysis of M22 Fab expression. A clear band of 
induced protein can be seen at in the T12 sample at approximately 50 kDa, 
corresponding to the predicted size of recombinant Fab molecule. A second smaller 
band (25 kDa) is also present in the induced sample and probably corresponds to 
monomeric heavy or light antibody chain. Recombinant Fab is maintained in dimer 
form by a single disuphide bond and the appearance of monomers is common 
phenomenon under SDS-PAGE conditions. The remaining induced culture was used to 
prepare bacterial extracts (2.2.22) and concentrated ten fold before the M22 Fab was 
purified via the 6xHis tag by metal affinity chromatography on a TALON nickel 
column. Pure Fab was eluted with 300 mM imidazole and dialysed overnight against 20 
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mM Tris pH 7.0 before being concentrated to approximately 200 mg/ml. A sample of 
the pure M22 Fab was analysed by non-reducing SDS-PAGE (Fig. 4.11) and showed a 
clear pure band of Fab at approximately 50 kDa. 
 
4.3.2.3 FACS Analysis of M22 Fab 
Direct binding to the TSHR was assessed by flow cytometric analysis using GPI-95 
cells, a stably CHO-K1 cell line that expresses the TSHR extracellular domain on the 
cell surface attached to a GPI anchor (Metcalfe, Jordan et al. 2002). An anti-TSHR 
mouse monoclonal A10 was used as a positive control. An anti-transglutaminase Fab 
TG2-8 was included as a negative control, and in addition binding was measured using 
control untransfected CHO-K1 cells. All antibodies were used at a concentration of 25 
µg/ml and the secondary antibody was FITC-conjugated anti-mouse . Fig. 4.12 shows 
the binding of M22 Fab  
4.3.2.4 cAMP Bioassay 
TSHR stimulatory activity was analysed using a bioassay based on CHO-K1 cells 
expressing the receptor. Cellular cAMP levels were determined using a commercial 
ELISA assay. Figure 4.13 shows the ability of M22 Fab to stimulate cAMP production 
at a range of concentrations from 10 to 1000 pmol/L. Maximal cAMP stimulation (30 x 
basal) was achieved with M22 Fab at approximately 300 pmol/L. Bovine TSH was used 
as a positive control and gave maximal cAMP production (30 - 40 x basal) at a 
concentration of approximately 1400 pmol/L. Negative controls Fab TG2-8 and pooled 
normal human serum showed no significant increase in cAMP production across the 
dose range. The results showed that recombinant M22 Fab exhibited TSHR stimulatory 
activity at nanomolar concentrations and confirmed the identity of the M22 Fab 
construct. 
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Figure 4.8 Digestion and gel purification of M22-pComb3. 
 0.8% agarose gel showing the digested M22-pComb3. Lane M: 100bp DNA ladder, 
and slot showing the M22 pComb3 construct digested with Spe I and Nhe I to release 
the phage coat protein (cpIII coding region) which is approximately 700bp and create 
compatible end s for the ligation of the His linker. 
 
Figure 4.9 Partial sequence of the M22 VH region of construct M22-pComb3-His. 
The sequence shows the C-terminal portion of the M22 Fab heavy chain. The 6 His tag 
coding sequence and stop codon is highlighted in purple. 
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Figure4.10: Non-reducing SDS-PAGE analysis of induced cultures of M22-
pComb3-His.  
Cell extracts were prepared from XL1-Blue containing plasmid M22-pComb3-His at 0 
hours (T0) and 12 hours (T12) after the induction of gene expression by the addition of 
1 mM IPTG. Lane M shows a molecular weight ladder. After 12 hours of induction cell 
extracts contained a significant level of M22 Fab (approx. 50 kDa). There was also 
evidence of some monomeric chains in the extract (heavy or light) which appear at 
approx. 25 kDa. 
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 Figure 4.11: SDS-PAGE analysis of purified M22 Fab. 
 A sample of M22 Fab obtained from metal affinity chromatography was analysed by 
non-reducing SDS-PAGE. The gel shows a band of pure Fab at approx. 50 kDa. 
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Figure 4.12 Flow cytometric analysis of M22 Fab binding to TSHR expressed on GPI-
95 cells.  
Antibody binding to the TSHR was assessed by FACS analysis using GPI-95 cells, a 
stable CHO-K1 cell line expressing TSHR extracellular domain at a high density on the 
cell surface. Binding was assessed for M22 Fab, positive control antibody 2C11, a 
commercial monoclonal against TSHR, and TG2-8 (Fab 8) an irrelevant monoclonal 
against tissue transglutaminase. Untransfected CHO-K1 cells were used as an 
additional control. Significant fluorescence was observed for positive control antibody 
2C11 against GPI-95 cells (A), but not TG2-8 (B), neither showed significant 
fluorescence with CHO-K1 cells. M22 Fab gave significant fluorescence with GPI-95 
cells, and low background signal against CHO-K1 (C) results shown are at least two 
independent experiments. 
. 
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Figure 4.13 JP09 Bioassay of TSHR Stimulation by Recombinant M22 scFv. 
 Stimulation of cyclic AMP production in TSHR-transfected Chinese hamster ovary cells 
by M22 Fab, irrelevant mAb TG2-8, and bovine thyrotropin (bTSH). Results shown are 
mean ± standard deviation (n=3). Basal cAMP production was determined in the 
presence of assay buffer only. M22 Fab at 100 pmol/L increased cAMP production 
approximately 140-fold over basal, and bTSH at 100 pmol/L increased cAMP 
productions approximately 100-fold.The EC50 of M22 Fab was approximately 80 ng/ml 
which was in the nanomolar range. Negative control Fab TG2-8 showed no significant 
increase of cAMP production compared to basal levels, the overall F-test gave a p-value of 
0.016 
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4.3.2.5 M22 Fab Phage Binding  
The M22-pComb3 construct expresses the TSAb monoclonal in Fab form on the surface 
of phage. The Fab moiety is approximately twice the size of the original scFv construct 
and should allow the antigen binding domain to project further from the phage surface. 
We investigated the binding of this M22 phage construct to commercial BRAHMS 
tubes coated with purified human TSHR. Binding was compared to phage derived from 
the original M22 scFv, a positive control Fab phage produced from a TSHR monoclonal 
A10 that recognise a different epitope of TSHR, and irrelevant Fab phage derived from 
an anti-transglutaminase monoclonal TG2-8.  
The results of phage binding experiments are shown in Fig. 4.14. Measurements of 
eluted phage determined by counting the number of colonies produced indicated no 
significant different between the binding of M22 Fab phage and any of the controls. Fab 
A10 is known to be specific for human TSHR, and recognises a linear determinant that 
does not require the receptor to in a native conformation. Negative control phage TG2-8 
does not recognise the TSHR at all. There was significant difference in binding and 
elution between M22 Fab phage, A10 phage, or TG2-8. The results suggested that there 
was a non-specific background that prevented discrimination between the different M22 
phage and controls. The reason for this lack of specificity was unclear. The TSHR itself 
could be the source of non-specific binding and is known feature "stickiness" in binding 
assays (Rapoport, Chazenbalk et al. 1998). An alternative possibility that it is some 
component of the BRAHMS kit or the the tubes themselves that are masking any 
specific binding  
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Figure 4.14: Binding of M22 Fab-phage to BRAHMS tubes.  
The number of phage eluted from TSHR-coated tubes. The number was estimated by 
plating of aliquots of infected host cells. Binding was determined for phage displaying 
M22 scFv, positive control phage displaying an anti-TSHR antibody A10, and irrelevant 
phage displaying an anti-transglutaminase antibody TG2-8. Data are the mean ± SD 
(n=3), the one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc comparison was 
performed on the data to confirm the statistical insignificant, p=0.062. 
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4.4 Construction of M22 Long Linker pComb3 Plasmid 
Aim: 
In an effort to address these potential steric problems after the use of a Fab construct, a 
long flexible linker was inserted between the phage capsid and the antigen binding site 
to increase the distance between the phage particle and the epitope. 
To investigate the possible effect of steric hindrance from the phage-antibody structure 
a long linker was introduced between the M22 Fab heavy chain and the phage coat 
protein cpIII. To test this possibility, we inserted a flexible peptide linker between the 
M22 heavy chain and the cpIII coat protein gene. This linker was based on a design that 
was optimised to produce a flexible peptide sequence with no secondary structure 
(Hennecke, Krebber et al. 1998). The linker comprised 20 aa residues and was inserted 
in duplicate into the M22 Fab phage construct to increase the existing distance of the 
M22 Fab from the phage capsid by approximately 80-100 Å.  
4.4.1 Methods 
4.4.1.1 Insertion of Peptide Linker into M22-pComb3 Construct 
The coding sequence of the peptide linker was constructed as two complementary 
oligonucleotides and inserted into the Spe I site of the M22-pComb3 Fab construct (Fig. 
4.15). Annealing of the oligonucleotides produced overhangs at the 5' and 3' end of the 
resulting DNA fragment that were compatible with the Spe I sites. Ligation of the linker 
DNA recreated the Spe I site upstream of the in-frame linker coding sequence but 
removed the potential second Spe I site at the 3' end of the insert (Fig 4.15). Using this 
remaining Spe I site is was possible to digest the intermediary construct containing one 
copy of the linker and insert a second, thus doubling the linker length to approximately 
40 amino acids and increasing the peptide tether length to approximately 50-100 Å (Fig. 
4.15). Using this construct we produced M22 phage featuring the long linker and 
investigated the effect of this structural alteration on receptor binding properties. 
M22-pComb3 (5 µg) was digested with 10 units of Spe I and phosphatased by the 
addition of 2 units of alkaline phosphatase (Promega) for 10 min at 37°C. We visualized 
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the digested
 
products on a 0.6% agarose gel, and the linearised M22-pComb3 was 
recovered from an agarose slot gel the Wizard DNA Cleanup kit (2.2.5). 
Digested M22-pComb3 was ligated to annealed oligonucleotide linker primers. The 
ligation mixture was then electroporated into XL1-Blue and plated out onto LB agar 
plates (100 µg/ml ampicillin). Five random colonies were picked and grown in 10 ml 
LB (100 µg/ml ampicillin), and plasmid DNA purified by miniprep. The clones were 
screened for recombinance by sequencing using primer pc3-prim2. A verified clone was 
isolated and confirmed by sequencing. This plasmid was digested with Spe I and 
purified by slot gel electrophoresis (2.2.4). The cloning was repeated to produce a 
second linker insert and following ligation and plating random colonies were picked for 
miniprep and sequencing. The final construct M22-pComb3-LL was confirmed by 
sequence analysis (Fig. 4.16). 
4.4.1.2 Generation of M22 Long Linker Phage 
A 10 ml culture of M22-pComb3-LL plasmid was superinfected with VCSM13 helper 
phage (2.2.16) and incubated at 37°C for 15 min. To generate phage particles the 
infected culture was put in 100 ml LB media (100 µg/ml of ampicillin, 20 µg/ml of 
kanamycin, and 20 µg/ml of tetracycline) and incubated overnight at 37°C with shaking. 
The culture was then centrifuged at 2,000 g for 15 min and the supernatant removed to a 
50 ml tube and 40% PEG 800 (5 ml) and 5 M NaCl (5 ml) were added and incubated at 
4°C overnight to precipitate phage particles. These were centrifuged at 2,000 g for 30 
min and the pellet resuspended in 1 ml of PBS. The phage suspension was titered 
(2.2.17) and suspended at a density of approximately 10
11
 pfu/ml. 
4.4.1.3 Phage Binding Experiments 
BRAHMS tubes were blocked with 400 µl of PBS/BSA 3% (w:v) for 1 hour at 37°C. 
The blocking solution removed and 100 µl of phage suspension added (typically 10
10 
pfu) and incubated for 1 hour at room temperature. Unbound phage were removed, and 
the tubes washed eight times with 2 ml PBS/Tween (0.1% v:v) at room temperature. 
Adherent phage were eluted by the addition of 100 µl of glycine buffer and incubation 
at room temperature for 10 min. Eluted phage were, and neutralised with 6 µl of 2 M of 
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Tris. Eluted phage were used to infect 1 ml of log phase culture of fresh XL1-Blue host 
for 20 min at 37°C. The number of eluted phage were monitored by plating 10 µl 
samples of infected host onto LB agar plates followed by overnight incubation at 37°C 
to allow colony growth. The resulting colonies were used to calculate the number of 
eluted phage. To provide a suitable negative control irrelevant antibody phage were 
prepared from a mouse anti-transglutaminase antibody (TG2-8). A positive control 
phage construct was produced using mouse anti-TSHR mAb A10. This antibody 
recognises a linear TSHR epitope remote from the key binding sites for TSHR 
autoantibodies, and does not require native protein conformation for recognition 
(Nicholson, Vlase et al. 1996). Binding of long linker M22 phage were also compared 
to M22 scFv and M22 Fab phage. Data shown was the result of three independent 
experiments. 
4.4.2 Results 
The results from BRAHMS tube binding experiments are shown in Fig. 4.17. There was 
no significant difference in binding to the receptor-coated tubes in any of the phage 
samples. All samples eluted approximately 10
4
 phage from the BRAHMS tubes, 
indicative of a significant degree of non-specific binding. The long linker M22 Fab 
construct bound to a similar extent as the other M22 antibody constructs and the 
negative control TG2-8 eluted approximately the same number of phage. It was 
apparent that either the TSH receptor-coated BRAHMS tubes did not represent a 
selective surface, or for some reason the M22 antibody binding sites were not able to 
access the stimulatory epitope on the receptor. Possible reasons for this could include 
steric hindrance between the phage-antibody structure and the receptor, or the 
orientation of the receptor in the coated tubes. BRAHMS tubes are coated with a 
specific monoconal antibody that serves to capture the recombinant receptor onto the 
surface. This would suggest that the orientation of receptor in the tubes is not random 
but determined by this capture antibody. It is possible that this particular arrangement 
prevents binding due to the large molecular size of the antibody-phage fusion. One 
possible way to explore this would be to study phage binding using alternative forms of 
the TSH receptor.  
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Figure 4.15 Strategy for introducing a flexible peptide linker into M22 Fab construct. 
A pair of complementary oligonucleotides LL1 and LL2 was designed to encode a 
peptide linker. When annealed the oligonucleotides produced a DNA fragment with 
overhangs suitable for cloning into the Spe I site of the M22-pComb3 plasmid. The new 
construct introduces two copies of a flexible peptide linker in-frame between the M22 
heavy chain and phage coat protein cpIII. 
 
Figure 4.16 Partial sequence of M22-pComb3-LL.  
The long linker construct was sequenced to confirm insertion of the two copies of the 
linker coding sequence between the C-terminus of the M22 VH chain and the N-
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terminus of phage coat protein cpIII, and to verify the reading frame. M22 VH sequence 
is highlighted in purple, and the linker coding sequence is highlighted in pink. 
 
 
 
Figure 4.17 Binding of M22 LL-Fab-phage to BRAHMS tubes.  
The number of phage eluted from TSHR-coated tubes. The number was estimated by 
plating of aliquots of infected host cells. Binding was determined for phage displaying 
M22 long linker Fab phage, M22 Fab phage, and M22 scFv phage. Positive control 
phage displaying an anti-TSHR antibody A10, and irrelevant phage displaying an anti-
transglutaminase antibody TG2-8 were also included as a negative control. Data are 
the mean ± SD (n=3). 
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4.5 Using different form of TSH receptors 
 Switching from the M22 scFv construct to the Fab form did not produce any change in 
phage binding properties. If the TSH receptor or the assay tubes were the source of this 
non-specific background then further experiments, using receptor in a different form 
may provide the solution to the enrichment problem. Steric hindrance may also still be 
an issue if the antibody in Fab form is still sufficiently close to the phage capsid that 
binding to the antibody paratope is physically prevented. A modified phage antibody 
construct may serve to investigate this possibility. 
4.5.1 Triton X114 Extraction of TSHRecd-GPI 
Phage binding experiments using a range of different M22 antibody constructs had 
consistently failed to show evidence for specific binding to recombinant TSH receptor 
using the commercial receptor-coated immunotubes. The reasons for this were unclear 
but could include steric interactions between the receptor, in this tube format, and the 
various phage antibody constructs. An alternative source of receptor was available in 
the form of the GPI-95 cell line. This cell line expresses a high density of TSH receptor 
extracellular domain on the cell surface via a glycosylphosphatidylinositol (GPI) anchor 
(Metcalfe, Jordan et al. 2002). The receptor density has been estimated to be 
approximately 300,000 per cell and represents a potential source of native receptor for 
binding studies. A useful feature of GPI-anchored proteins is that they can be simply 
extracted using selected detergents. Triton X114 has been used previously to efficiently 
separate and purify GPI-anchored proteins (Ko and Thompson 1995). In this section of 
the study we will use GPI-95 cells to provide a enriched source of TSH receptor. GPI-
95 cells will be extracted using Triton X114, and the GPI-linked receptor domain 
partitioned as a semi-purified extract for use in binding assays. 
4.5.1.1 Method of Detergent Extraction of TSHR Extracellular Domain 
Triton X114 phase partitioning was used to separate GPI-anchored proteins from crude 
cellular homogenates as described in section 2.2.31. Briefly, approximately 5 million 
GPI-95 were grown to 75% confluence in 75 cm flasks in RBMI medium. The cell 
monolayers were washed in 10 ml of PBS, pelleted by centrifugation, and incubated in 
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400 µl of lysis buffer for 20 min on ice with frequent stirring. The detergent and 
aqueous phases were separated at 30ºC for 5 min into aqueous and detergent phases and 
centrifuged at 4,000 g for 10 min. The Triton X114 fraction was recovered in 
approximately 1 ml and stored at -80°C until use. Both phases were analysed by SDS-
PAGE and western blotting to confirm recovery of receptor. 
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4.5.1.2 Binding of M22 Fab to Extracted TSHRecd-GPI 
 
To determine the binding activities and the specificity of M22 Fab, an ELISA plate was 
coated with 100 µl of 100 µg/ml of detergent extracted TSHR in coating buffer using 
additional wells coated with PBS (no TSHR) as a negative control and incubated 
overnight at 4ºC. After four washes with 400 µl of PBS/Tween, 300 µl of blocking 
solution (5% skimmed milk in PBS/0.05% Tween) was added to each well and 
incubated at 37ºC for 1 hour. After washing twice with PBS/Tween, samples of 
antibody were added at the appropriate dilution in 5% skimmed milk in PBS/Tween and 
incubated at 37ºC for 2 h. The wells were washed  five times with 400 µl of 
PBS/Tween, and 100 µl of secondary antibody added. M22 Fab binding was detected 
with alkaline phosphatase conjugated Fab-specific goat anti-human antibody (A8542; 
Sigma; 1:2000), and alkaline phosphatase conjugated Fab-specific goat anti-mouse 
antibody was used for the control Fabs, A10, an anti-TSHR monoclonal, and TG2-8, an 
irrelevant antibody against tissue transglutaminase. Following incubation for 1 hour at 
room temperature the wells were washed 10 times with PBS/Tween and developed 
using pNPP alkaline phosphatase substrate (Sigma) and read in a plate reader at 405 nm.  
4.5.1.3 Binding of M22 Phage to Extracted TSHRecd-GPI 
 
To determine the binding of M22 Fab phage and controls to TSHR extracts, ELISA 
plates were coated with 50 µl of TSHR detergent extract (100 µg/ml total protein) 
mixed with 50 µl of coating buffer (2.1.8) and incubated overnight at 4ºC. After five 
washes with PBS/Tween, 300 µl of blocking solution (5% skimmed milk in 
PBS/Tween) was added to each well and incubated at 37ºC for 1 hour. After five 
washes with PBS/Tween, 100 µl of test phage (approximately 10
9
 particles) in 
PBS/Tween containing 5% (w:v) skimmed milk was added to the wells and incubated at 
37ºC for 2 hours. Each well was washed eight times with PBS/Tween and 100 µl of 
1:2000 of horseradish peroxidase conjugated anti-M13 monoclonal antibody (GE 
Healthcare) in PBS/Tween 5% skimmed milk (w:v) was added. After incubation at 
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37ºC for 1 hour, wells were washed ten times with PBS/Tween and bounded phage 
detected by addition of 50 µl of TMB substrate (Sigma). The reaction was stopped by 
addition of 50 µl of stopping solution and the absorbance at 450 nm measured. 
4.5.2 Results 
4.5.2.1 Extraction of TSHRecd from GPI-95 
 
Detergent extracts of TSHR extracellular domain from GPI-95 cells were analysed by 
SDS-PAGE (Fig. 4.18). Total protein content of the extract was determined using 
measurements of OD280nm using a Nanodrop and was approximately 100 ug/ml. 
Based on SDS-PAGE we estimated that approximately 75% of this protein was in the 
size range corresponding to the TSHR domain, but it was not possible to precisely 
determine this ratio. Analysis by western blotting using a specific anti-TSHR antibody 
(A10) showed that the recombinant protein migrated at its predicted molecular weight 
(approximately 50 kDa) and the vast majority had partitioned into the detergent-
enriched phase with no detectable protein visible in the aqueous phase (Fig. 4.19). 
4.5.2.2 Binding of M22 Fab to Extracted TSHRecd 
 
Binding of recombinant M22 Fab to the TSHR extract was analysed by ELISA. Binding 
was compared to that of a positive control anti-TSHR Fab A10, and an irrelevant Fab 
TG2-8. All Fabs were used at a concentration of 1 µg/ml The results showed a high 
level of binding by M22 Fab, indicating that the recombinant antibody was able to 
recognise the receptor in GPI-95 extracts (Fig. 4.20). As M22 recognition is dependent 
on native confirmation this result also demonstrates that the extract contained properly 
folded receptor. Positive control antibody A10 also gave a strong signal against the 
receptor-coated wells. Both M22 Fab and A10 showed a low level of binding to 
uncoated wells, and negative control antibody TG2-8 gave no binding to either receptor-
coated or uncoated wells. 
154 
 
 
4.5.2.3 Binding of M22 Phage to Extracted TSHRecd 
 
Following demonstration of M22 Fab binding to receptor extract the experiment was 
repeated using the antibodies in phage format. M22 antibody phage in both Fab and 
scFv format were assessed for binding to the receptor by ELISA. Positive control phage 
were derived from anti-TSHR monoclonal A10. Negative controls were provided by 
irrelevant phage derived from transglutaminase antibody TG2-8, and VCSM13 helper 
phage. The results showed no evidence for receptor binding by any of the M22 phage 
constructs (Fig. 4.21). In contrast, A10 phage showed very strong binding to the 
receptor extract. Negative control phage TG2-8 and helper phage did not exhibit 
binding to receptor. None of the phage tested gave a signal on the uncoated wells.  
  
155 
 
 
 
Figure 4.18: SDS PAGE for the GPI-anchored TSHRecd extracted by triton X-114  
Detergent partitioned extracts of GPI-95 cells were analysed by SDS-PAGE Lane 1: 
Molecular weight markers; Lane 2: 30 µl of Triton X-114 phase. 
 
 
 
 
Figure 4.19 Western blot for the GPI-anchored TSHRecd extracted by triton X-114 
Detergent partitioned extracts of GPI-95 cells were analysed by SDS-PAGE and 
transferred to PVDF membrane before blotting with anti-TSHR monoclonal A10. 
Receptor protein was detected at the predicted molecular weight in the detergent 
extracts only. Lane 1: Molecular weight markers; Lane 2: 30µl of aqueous phase; Lane 
156 
 
3: 30 µl of Triton X-114 phase; Lane 4: 10ul of aqueous phase; Lane 5: 10ul of Triton 
X-114 rich phase. 
 
 
 
 
Figure4.20 Binding of M22 Fab to detergent extracts of TSHR. 
 M22 Fab binding to detergent extracted TSHR was determined by ELISA. Wells were 
coated with TSHR extract (0.5 µg/well). Anti-TSHR antibody A10 was used as positive 
control, and irrelevant antibody TG2-8 was included. Data shown are the mean ± SD 
and were derived from three independent experiments. One-way analysis of variance 
(ANOVA) was performed on the data to confirm the statistical significant different between the 
binding of M22-Fab, A10 Fab to wells coated with the extracted TSHR and uncoated wells, 
p=0.002-0.003. 
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Figure 4.21 Binding of M22 Fab-phage to detergent extracts of TSHR.  
Phage binding to detergent extracted TSHR was determined by ELISA. Equal numbers 
of phage (109) were added to ELISA wells coated with TSHR extract (0.5 µg/ well). 
M22 scFv and Fab phage constructs were tested. Positive control phage were derived 
from anti-TSHR antibody A10. Irrelevant antibody TG2-8 and VCMS13 helper phage 
were used as negative controls. Binding was compared to uncoated wells. Data shown 
are the mean ± SD and were derived from three independent experiments. One-way 
analysis of variance (ANOVA) was performed on the data to confirm the statistical insignificant 
different between the binding of M22-Fab phage to wells coated with the extracted TSHR and 
uncoated wells  , p=0.0820 and significant different between the binding of A10 Fab to wells 
coated with the extracted TSHR and uncoated wells, p=0.002 
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4.6 Binding to GPI-95 Cells 
4.6.1 Binding of M22 Fab to GPI95 Cells 
Both FACS analysis and the detergent extract experiments described above 
demonstrated that stable cell line GPI-95 was a useful source of high level expression of 
native TSH receptor. In this section we investigated the use of this cell line in a direct 
binding assay in a cell ELISA format. As an alternative source of antigen we 
investigated the use of TSHR expressing cell line GPI-95. It is well established that 
thyroid stimulating antibodies only recognise native receptor, and that as a protein the 
TSHR is rather unstable and prone to spontaneous unfolding and denaturation upon 
purification (Rapoport, Chazenbalk et al. 1998). If it was possible to use a stable cell 
line for phage binding experiments this would offer the opportunity to access native 
antigen as a binding surface. 
4.6.1.1 Methods 
GPI-95 and control CHO-K1 cells were seeded into a Poly-D-lysine 96-well ELISA 
plate at a denisty of 1,500 cells per well in 300 µl of XXX medium. The plates were 
incubated overnight at 37°C in a CO2 incubator. When the wells reached 75% 
confluence they were washed three times with 400 µl of PBS, and 300 µl of blocking 
solution (10% FCS in RBMI media) added to each well and incubated at 37ºC for 1 
hour. After one wash with 400 µl of PBS, 100 µl of test antibody (50 µg/ml) was added. 
The antibodies were used were recombinant M22 Fab, positive control mouse anti-
TSHR antibody A10, and irrelevant anti-transglutaminase antibody TG2-8 as negative 
control. Plates were sealed and incubated at room temperature for 1 hour. Each well was 
washed five times with 400 µl of PBS, and 100 µl of anti-mouse or anti-human HRP-
conjugated anti-IgG added to each well. After incubation at room temperature for 1 
hour, each well was washed five times with PBS. Plates were examined under the 
microscope to confirm cells were still attached and then 100 µl of freshly prepared 
substrate solution was added to each well. The plate was incubated at room temperature 
for 15-30 min until colour development occurred and 100 µl of stopping solution was 
added and the OD405nm was measured in the plate reader. All samples were tested in 
triplicate (Fig. 4.22). 
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4.6.2 Binding of M22 Phage to GPI95 Cells 
Following demonstration of M22 Fab binding to GPI95 cells, the experiment was 
repeated using the antibodies in phage format. M22 antibody phage in both Fab and 
scFv format were assessed for binding to the receptor by ELISA. Positive control phage 
were derived from anti-TSHR monoclonal A10. Negative controls were provided by 
irrelevant phage derived from transglutaminase antibody TG2-8, and VCSM13 helper 
phage. The results showed no evidence for receptor binding by any of the M22 phage 
constructs (Fig. 4.23). In contrast, A10 phage showed very strong binding to the GPI95 
cells. Negative control phage TG2-8 and helper phage did not exhibit binding to 
receptor. None of the phage tested gave a signal on the uncoated wells.  
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4.6.2 Results 
 
 Figure 4.22 M22 Antibody Binding to GPI-95 cells. 
 M22 binding to GPI-linked TSHR was determined by cell ELISA using the GPI-95 cell 
line. The Fab, scFv (M22 scFv), A10 Fab andTG2-8 Fab as a negative control were 
assessed for binding to ELISA wells coated with monolayers of GPI-95 cells. Positive 
control phage were derived from anti-TSHR antibody A10, and TG2-8 was the negative 
control. Binding to untransfected CHO-K1 cells was also assessed. Data shown are the 
mean ± SD and were derived from three independent experiments. Statistical analysis 
was performed using a one way analysis of variance (ANOVA), showed significant 
difference between the bindings of M22 Fab, A10 Fab to TSH-R transfected and    
untransfected CHO cells (p= 0.002-0.005) 
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Figure 4.23 Phage binding to GPI-95 cells. 
Phage binding to GPI-linked TSHR was determined by cell ELISA using the GPI-95 cell 
line. The Fab , Fab long linker (M22 LL) and scFv (M22 scFv) M22 antibody phage 
constructs were assessed for binding to ELISA wells coated with monolayers of GPI-95 
cells. Positive control phage were derived from anti-TSHR antibody A10, and helper 
phage VCSM13 was the negative control. Binding to untransfected CHO-K1 cells was 
also assessed. Data shown are the mean ± SD and were derived from three 
independent experiments. Statistical analysis was performed using a one way analysis 
of variance (ANOVA), showed insignificant difference between the bindings of M22 
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phage to TSH-R transfected and untransfected CHO cells (p= 0.09-0.15) and 
significant difference between the binding of A10 phage to to TSH-R transfected and 
untransfected CHO cells (p= 0.001) 
 
4.7 Discussion  
Initial phage binding experiments with the M22-scFv construct failed to demonstrate 
any evidence for specific binding of the recombinant antibody to tubes coated with TSH 
receptor. This result was rather surprising given that the antibody construct had been 
shown to contain the functional sequence of the human TSHR monoclonal M22. The 
soluble form of the recombinant antibody was shown to bind to the TSH receptor in 
FACS analysis, and stimulated cAMP production in the JP09 TSHR bioassay. These 
results showed that the antibody itself possessed the required specificity, but the phage 
display antibody was unable to bind its corresponding epitope on the TSH receptor 
when attached to the BRAHMS tubes.  
The most probable reason for this failure was involvement of some steric factor. It is 
clear that the M13 phage capsid is a relatively huge structure when compared to the 
displayed antibody. With approximate dimensions of 6 nm x 900 nm phage particles is 
effectively a long cylinder with a small antibody moiety of between 4-8 nm attached to 
the end (Fig xx). It seems logical that this structure may prevent binding to some 
epitopes if they were partially obstructed by domains of the antigen.  
In an effort to address these potential steric problems we investigated the use of a first a 
Fab construct, effectively doubling the size of the antibody fragment, and a Fab variant 
in which a long flexible linker was inserted between the phage capsid and the antigen 
binding site. Disappointingly neither of these approaches resolved the binding 
difficulties, and no evidence of specificity for the receptor was observed in phage 
binding experiments. 
A second consideration was the orientation of the target antigen and physical access to 
the target epitope. The initial experiments relied on the commercial TSHR-coated 
BRAHMS tubes. In this system the receptor is captured onto the tube surface using a 
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specific monoclonal antibody. There is at least the potential for the antigen to be coated 
in a uniform fashion in relation to its orientation. The data we obtained could be 
explained if this arrangement was unfavourable for phage antibody binding. In an effort 
to address this possibility we attempted to extract native receptor from a transfected cell 
line GPI-95, which expresses a high level of TSHR extracellular domain on the cell 
surface. Partitioning the GPI-anchored receptor using detergent enabled the recovery of 
useful quantities of antigen, and this material was used in a series of ELISA 
experiments. Soluble M22 Fab was able to recognise this material, which was an 
important result as it showed that the material contained receptor in native form, a 
prerequisite for the binding of TSAb. M22 in single chain form also bound the receptor 
extract. However, the M22 antibody phage fusions, including the long linker variant, 
failed to recognise the receptor in these ELISA assays. M22 phage antibodies were also 
unable to recognise the receptor on the surface of the transfected cell line GPI-95. These 
were significant findings as it can be assumed that the receptor would be bound to the 
ELISA wells in, essentially, a random arrangement. This suggested that the failure of 
M22 phage to bind TSHR was unlikely to be due to the arrangement of antigen on the 
supporting surface, but due to the intrinsic nature of the receptor itself, an observation 
supported by the failure of M22 phage antibodies to bind receptor on the surface of 
GPI-95 cells in ELISA. Accumulating evidence suggested that modifications to the 
structure of the TSH receptor may be necessary to overcome the apparent inability of 
antibody phage fusions to access the key target epitope.  
 
  
164 
 
 
CHAPTER 5 
 
 
CONSTRUCTION OF CHO TSHR260-GPI   
165 
 
5.1 Introduction 
The preceding chapters have described my attempts to selectively bind a recombinant 
phage expressing a human TSAb monoclonal antibody to various preparations of 
recombinant TSH receptor. Although we were able to demonstrate that the recombinant 
antibody, in soluble form, could bind the receptor and possessed the characteristic 
agonistic activity behaviour, we were unable to show specific binding of the phage 
antibody. This was a surprising result given that M22, and other TSAb antibodies, have 
been shown to have a very high affinity for the receptor, in the order of 10
-11
 nM. The 
reasons for these results were unclear but given the functional activity of soluble 
antibody it appeared attachment to the phage viral coat was the problematic issue, 
suggesting a role for steric interference. 
X-ray analysis of the TSHR-M22 complex for first time produced structural data for the 
TSH receptor, confirming the predicted structure of the "horseshoe" shaped ligand 
binding LRR domain (Sanders, Chirgadze et al. 2007), and showing similarities to the 
previously crystallied FSH receptor (Fan and Hendrickson 2005). Interestingly, the 
recombinant receptor construct used for the M22 crystal only comprised the first 260 
amino acid residues of the TSHR. This subunit had been previously shown to be 
sufficient for both ligand and receptor binding and in recombinant form was stable in 
solution, enabling crystallisation. Sequence homology shows that the TSH receptor is 
similar to other glycoprotein receptors, including the hCG, FSH, LH receptors. This 
similarity is most pronounced in the region between amino acids 58-288, which 
includes the LRR domain (Rapoport, Chazenbalk et al. 1998). The sequence of the 
TSHR differs from the other glucoprotein receptors in having an "extra" 50 amino acids 
inserted in the region downstream of the LRR (Rapoport, Chazenbalk et al. 1998), the 
so-called "hinge" region. The function of this significant stretch of amino acids is 
unknown. Evidence suggests that the TSHR seems to be unique among the glycoprotein 
hormone receptors in that it undergoes intramolecular cleavage at the cell surface to 
create two subunits A and B, the A subunit comprising the ligand binding domain, and 
subunit B containing the transmembrane domains (Hamidi, Chen et al. 2011). The 
"extra" 50 amino acid residues, or C peptide, are removed in this cleavage reaction, and 
in vitro experiments have shown that the C peptide residues can be removed without 
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affecting antibody or ligand binding (Rapoport, Chazenbalk et al. 1998). The published 
TSHR structural data was limited to the LRR domain and X-ray information was only 
available for amino acids up to position 260 (Sanders, Chirgadze et al. 2007). A 
possible hypothesis for the observed failure of antibody-phage binding is that amino 
acid residues beyond position 260 are in some way forming a structure that interferes 
with phage binding by steric hindrance. Evidence supporting this hypothesis comes 
from the recent structural data regarding the entire FSHR and its ligand (Jiang, Liu et al. 
2012). In this study it was shown that residues from the hinge region actually project 
into the anterior face of the LRR domain and contribute to ligand binding. The GPI-95 
cell line expresses the entire TSHR extracellular domain from amino acid position 1 to 
412 (Metcalfe, Jordan et al. 2002), which was the conventional approach to TSHRecd at 
the time the cell line was produced.  
The aim of this section of the project was to construct a novel cell line in which a 
smaller region of the TSHR, extending from amino-acids 1-260, was expressed on the 
cell surface at high density using a GPI anchor. The effect of removing the receptor 
"hinge" region on phage antibody binding will be investigated. 
5.2 Methods and Results 
5.2.1 Cloning of TSHR 1-260 as a GPI Anchored Membrane Protein (TSHR260-GPI) 
Primers were designed to amplify the TSHR coding sequence corresponding to Met-1 at 
the start of the secretion leader, and Leu-260, and included BamHI and XhoI restriction 
sites at the 5' and 3' end of the amplicon respectively (Table 5.1). To produce a DNA 
template for amplification the original TSHR-GPI construct (Metcalfe, Jordan et al. 
2002) was diluted 1:1000 in H2O. This was subject to 30 cycles of PCR amplification 
(2.2.3) using the TSHR260-1 and TSHR260-2 primers and the following conditions; 
94ºC for 35 s, 52ºC for 1 min, 72ºC for 2 min and 72ºC for 10 min for termination. An 
amplification product of approximately 800 bp was obtained (Fig. 5.1), and cloned into 
the pCR3.1 vector using the TOPO TA cloning kit (Invitrogen). The ligation was 
transformed into TOP10 competent cells (Invitrogen) and plated onto LB agar (100 
µg/ml ampicillin). Five random clones were used to produced minipreps, and the 
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identity of the clone verified by sequencing. This construct was designated 
pCR3.1/TSHR260. 
A DNA fragment encoding the GPI attachment motif was produced by annealing a 
series of seven complementary oligonucleotides (Table 5.1). The attachment motif used 
was based on the sequence of domain 3 and 4 of rat CD4, which has been previously 
shown to contain a fortuitous recognition sequence for the glycosylphophatidylinositol 
processing pathway (Johnstone, Cridland et al. 1994). The annealed oligos were 
designed to produce Xho I compatible DNA overhangs at the 5' and 3' end. The 
sequence of the 5' overhang was designed to eliminate the Xho I site after ligation so 
that this site could be re-used for sub-cloning of the final receptor construct into an 
expression vector. The oligonucleotides were prepared at a concentration of 10  
and heated to 90˚C for 1 min and cooled slowly to 0˚C to allow annealing. The annealed 
oligonucleotides were diluted 1:100 to final concentration (0.1 pmol/µl) in the annealing 
buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl and 1 mM EDTA). The 
pCR3.1/TSHR260 TOPO clone DNA was digested with XhoI, treated with 2 units of 
alkaline phosphatase (Promega) for 20 min at 37°C. Results of the digest were analysed 
by gel electrophoresis (Fig. 5.2), and the linearised vector DNA purified by slot gel 
electrophoresis. Annealed oligonucleotides (4 µl) were ligated to 200 ng of digested 
pCR3.1/TSHR260 plasmid. An aliquot of the ligation mixture (3 µl) was electroporated 
into XL1-Blue (2.2.11) and transformed cells plated onto LB agar plates (100 µg/ml 
ampicillin) (2.210). Four random colonies were picked and grown in 10 ml LB (100 
µg/ml ampicillin) and plasmid DNA purified by miniprep (2.2.12). The identity of the 
construct was confirmed by DNA sequencing and this intermediate construct designated 
pCR3.1/TSHR260-GPI 
The final step was excision of the TSHR260-GPI assembly and subcloning into 
mammalian expression vector pcDNA3.1. The verified pCR3.1/TSHR260-GPI 
construct (5 µg) was digested with Bam HI and Xho I and the insert, approximately 800 
bp, recovered by slot gel electrophoresis. The expression vector pcDNA3.1 was 
digested with Bam HI and Xho I and purified by slot gel electrophoresis. Both DNA 
fragments were recovered using the Wizard DNA Cleanup kit. Vector DNA, 
approximately 200 ng, was mixed with 100 ng of TSHR260-GPI insert and ligated in a 
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20 µl ligation reaction containing 2 µl of ligase buffer and 1 unit of T4 DNA ligase 
(Promega). The reaction was incubated overnight and transformed into competent XL1-
Blue cells. The tranformed cells were plated onto LB agar (100 µg/ml ampicillin). Five 
random colonies were picked and used to prepare miniprep DNA. The correct construct 
was verified by DNA sequencing and designated pTHSR260-GPI, the sequence is 
shown in Fig. 5.3. 
 
5.2.2 Expression of TSHR 1-260 on CHO-K cells 
To verify functional expression of the truncated TSH receptor transient transfections 
were performed and the expressed protein analysed by SDS-PAGE and western blotting 
with TSH receptor antibodies. 
5.2.2.1 Transient Expression of TSHR260 and Protein Analysis 
CHO-K1 cells lines (2.1.6) were used for DNA transfection. These cells were grown in 
DMEM-medium (Dulbecco’s MOD Eagle medium) (2.1.6). A calcium phosphate 
transfection technique (2.2.28) was used to transiently transfect CHO-K cell lines with 
pCR3.1/1-260TSHR-GPI. In brief, for small-scale expression of pCR3.1/TSHR1-260-
GPI protein the cells were plated out at a density 2 x 10
5
 cells/ml in T75 tissue culture 
flask and grown until 50-60% confluent. The cells were split to approximately 20-30% 
confluence in a 6-well plate in DMEM medium and incubated for at least 2 hours prior 
to transfection. Transfectant solutions were prepared, solution A was consist of: 10 µg 
of pCR3.1/TSHR260-GPI, 12.2 µl of 2 M CaCl2 and 88.0 µl distilled water, and 
solution B contained HEPES buffered saline (HBS). Solution A and B were then 
combined dropwise by adding the solution B into solution A, whilst bubbling air 
through solution B and mixed gently. The suspension was incubated at room 
temperature for 30 min and then used for transfection by adding slowly and evenly into 
medium of each well, trying to cover as much of the plate as possible. Plates were then 
incubated at 37°C in a 5% CO2 incubator for 48-60 hours before harvesting. After 60 
hours of incubation 3 dishes of cells were washed 3 times with ice cold PBS, scraped 
and combined for protein extraction and purification. 
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Following incubation for 48-60 hours after transfection, the proteins were extracted 
from transfected cells as described previously in 2.2.33. Untransfected CHO-K1 cells as 
a negative control as well as GPI-95 cells (2.1.3) as a positive control were subjected to 
the same protocol. All the samples were stored at -20ºC prior to further analysis. 
5.2.2.2 SDS-PAGE and Western Blotting 
SDS-PAGE and western blotting were performed essentially as described in (2.2.26). 
The crude cell extracts and the purified protein prepared from transfected cells as well 
as from positive and negative control cells were separated by SDS-PAGE and subjected 
to western blotting analysis. For western blotting, proteins separated by SDS-PAGE 
were electrophoretically transferred onto nitrocellulose membrane and stained with 
5µg/ml mouse anti-human TSHR monoclonal antibody 2C11 (Serotec) as a primary 
antibody and 1:2000 (2 µg/ml) of horseradish peroxidase-conjugated goat-anti-mouse 
antibody (DAKO) as secondary. The blots were visualised using an enhanced 
chemiluminescent (ECL) system (Roche Diagnostics). 
The results showed the presence of the predicted truncated receptor protein in cell 
extracts (Fig. 5.5). Cells transfected with the pTSHR260-GPI plasmid gave a band of 
approximatly 37 kDa. This was compared to extracts from the original TSHRecd-GPI 
cell line GPI-95 gave a band of approximately 50 kDa. 
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5.2.2.3 Production of Stable CHO-K1 Transfectants 
Following successful confirmation of the construct by wester blotting of cell extracts we 
transfected CHO-K1 cells once more and produced stable clones expressing the 
truncated TSH receptor GPI construct. Duplicate dishes were seeded out at low density 
and grown in DMEM medium containing 800 µg/ml of G-418. This dose of G-418 
killed untransfected or transiently transfected CHO-K1 cells over a period of two weeks 
of incubation. By visual inspection culture dishes containing 50-100 isolated clumps of 
growing cells were selected and the clonal cell clumps picked under the microscope 
using a 20 µl pipette and placed in separate wells of a 24-well plate containing 300 µl of 
DMEM medium (800 µg/ml G-418). Following another two weeks of incubation the 
cells were of sufficient density to be screened for TSHR260 expression by FACS 
analysis.  From 40 picked clones we were able to isolated 3 cell lines which showed a 
significant fluorescent shift in FACS when stained for TSHR260 expression. 
We selected a stable CHO-K1 cell line transfected with pTSHR260-GPI and 
investigated cell surface expression of receptor using a specific murine anti-THSR 
antibody A10. Untransfected CHO-K1 cells were used as a negative control. Flow 
cytometric analysis was performed as described in section 2.2.30. After cells were 
counted, resuspended at a density of 1x10
7
 cells/ml and 100 µl aliquoted into LP4 tubes 
(Becton Dickinson). Mouse monoclonal A10 (2 µg/ml) was added to the cells, 
thoroughly mixed and the reaction incubated for 20 min on ice. After washing twice 
with 2 ml PBS centrifuged at 1,000 g for 3 min and resuspended in 1:100 (2 µg/ml) 
goat-anti-mouse immunoglobulin FITC conjugate (Serotec) and incubated on ice for 20 
min. After a final wash, cells were analysed using a fluorescence activated cell sorter 
(FACScan, Becton Dickinson).  
The results showed a significant fluorescent signal from the CHO/TSHR260 cells with 
A10 antibody (Fig. 5.6), indicating a high density of receptor expression on the cell 
surface. Untransfected control CHO-K1 cells displayed an insignificant level of 
fluorescence. This cell line was sub-cultured in DMEM (800 µg/ml G-418) and re-
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tested by FACS to confirm stability. CHO/TSHR260 cells were used for subsequent 
antibody and antibody-phage binding studies. 
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 Primers for TSHR260-GPI synthesis 
TSHR260-
1 
GCGCGCGGATCCATGAGGCCGGCGGACTTGCTGCA 
TSHR260-
2 
GCGCGCCTCGAGAAGAGTCCAGCTGTTTCTTGCTATCA 
  
 GPI Oligos 
Sense  
GPI#1 TCGAGCTGGTGCCAAGAGGCTCTATCGAGGGCAGA 
GPI#3 GGCACATCCATCACGGCCTATAAGAGTGAG 
GPI#5 GGGGAGTCAGCGGAGTTCTTCTTCCTACTC 
GPI#7 ATCCTTCTGCTCCTGCTCGTGCTCGTCTAAT 
Antisense  
GPI#2 CGTGATGGATGTGCCTCTGCCCTCGATAGAGCCTCTTGGCACCAGC 
GPI#4 CTCCGCTGACTCCCCCTCACTCTTATAGGC 
GPI#6 TCGAATTAGACGAGCACGAGCAGGAGCAGAAGGATGAGTAGGAAGAAGAA 
 
Table 5.1 Oligonucleotides used in construction of GPI-anchored TSHR1-260 with 
[His]10 tag.  Sense and antisense oligonucleotides were designed to anneal and generate 
the [His]10 and GPI motif coding region. The double stranded product was cloned into 
the Xho I site of pCR3.1/TSHR260. 
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Figure 5.1 PCR amplification of TSHR 1-260 
PCR (25 cycles) was performed using a high fidelity polymerase and primers contain 
Bam HI and Xho I restriction sites. The PCR products were run on a 1% agarose gel, 
Lane1: 1kb DNA ladder, Lane2: TSHR 1-260 PCR product of the expected size 
(~700bp). Lane3: PCR negative control (primers only without template). 
 
Figure 5.2 Enzymatic digestions of the pCR3.1/GPI and the TSHR1-260 PCR 
products. 
pCR3.1/GPI plasmid and TSHR1-260 PCR product were digested with Xho I 
and Bam HI and run on 1.0 % agarose gels. In 3.5 (a) lane1: 100bp DNA 
ladder, lane2: undigested TSHR1-260 PCR product, lane3: digested TSHR1-
260 PCR product. In 3.5 (b) lane1: the 1kb DNA ladder, lane 2: undigested 
vector, lane 3: Xho I single digest vector, lane 4; Bam HI single digest vector, 
lane5: double digested vector.  
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Figure 5.3  Sequencing data and translation for pTSHR260-GPI construct.  
GPI motif is shown in red. The selected construct was sequenced in both directions 
and verified by BLAST comparison to the human TSHR cDNA sequence. 
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Figure 5.4 Western blots of TSHR260-GPI and GPI-95. 
 CHO cells were either untransfected or transiently transfected with either TSHR-ecd 
(GPI-95) as positive control or TSHR260-GPI. Cells were then lysed and the cellular 
lysates were run on 15% SDS-PAGE and plotted with A10 IgG mAb antibody. Lane1 
shows no detectable antigen in untransfected cells, lane 2 GPI-95 and lane 3 
TSHR260-GPI transfected cells show positive detection of the proteins. 
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Figure 5.5 Flow Cytometric analysis of constructed TSHR-260.  
The expression of TSHR260-GPI on the cell surface of stably transfected CHOK1 cells 
was demonstrated by flow cytometry. Stable cell line CHO/TSHR260 was stained with 
murine anti-TSHR mAb A10. As a control untransfected CHO-K1 were also stained. 
Binding was detected by FITC-conjugated goat-anti-mouse immunoglobulin (40 µg/ml). 
FACS analysis showing a significant fluorescence shift with mAb A10 for the stable 
CHO/TSHR260 cell line (blue line) versus untransfected CHO-K1 cells (red line 
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5.2.4 Binding of M22-Fab to CHO/TSHR260 Cells 
The stable CHO/TSHR260 cell line was used to setup a cell ELISA methodology to 
demonstrate binding of the recombinant M22 Fab and confirm that, as reported, this 
receptor subunit was sufficient to bind TSAb. CHO/TSHR260-GPI cells, 70,000 per ml 
in DMEM medium, were aliquoted into each well of a Poly-D-Lysine 96-well ELISA 
plate, 200 µl per well. The original TSHR-GPI cell line GPI-95 (expressing amino acid 
residues 1-412), and control untransfected CHO-K1 cells were plated in identical 
fashion. The plates were incubated overnight at 37°C in a CO2 incubator. After five 
washes with 400 µl of PBS, 300 µl of blocking solution (10% FCS in DMEM media) 
was added to each well in both plates and incubated at 37ºC for 1 hour. After five 
washes with PBS, 100 µl of the M22 Fab, mouse anti-TSHR control A10 IgG, and 
irrelevant Fab (TG2-8) as negative control, were added to the plates. All antibodies 
were at 2 µg/ml. Plates were incubated at room temperature for 1 hour and then washed 
five times with 400 µl of PBS. 100 µl of the appropriate dilution of HRP-conjugated 
anti-IgG secondary antibody (human for M22-Fab and mouse for A10 and TG2-8) 
added to each well. After incubation at room temperature for 1 hour, each well was five 
times with PBS, and, after visually checking cell adherence under the microscope, 100 
µl of freshly prepared substrate solution was added to each well. Plates were incubated 
at room temperature for 15-30 min until colour development occurred, 100 µl of 
stopping solution added, and the OD450 was measured in the plate reader. All samples 
were tested in triplicate and results were presented graphically as the mean of 
absorbance of each sample ± SD. 
 
The results are shown in Fig. 5.6. Both M22 Fab and mouse mAb A10 samples showed 
high binding signals against the CHO/TSHR260 cell line, confirming that the receptor 
configuration was suitable as a target for TSAb antibodies. Control untransfected CHO-
KI cells showed a low level of background staining, as did the negative control antibody 
TG2-8. Antibody binding was also assessed for both the CHO/TSHR260 cell line and 
the original TSHR cell line GPI-95, which expressed the large TSHRecd domain. Both 
the recombinant M22 Fab and the control mouse TSHR antibody A10 showed 
comparable binding to the two TSHR expressing cell lines. The signal from mouse mAb 
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A10 was rather higher against the GPI-95 cell line, and the reason for this is not clear. 
Negative control antibody TG2-8 showed a low level of background binding. 
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Figure 5.6 ELISA Fab binding of recombinant M22 Fab antibody to the 
CHO/TSHR260. 
The binding of recombinant M22 Fab antibody to the CHO/TSHR260 was measured by 
cell ELISA. Positive control antibody was the mouse anti-TSHR antibody A10, and the 
negative control antibody was an irrelevant antibody TG2-8. Binding was also 
assessed also for GPI95 and untransfected CHO-K1 cells. Data shown are the mean ± 
SD and were derived from three independent experiments. Statistical analysis was 
performed using a one way analysis of variance (ANOVA), showed significant 
difference for the bindings of M22-Fab, M22-scFv, A10 Fab to CHO/TSHR260 in 
comparision to untransfected CHO-K cells, p=0.03. 
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5.2.5 M22 phage binding to CHO/TSHR260-GPI 
Having established that the CHO/TSHR260-GPI cell line presented suitable antigen for 
antibody binding we then investigated the binding of antibody-phage fusions to these 
cells using a cell ELISA approach. CHO/TSHR260 cells (70,000 per ml) in DMEM 
medium, were aliquoted into each well of a Poly-D-Lysine 96-well ELISA plate, 200 µl 
per well. The original TSHR-GPI cell line GPI-95 (expressing amino acid residues 1-
412), and control untransfected CHO-K1 cells were plated in identical fashion. The 
plates were incubated overnight at 37°C in a CO2 incubator. After five washes with 400 
µl of PBS, 300 µl of blocking solution (10% FCS in DMEM media) was added to each 
well in both plates and incubated at 37ºC for 1 hour. After five washes with PBS, 100 µl 
of the M22-phage, M22 scFv, M22 Fab-LL, A10 phage, and helper phage VCSM13 
was a negative control in both plates (CHO-TSHR1-260-GPI and CHO-K1). Each well 
was washed eight times with PBS/0.05% Tween and 100 µl of 1:10,000 of horseradish 
peroxidase conjugated anti-M13 monoclonal antibody (GE Healthcare) in 5% skimmed 
milk in PBS/0.05% Tween was added to each well. After incubation at 37ºC for 1 hour, 
each well was washed ten times with PBS/0.05% Tween and bounded phage detected 
by addition of 100 µl TMB peroxidase substrate (Promega). 
 
The ELISA was developed by incubation at room temperature for 10-15 mins and the 
reaction was stopped by addition of 100 µl/well of stopping solution and the absorbance 
at 450 nm was measured in the iEMS platereader. 
The results for the comparison of binding to CHO/TSHR260 versus untransfected 
CHO-K1 are shown in Fig. 5.7. The various M22 phage constructs all showed 
significant binding to the CHO/TSHR260 cell line, as did positive control phage A10. 
The negative control helper phage VCSM13 showed low level binding to both cell 
lines, and the binding of all phage to untransfected CHO-K1 cells was insignificant. 
Phage antibody binding was next assessed for the CHO/TSHR260 cell line in 
comparison to the original TSHR GPI-95 cell line which expresses amino acid residues 
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1-412 on a GPI linkage. The results are shown in Fig. 5.8. Once again all the M22 
phage antibody constructs, and positive control A10, showed significant binding against 
the CHO/TSHR260 cell line, but this contrasted with the results for the GPI-95 cell line. 
The positive control A10 phage also showed significant binding to the GPI-95 cell line, 
as previously observed, but no binding was observed for any of M22 phage antibody 
constructs, that is the Fab, scFv, and long linker Fab variants. The negative control 
TG2-8 phage did not show binding to either cell line. 
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Figure 5.7 Binding of Antibody Phage Constructs to TSHR260 Determined by Cell 
ELISA.  
Phage binding to GPI-linked TSHR was determined by cell ELISA using the 
CHO/TSHR260 cell line. The M22 Fab, Fab long linker (M22 LL) and scFv (M22 scFv) 
M22 antibody phage constructs were assessed for binding to ELISA wells coated with 
monolayers of CHO/TSHR260 cells. Positive control phage were derived from anti-
TSHR antibody A10, and helper phage VCSM13 was the negative control. Binding to 
untransfected CHO-K1 cells was also assessed. Data shown are the mean ± SD and 
were derived from three independent experiments. 
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Figure 5.8 Binding of M22 phage antibody constructs to CHO/TSHR260 and GPI-
95 cells determined by cell ELISA.  
Comparison of antibody-phage binding to GPI-linked TSHR using the CHO/TSHR260 
and original GPI-95 cell lines. The M22 Fab, Fab long linker (M22 LL) and scFv (M22 
scFv) M22 antibody phage constructs were assessed for binding to ELISA wells coated 
with monolayers of CHO/TSHR260 cells. Positive control phage were derived from 
anti-TSHR antibody A10, and helper phage VCSM13 was the negative control. Data 
shown are the mean ± SD and were derived from three independent experiments. 
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5.3 Discussion 
The aim of this stage of the project was to investigate the possible basis for the failure 
of M22 antibody phage to bind the various forms of TSH receptor investigated in our 
initial studies. Using commercial TSH receptor-coated tubes we were able to 
demonstrate binding for the recombinant form of the M22 antibody, and this was also 
observed using detergent extracted receptor from the GPI-95 cell line, and cell ELISA 
assays using the same GPI-95 cell line. We were also able to demonstrate stimulation of 
cAMP production in cell lines transfected with the full length receptor, showing the 
agonist properties of the recombinant antibody, and demonstrating its identity with the 
original human monoclonal.  
Analysis of the preliminary binding data suggested that antibody binding was 
eliminated when the antibody was physically attached to the phage surface. The large 
difference in molecular size between the antibody domain and the phage capsid 
suggested an explanation based on steric hindrance. This phenomenon is not unknown 
and it has been previously reported that for other antigens certain epitopes may prove 
inaccessible to phage-antibody fusions (Hoogenboom, Lutgerink et al. 1999). 
Accordingly we investigated the possibility that the relatively large “hinge” region of 
the TSHR extracellular domain may adopt a conformation that physically prevents close 
approach of the phage capsid to the key receptor epitope contained in the LRR ligand 
binding domain. X-ray data has been published for the TSH receptor but was limited to 
amino acid residues 1-260, which encompasses the LRR domain. The conformation of 
“hinge” region thus remains unknown.  
As TSH receptor residues 1-260 are sufficient to bind TSAb and is know to form a 
stable structure in recombinant form (Sanders, Jeffreys et al. 2004) we produced a stable 
cell line expressing this domain on the plasma membrane via a GPI linkage. After 
confirming the properties of the cell line by flow cytometry, antibody and phage 
binding studies were carried out using a cell ELISA approach. The results showed that, 
in contrast to the results obtained with the original GPI-95 cell line, we were able to 
demonstrate significant binding of M22 phage antibody constructs to the new TSHR260 
cell line. The results confirmed that the full length TSHR extracellular domain, 
expressed by GPI-95, was unable to bind the phage but truncation of the receptor to the 
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minimal LRR domain appeared to remove some form of steric hindrance and antibody 
phage binding was observed. This was a significant result as phage selection of novel 
TSAb antibodies from phage libraries can only be possible if an appropriate binding 
surface is available. The new CHO/TSHR260 cell line represents an important advance 
and should enable progress in this field. 
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CHAPTER 6 
 
 
ISOLATION OF ANTI-IDIOTYPIC ANTIBODIES AGAINST 
M22 
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6.1 Introduction 
In Graves’ disease thyroid stimulating antibodies (TSAb) are the basis of patient 
symptoms, producing chronic overactivity of the thyroid gland and excessive levels of 
thyroid hormone. Evidence suggests that this important class of autoantibodies has a 
restricted origin and are produced by a small subset if human immunoglobulin genes 
(Williams, Marshall et al. 1988; Weetman, Yateman et al. 1990; Rapoport, Chazenbalk 
et al. 1998). Evidence for this restriction has been limited to biochemical 
characterisation of patient sera as the lack of examples of monoclonal TSAb have 
prevented extensive DNA analysis. Genetic restriction of these antibodies is not simply 
of academic interest, knowledge of the variable gene usage may shed light on the 
immunological origins of thyroid stimulating antibodies, and could highlight novel and 
specific therapeutic approaches.  
Phage display is a powerful technique for the rapid isolation of specific monoclonal 
antibodies, and has been applied with success to the study of autoimmune thyroid 
disease (Hexham, Partridge et al. 1994; McIntosh, Asghar et al. 1997; McIntosh and 
Weetman 1997). The larger part of this current study has been an attempt to develop a 
selection for the recovery of TSHR antibodies using patient phage libraries. Clearly, as 
has been described, the use of recombinant TSH receptor, in a variety of forms, presents 
challenges to this approach. TSAb require a native receptor for binding and the TSH 
receptor is a difficult protein to produce in recombinant form without loss of 
conformation (Rapoport, Chazenbalk et al. 1998). In an attempt to overcome these 
limitations an entirely novel strategy was devised involving the use of anti-idiotypic 
antibodies.  
Anti-idiotypic antibodies have been known and studied for some time, both naturally 
occuring and artificially produced (Pan, Yuhasz et al. 1995). By definition an anti-
idiotypic antibody is one that recognises and binds sites on a second antibody. If the 
target epitope on the second antibody is the antigen binding variable regions (or 
paratope) then the anti-idiotypic antibody may possess interesting properties, including 
the ability to neutralise the binding of the target antibody. In this case we aimed to 
generate an anti-i antibody against the monoclonal human TSAb M22. This reagent, if 
specific for the antigen binding domain, would provide us with a selective surface for 
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the enrichment of phage antibodies with an identical or similar variable region. Tbis 
would be a powerful approach for the enrichment of further examples of TSAb from 
patient antibody libraries and would not be susceptible to the steric difficulties we 
encountered with recombinant TSH receptor itself. Other applications of this anti-i 
reagent could include the staining and enumeration of circulating TSAb-producing B 
cells in samples of Graves’ patient blood. These B cells could also be recovered using 
magetic bead techniques, or through flow cytometric cell sorting. These experiments 
would provide a great deal of novel data concerning the frequency of TSAb-producing 
B cells in patients, and may assist in the cloning of further monoclonals. Finally, a 
TSAb-specific anti-i with the ability to block antigen binding should eliminate thyroid 
stimulating activity and thus provide a novel approach to Graves’ disease therapy. 
To generate anti-idiotypic reagents we will immunise mice with recombinant M22 scFv. 
This is the smallest subunit of immunoglobulin that retains the antigen specific domain 
and was chosen to minimise the availability of alternative epitope targets for the 
immunised mouse immune response. The immune mice spleens will be used to generate 
a recombinant antibody library, and phage selection will be used to rapidly isolate  a 
series of scFv antibodies that target M22. These will be characterised by ELISA. 
6.2 Cloning of M22 scFv into pET21a (+)  
M22-scFv-pAK100 construct (described in chapter 3) was diluted 1:1000 in dH2O as 
template and amplified by PCR using the primers M22-Pet-1 5’ GCGCGC GCT AGC 
CTT ACG GTT CTG ACC CAA CCA 3’, and M22-Pet-2 5’ GCGCGC AAG CTT 
GCT AGA CAC CGT CAC AAG AGT GCC T 3’. The primers introduced NheI and 
HindIII sites at the 5’ and 3’ end of the amplification product respectively for sub-
cloning into expression vector pET21a. The PCR product was purified using the Wizard 
PCR Prep kit (2.2.5) and digested for 5 hours at 37°C with 10 units each of NheI and 
HindIII in 100 µl reaction with 10 µl of Buffer B (Promega). The digested PCR product 
was purified by gel electrophoresis and purified using the Wizard PCR Prep kit before 
ligation into pET21a digested with NheI and Hind III. The double digestion of the M22-
scFv PCR products and the pET21a vector with NheI and HindIII restriction enzymes 
can be seen in Fig. 6.1(b). Following transformation, a number of clones were picked, 
minipreps prepared and the construct confirmed by double digestion with NheI and 
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HindIII (Fig. 6.1(c)) and by sequencing. The sequencing data of the construct M22-
scFv/pET21a revealed the presence of the M22-scFv sequence, His-tag in addition to 
NheI and HindIII restriction enzymes sites. 
 
6.3 Expression of M22 scFv 
6.3.1 Preliminary E.coli Expression of M22-scFv Proteins 
The M22-scFv/pET21a plasmid has been transformed into BL21 [DE3] pLysS, a 
specialised E. coli expression host for T7 vectors, containing the T7 RNA polymerase 
gene under the control of the lacZ operon (Novagen). Initial small scale cultures were 
carried out to assess expression of the M22-scFv construct (2.2.18.1). Briefly, a fresh 
colony was picked and grown in 10 ml culture of LB medium (100 µg/ml ampicillin, 30 
µg/ml chloramphenicol, 1% glucose) in a shaking incubator at 37°C. Following 
overnight growth 500 µl of the 10 ml culture was added to 10 ml of LB medium 
containing 100 µg/ml ampicillin, 30 µg/ml chloramphenicol and grown at 37°C in a 
shaking incubator with high aeration until the OD600nm was 0.4. IPTG added to a final 
concentration of 1 mM to induce expression. Culture samples were taken at initiation, 
and at intervals up to 6 h of induction. Bacterial were pelleted by centrifugation and 
protein extracted by sodium deoxycholate treatment and sonication (2.2.18) (Fig. 6.2). 
Samples were analysed by SDS-PAGE and western blotting (2.2.23; 2.2.24). The 
preliminary induction of BL21 cells using 1 mM IPTG in 2YT medium at 37°C has 
shown  a significant band being produced with molecular weight about 25 kDa 
visualized by coomassie blue staining in PEG (Fig. 6.3). The solubility test has shown a 
predominant presence of the protein in the insoluble fraction rather than the soluble 
proteins fraction.  
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6.3.2 Large Scale Expression of M22 scFv Protein 
pET-21a containing the M22 scFV was transformed into BL21 (DE3) pLysS cells and 
inoculate to a 1L of 2YT media.  Induction of transformed BL21 cells with 1 mM IPTG 
stimulated expression of a 25 kDa band on a 15% reducing SDS PAGE.  This band 
corresponds to the M22-scFv. The step of extraction was modified to included 500 
µg/ml of lysozyme to break the cells (Fig. 6.4). Detergent extraction by 1% Triton x100 
was performed and the fractions were loaded on to a SDS-PAGE (Fig. 6.5).  Analysis of 
those fractions showed M22 scFv was in the insoluble fraction.    
  
191 
 
 
 
 
Figure 6.1: Cloning of M22 scFv into pET21a gel images  
6.1(a), the figure represents the amplified M22-scFv using PCR. The figure shows the 
1% agarose gel with the 1kb DNA ladder in lane 1, PCR negative control in lane 2 and 
the (~800bp) M22-scFv PCR product in lane 4. 6.1(b), the pET21a plasmid and the 
M22-scFv PCR product were double digested before they can be ligated and run on 
1% agarose gel. The pET21a plasmid was either undigested (Lane 2), single digested 
with NheI (Lane 3), HindIII (Lane 4) or double digested (Lane 5). The undigested next 
to double digested M22-scFv products are shown in Lanes 6&7 respectively.6.1(c), 
double digestion check was performed on three plasmid mini-preps and confirmed the 
presence of the correct insert (~800bp) in all of them. Lanes 2-7 represents the 
undigested next to the double digested plasmid of the three minipreps. 
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Figure 6.2: Flow diagram of preliminary fractionation of M22-scFv protein.  
TC = Total cell protein expression,  SPF = Soluble protein fraction,   IPF = Insoluble 
protein fraction (i.e. Inclusion body)  
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Figure 6.3SDS PAGE for the induction of M22-scFv.  
15% SDS-PAGE, stained with Coomassie blue shows the separated proteins 
from BL21 (DE3)-RIPL cells after the preliminary induction of M22 scFv (1-2) and 
the solubility test (3-5). Lane 1 shows the proteins from the BL21 cells before 
induction of the expression with IPTG, Lane 2 represents the proteins after 4 
hours of induction, the expected size of M22 scFv can be seen at about 25 kDa in 
lane 2. The solubility test was performed is indicated in the last three lanes. Lane 
3 represents total cell proteins fractions, lane 4; soluble proteins fraction, Lane 
5; insoluble proteins fraction. M22 scFv band was lost in lane 4; indicating that 
M22 scFv protein was insoluble. 
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Figure 6.4Fractionation protocol for large scale expression of M22-scFv protein.  
SPF1 = Soluble protein fraction 1; SPF2 = Soluble protein fraction 2; D1 = Detergent 
extraction fraction wash 1; D2 = Detergent extraction fraction wash 2; D3 = Detergent 
extraction fraction wash 3; W1 = Water fraction wash 1 
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Figure 6.5SDS-PAGE for protein fractions of M22 scFv expression.  
Protein fractions and washes were loaded onto a 15% reducing SDS-PAGE. The gel is 
showing E. coli expression of the M22 scFv in various cell fractions. M = Molecular 
weight of precision plus protein marker, lane T4: IPTG induced total cell extract after 4 
hours, lane SPF1: soluble protein fraction 1, lane SPF2: soluble protein fraction 2, lane 
D1: Detergent extraction fraction wash 1: lane D2: detergent extraction fraction wash 2 
lane D3: detergent extraction fraction wash 3, lane W1: water fraction washes 1, lane 
I.B = Inclusion body. A 15 kDa band, corresponding to the M22 scFv, was observed 
upon induction with 1 mM IPTG (arrow 1), which was strongly seen in inclusion bodies 
(arrow 2). 
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6.3.3 Solubilisation of Aggregated M22 scFv Insoluble Fraction  
M22-scFv was predominantly found in inclusion bodies and thus required solubilisation 
and refolding in an appropriate buffer. The protein aggregate of M22 scFv was 
solubilised in 40 mM Tris-HCl plus 6M guanidine hydrochloride. The DTT 
(dithiothreitol) was also used as a reducing agent to aid solubilisation of inclusion body 
protein.   
6.3.4 Post- M22 scFv Solubilisation Buffer Exchange  
Having soluble protein it was then required to put it in a suitable buffer to assist the 
purification process by nickel column chromatography, but also need natural protein 
folding to increase the immunogenic response (2.2.19). Soluble M22-scFv was buffer 
exchanged by dialysis in dialysis tubing with 10,000 kDa cut-off, against 2 L of 10 mM 
Tris, pH 8.0 and 300 mM NaCl at 4°C with 2 x buffer exchanges over 24 hrs.  
6.3.5 Purification of M22 scFv Protein   
M22-scFv protein was purified after dialysis by Ni MAC
TM
 purification 
chromatography. Ni column selectively binds the histidines tag at the C-terminus of the 
M22 scFv proteins immobilising it on the column. After washing of the Ni column, the 
protein is eluted with 400 mM imidazole (Fig. 6.6). M22-scFv proteins in each elution 
fraction were measured by Bradford assay. Eluted M22-scFv was dialysed against 2 L 
of 40 mM Tris-HCl, and 150 mM NaCl, pH 8.0 at 4°C, to remove imidazole.  
Purification was tested by SDS-PAGE (Fig. 6.7), and Bradford assay. The total amount 
of purified M22 scFv was measured by Nanodrop and Bradford and it gave an average 
concentration of 0.522 mg/ml. This material was analysed by SDS-PAGE to confirm 
the size of the protein, and identity also confirmed by western blotting, using anti-His 
conjugated with HRP (Fig. 6.8). 
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Figure 6.6Elution of purified M22 scFv.  
Following washing the HIS-tagged M22 scFv material was eluted using elution buffer 
containing 400 mM imidazole. The UV absorbance was monitored and the peak elution 
fraction collected in a series of 400 µl samples to tested by Bradford assay. 
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Figure 6.7SDS–PAGE of Purified M22 scFv.  
SDS-PAGE (15%) showing purified M22 scFv before and after dialysis, lane 1: 
protein marker, lane 2: purified M22 scFv before dialysis and lane3 purified 
concentrated M22 scFv after dialysis.  
 
Figure 6.8 Western blot analysis of purified M22 scFv.  
Recombinant human M22 scFv was resolved by SDS-PAGE (20 ng per well) and 
transferred to PVDF membrane.  Detection was by HRP-conjugated anti-His 
antibody and enhanced chemiluminescence and was recorded on X-ray film 
(2.2.24). 
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6.4 Immunisation 
Four BALB/c mice were immunised with the recombinant M22 scFv as described in 
materials and methods (2.2.33). Ten days after the final booster immunisation sera from 
each mouse were collected and serial dilutions screened for M22 scFv reactivity by 
ELISA. ELISA screening of tail bleeds showed that the immunised mice had developed 
a high level of IgG response to the recombinant M22 scFv, with high ELISA signal at 
dilutions up to 1:25,600 (Fig. 6.9). Ten days after the final booster immunisation sera 
from each mouse were collected for the second time and serial dilutions screened for 
M22 scFv reactivity by ELISA, which showed high signal at dilutions up to 1:53,000 
(Fig. 6.10). The 2 immunised mice with highest ELISA titres (mice 1 and 2) were 
sacrificed and splenocytes isolated for RNA extraction. 
6.5 Cloning of anti-M22-idiotype  
6.5.1 Cloning of anti-M22-idiotype scFv 
Total RNA was extracted from immunised mouse spleen and reverse transcribed using 
random primers and reverse transcriptase (2.2.1) (Fig. 6.11). Heavy and light chain 
variable regions were amplified by PCR (2.2.3) using a large set of primers designed to 
amplify all murine immunoglobulin variable regions with the minimum level of 
degeneracy (Krebber, Bornhauser et al. 1997). The upstream light chain primers 
included a SfiI cutting site and encoded a FLAG tag. The downstream light chain 
primers included the coding sequence for a flexible Gly4Ser peptide linker. The 
upstream heavy chain primers including a portion of this Gly4Ser coding sequence, and 
the downstream primers included a second non-complementary SfiI site. The LB 
primers were combined with the LF primers to produce 5 different primers mixes; LB-1 
(LB1-LB4); LB-2 (LB5-LB8); LB-3(LB9-LB12); LB-4 (LB13-LB15); and LB-5 (LB16 
& LB18) (Fig. 6.12).The HB primers were combined with the HF primers to produce 5 
different primers mixes; HB-1 (HB1-HB4); HB-2 (HB5-HB8); HB-3(HB9-HB13); HB-
4 (HB14-HB17); and HB-5 (HB18 & HB19). Heavy and light chain genes of anti M22  
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Figure 6.9Post-immune mouse response to M22 scFv (first boost). 
Mouse immune response was assessed by ELISA ten days post first immunisation. 
Plasma was obtained from the four mice, diluted serially and screened by ELISA 
against M22 scFv. Plasma from a non-immunised mouse was included as a negative 
control and detected by ϒ chain specific secondary antibody (2.2.28), all samples were 
tested in duplicate and mean absorbance calculated 
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Figure 6.10Post-immune mouse response to M22 scFv (final boost).  
Mouse immune response was assessed by ELISA ten days post final immunisation. 
Plasma was obtained from the four mice, diluted serially and screened by ELISA 
against M22 scFv. Plasma from a non-immunised mouse was included as a negative 
control and detected by gamma chain specific secondary antibody (2.2.28), all samples 
were tested in duplicate and mean absorbance calculated 
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obtained were approximately 400 bp (Fig 6.13 (a) and (b)). The PCR products were gel 
purified (2.2.5) and used in a PCR overlap extension reaction, with primers SCFOR and 
SCBACK, to generate the final scFv product. The scFv products were cloned into the 
SfiI cloning sites of phage display vector pAK100. The assembly reaction was 
successful and yielded an approximately 800 bp product, and the negative control 
reaction did show a band (Fig. 6.13(c)). Ten assembly reactions were carried out and 
these were pooled, cleaned up with the Wizard PCR prep kit and eluted in 50 µl of 
dH2O. Restrictions digest by 20 units of SfiI (NEB) The reaction was mixed and 
incubated for 3-4 houts at 50°C, after covered with a drop of mineral oil. The digest was 
loaded onto a 1% agarose gel (Fig. 6.14), and purification of digested scFv antibody 
gene and vector were carried out from agarose gel using Wizard PCR prep kit (2.2.5). A 
ligation reaction was prepared as described previously in 2.2.8. The reaction was mixed 
and incubated overnight at 16°C. Ligation were ethanol precipitation and resuspended 
in 20 µl TE buffer, The ligation reaction was electroporated XL1-Blue cells (Stratagene) 
(2.2.10), and aliquots plated onto solid media to assess ligation quality while the 
remaining cells were stored on ice overnight. Library quality was confirmed by 
counting of the number of transformants with 200,000 independent clones being 
considered the cut-off point for a successful library. The percentage of recombinants 
was determined by PCR amplification of random colonies using the scback and scfor 
primers and by sequencing.  
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Figure 6.11Total RNA of mouse spleen after immunisation with M22 scFv.   
Samples of total RNA recovered from immunised mouse spleen, analysed by agarose 
gel electrophoresis. RNA was recovered by using Trizol (Gibco). 
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Figure 6.12List of primers for cloning mouse scFv fragments. 
Sequence degeneracy is indicated using the IUPAC system, R=A/G; Y=C/T; M=A/C; 
K=G/T; S=C/G; W=A/T; H=A/C/T; B=C/G/T; V=A/C/G; D=A/G/T. The LB primers 
encode the short form of the FLAG tag (Knappik and Pluckthun, 1994) and anneal to 
20 bp of matur
include two copies of the Gly4Ser sequence and anneal to 20 bp of mouse 
are complementary to mouse JH regions and 
include an SfiI restriction site. Primers SCBACK and SCFOR annealed to the 5' 
205 
 
terminus of the light chain Fv sequence and the 3' terminus of the heavy chain Fv 
sequence, and were used to amplify the final assembled scFv product. 
 
 
Figure 6.13Cloning of anti M22 idiotype scFv into pAK100 gel images. 
In 6.13(a), the figure represents the amplification of heavy variable gene from anti-M22 
scFv cDNA. Samples of cDNA were amplified for 30 cycles and included non-template 
negative controls. Lane 1 was a 100 bp ladder (Promega) and indicated that products 
were approximately 400 bp. In 6.13(b) the figure represents the amplification of kappa 
variable genes from anti-M22 scFv cDNA. Samples of cDNA were amplified for 30 
cycles and included non-template negative controls. Lane 1 was a 100 bp ladder and 
indicated that products were approximately 400 bp. In 6.13(c), the figure represents the 
assembly PCR of scFv fragments of anti M22 scFv. Purified VL and VH PCR products 
were mixed together and amplified for 25 cycles with primers ScFor and ScBack. 
Assembled scFv products were obtained and by comparison to the 100 bp DNA 
markers (1) had the expected size of 800 bp. 
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Figure 6.14Gel purification of digested scFv fragments of anti-M22 scFv.   
Assembled M22 scFv fragment was digested for 5 h with SfiI and purified by slot 
gel electrophoresis. The marker lane (1) was 100 bp ladder (Promega) and the 
appropriate bands (approximately 800 bp) were excised and purified for cloning 
into vector pAK100. 
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6.5.2 Sequence Analysis of Anti M22-scFv Library 
Random colonies of anti M22 idiotype scFv library were picked and grown in 10 mls of 
LB (30µg/ml chloramphenicol, 10µg/ml tetracycline). Miniprep plasmid DNA was 
prepared (2.2.11) and templates sequenced by fluorescent dye terminator method on an 
ABI310 machine in the Sheffield University Core Sequencing Facility. The sequencing 
primer was scback. Immunoglobulin gene sequences were analysed using the DNAPLOT 
software suite and matched to a database of all known germline gene sequences. 
 
6.5.3 Anti M22-scFv Library Rescue 
Immediately following electroporation of pAK100 ligations the transformed cells were 
stored on ice until the assessment of ligation efficiency was completed. The transformed 
cells were cultured in 100 ml of LB (30µg/ml chloramphenicol, 10µg/ml tetracycline) for 
1h in a 37°C shaking incubator. VCSM13 helper phage was added (50 µl of 10
11
 pfu/ml) 
and the culture incubated for 15 min at 37°C. Kanamycin was added (10 µg/ml) and the 
100 ml culture was grown overnight in a 37°C shaking incubator. The next day library 
phage particles were recovered as described in 2.2.15 and resuspended at approximately 
10
11
 cfu/ml. 
 
6.5.4 Enrichment of anti-M22-scFv library on M22 scFv 
Briefly ELISA wells coated with the recombinant M22-scFv, the wells were blocked by 
400 µl of 3% bovine serum albumin (BSA) in phosphate buffer saline (PBS) with 0.05% 
(v/v) Tween 20 (PBS/Tween) for 1 hour at 37°C. The blocking solution was taken out, and 
100 µl of phage library was added (typically equivalent to 10
10 
phage particles) and 
incubated for one hour at room temperature. The phage library was removed, and the tube 
washed ten times with 400 µl PBS/Tween at room temperature. To elute adherent phage 
100 µl of glycine buffer (0.1 M glycine/HCl, pH 2.2) was added and the tube incubated on 
ice for 10 min. The eluted phage were neutralized with 6 µl of 2 M Tris and used to infect 
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1 ml of log phase culture of fresh XL1-Blue host. Aliquots of infected host were plated 
onto selective medium and following overnight the resulting colonies were used to 
calculate the number of phage eluted from the coated tubes at each round. The remaining 
infected host was added to 100 ml of LB medium (30 µg/ml chloramphenicol, 10 µg/ml 
tetracycline) and grown for 1h in a 37°C shaking incubator. The culture was superinfected 
with 50 µl of helper phage VCSM13 (10
11
 pfu/ml), adjusted to 14 µg/ml kanamycin, and 
grown overnight in a 37°C shaking incubator. The rescued phage libraries were recovered 
as described (2.2.15), titered and used for the next round of enrichment. 
The anti-M22 idiotype phage library was enriched for 5 rounds on the wells coated with 
M22 scFv. As a negative control an existing laboratory human anti-TG2 antibody phage 
library was also subjected to enrichment to reveal the effects of any non-specific binding 
(Fig. 6.15). Each panning experiment was repeated a minimum of three times and in some 
cases more. Variations in the washing and elution procedure produced no significant 
change in outcome. 
6.5.5 M22 scFv ELISA of Selected Anti-idiotypic Phage Libraries  
The phage display anti M22 idiotype scFv library obtained from final rounds of panning 
(round 1-5) were tested for binding to M22 scFv by ELISA. The phage display scFv library 
selected from final round of panning (round 5) shows a higher binding to M22 scFv than 
phage display scFv library selected from other rounds (Fig. 6.16). The result suggested that 
the phage display scFv selected from final round of panning could specifically bind to M22 
scFv. ELISA plates were coated with µl of M22 scFv mixed with 50 µl of coating buffer 
(2.1.8) and incubated overnight at 4ºC. After five washes with PBS/Tween, 300 µl of 
blocking solution (5% skimmed milk in PBS/Tween) was added to each well and 
incubated at 37ºC for 1 hour. After five washes with PBS/Tween, 100 µl of round 1-5 
phage (approximately 10
9
 particles) in PBS/Tween containing 5% (w:v) skimmed milk 
was added to the wells and incubated at 37ºC for 2 hours. Each well was washed eight 
times with PBS/Tween and 100 µl of 1:5000 of horseradish peroxidase conjugated anti-
M13 monoclonal antibody (GE Healthcare) in PBS/Tween 5% skimmed milk (w:v) was 
added. After incubation at 37ºC for 1 hour, wells were washed ten times with PBS/Tween 
and bounded phage detected by addition of 50 µl of TMB substrate (Sigma). The reaction 
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was stopped by addition of 50 µl of stopping solution and the absorbance at 450 nm 
measured. 
6.5.6 ELISA Analysis of Random M22 scFv Anti-Idiotype Clones 
According to rounds ELISA result, 50 colonies of round 5 were cultured each in 10 ml of 
LB (30µg/ml chloramphenicol, 10 µg/ml tetracycline) for 3 hours in a 37°C shaking 
incubator. VCSM13 helper phage was added (50 µl of 10
11
 pfu/ml) and the culture 
incubated for 15 min at 37°C. Kanamycin was added (10 µg/ml) and the 100 ml culture 
was grown overnight in a 37°C shaking incubator. The next day phage particles in each 
clone were recovered as described in 2.2.15 and resuspended at approximately 10
11
 cfu/ml. 
On wells coated with M22 scFv. Phage ELISA was done as described in 2.2.28, (Fig. 6. 
17). 
6.6 Production of Anti M22 scFv protein 
6.6.1 Cloning of anti M22 Idiotype scFv From pAK 100 to pAK 400 
In order to increase the functional yield of antibody fragments the anti M22 gene was 
sub-cloned into vector pAK400. This construct enabled the increased expression of 
scFv and added a 6 His tag at the carboxy terminus to allow rapid purification by metal 
affinity chromatography. The highest signal clone in the previous ELISA which reacts 
with M22 scFv (ID-43) was grown as a midiprep to provide sufficient DNA for 
subcloning. Briefly 8 µg of pAK100 ID-43-scFv plasmid prepared from glycerol stock 
of this clone was digested with SfiI enzyme as described (2.2.7) and the resulting DNA 
fragments resolved using an agarose slot gel (2.2.4).  
Approximately 800 bp scFv antibody fragment was excised from the gel and purified 
using the Wizard DNA Cleanup kit (2.2.5). Two µg of pAK400 vector was also 
restricted with SfiI enzyme and purified, following agarose gel electrophoresis. The 
purified digested ID-43 fragment was ligated into SfiI sites of the pAK400 to create ID-
43-pAK400. The ligation reaction was purified by ethanol precipitation and 
resuspended in 20 µl TE. 5 µl of ligated mixture was electroporated into 60 µl of a non-
suppressor E. coli BL21 (2.2.10), 2 µl was plated out onto an agar plate containing 30 
µg/ml chloramphenicol and incubated at 37ºC overnight. Positive clones were 
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confirmed by restriction digest and glycerol stocks prepared and stored at -80ºC to be 
used for expression and purification of ID-43 scFv protein. 
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Figure 6.15Panning of anti-M22 scFv library to M22 scFv-coated wells. 
A significant increase in the number of bound phage was observed over 5 rounds of 
selection. There was evidence of selective enrichment of the anti M22 scFv library. The 
number of phage eluted from M22 scFv coated wells and negative control was 
estimated by plating of aliquots of infected host cells. Data are the mean of three 
independent experiments ± SD (n=3). 
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Figure 6.16Binding of selected anti-M22 idiotype scFv libraries to M22 scFv. 
 
The phage display scFv library were rescued from different rounds and tested by 
ELISA for their ability to bind to M22 scFv. The ELISA wells were coated with M22 
scFv. The phage rounds display scFv were added to each corresponding wells after 
eight time washing, 1:5000 of horseradish peroxidase conjugated anti-M13 monoclonal 
antibody. Data are the means of three independent experiments ± SD. 
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Figure 6.17 ELISA screening of random phage clones for binding to M22 scFv. 
Random colonies from the final selected phage antibody library were picked and 
grown and rescued to produce phage. Phage supernatants were screened for 
binding to M22 scFv by ELISA. Phage binding was detected using horseradish 
peroxidase conjugated anti-M13 (GE Healthcare). Uncoated wells were included 
as a negative control and VCSM13 helper phage. Data are the means of three 
independent experiments ± SD. 
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6.6.2 Expression of ID-43-scFv  
The induction procedure of scFv expression was carried out as described in 2.2.20. 
Briefly, 10 ml of LB medium containing, 10 µl of 30 µg/ml chloramphenicol was 
inoculated with 10 µl of glycerol stock of ID-43-pAK400 and grown overnight in a 
shaking incubator at 37ºC. This culture was used to inoculate 1L of LB (30 µg/ml 
chloramphenicol) and grown at 25ºC with shaking until the OD600nm reached 0.6. At 
this point gene expression was induced by the addition of IPTG to a final concentration 
of 1 mM, and the culture was grown overnight in a shaking incubator at 25ºC. The 
following day the induced culture was centrifuged at 2,000 g for 10 min, the supernatant 
was removed for further analysis, and the bacterial pellet was used for periplasmic 
extraction, using osmotic shock method as previously described (2.2.20). The 
periplasmic extract and the supernatant were then concentrated ten-fold using a micro-
concentrator (Amicon). The protein content was estimated by Bradford assay (2.2.22) or 
by measurement the OD280 and analysed by SDS-PAGE (2.2.23).  
6.6.3 SDS-PAGE and Western Blot Analysis of Bacterial Extracts 
SDS-PAGE and western blotting were performed essentially as previously described 
(2.2.23 and 2.2.24). Extracts of pAK400 approximately 20 µg of supernatants and 
periplasmic extracts were analysed by SDS-PAGE, stained with Coomassie blue 
staining as described in 2.2.23, and following transfer western blotted using a 1:1000 
dilution of anti-His in 1% skimmed milk PBS/0.05% Tween for 2 hours at room 
temperature. After washing 4 times with PBS/0.05% Tween, 1:5000 goat anti-mouse 
IgG-HRP conjugate (Southern Biotech) in 1% skimmed milk PBS/0.05% was added 
and incubated for 1 hour at room temperature. The blot was then visualised using an 
enhanced chemiluminescent (ECL) system (Roche Diagnostics) according to 
manufacturer’s instructions, Fig. 6.18. 
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Figure 6.18 SDS-PAGE analysis of purified ID-43 scFv protein. 
 Lane 1: Protein markers; Lane 2: 10 µg; Lane 3: 20 µg; Lane 4: 30 µg. Purified ID-
43 scFv ran at the appropriate molecular weight of approximately 25 kDa. 
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6.6.4 Purification of Histidine Tagged ID-43 from Bacterial Extracts  
The purification of histidine tagged ID-43 protein was achieved by metal chelate resin 
using TALON Metal Affinity Resins (BD Biosciences) according manufacturer’s 
instructions (2.2.21.1). The eluted fractions were then collected, neutralized, dialysed 
against PBS and concentrated ten-fold using a micro-concentrator (Amicon), the protein 
content were assessed by Bradford assay (2.2.22). 
6.6.5 Confirmation of Binding Properties 
To confirm the predicted binding properties of the ID-43 ELISA assays were carried out 
using different concentrations of purified ID-43 scFv. ELISA wells were coated with 10 µg 
of M22 scFv in coating buffer (2.2.14). The wells were blocked for 1 hour with PBS/5% 
milk (w:v), washed five times with 400 µl of PBS/Tween. A control well of M22 scFv was 
incubated with anti-FLAG-M1 alone (1:1000) and irrelevant mouse mAb IgG control was 
included. 50 µl of anti-FLAG M1 (Sigma) diluted in PBS/Tween (1 mM CaCl2) was added 
to the wells. The plate was incubated for 1 hour at room temperature and then washed five 
times with PBS/Tween. 50 µl of anti-mouse IgG HRP conjugate (Sigma) 1:5000 in 
PBS/Tween was added and the plates incubated for 1 hour at room temperature. The plates 
were washed five times and developed with 50 µl of HRP substrate for 20 min. The 
reaction was stopped with 20 µl of 0.1 M H2SO4 and the absorbance readings determined 
at 450nm using an Multiskan Ascent spectrophotometer. 
The results are shown in Fig. 6.20. Significant binding was obtained with ID-43 
concentrations ranging from 8 µg/ml down to 0.5 µg/ml. No significant signal was 
obtained from negative control wells containing no M22 scFv and from antigen coated 
wells incubated with PBS alone. 
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Figure 6.19 Binding of anti-idiotypic mAb ID-43 to purified M22 scFv. 
 Binding of ID-43 to M22 scFv was confirmed by ELISA. Wells were coated with 
M22 scFv and ID-43 scFv added in a range of concentrations. Binding was 
detected using anti-FLAG M1 (Sigma). Negative controls were wells with only 
coating buffer (no scFv) and antigen coated wells incubated with PBS. Data are 
the means of three independent experiments ± SD. 
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6.6.6 Inhibitory Effect of ID-43 on M22-scFv Phage Binding to TSHR 
To investigate the paratope binding properties of ID-43 a phage binding experiment was 
designed using M22-scFv phage and CHO/TSHR260 cells in an ELISA format. If ID-
43 recognised the antigen binding domain of M22 then it can be predicted that ID-43 
would block binding of M22 scFv phage to the TSH receptor.  
CHO/TSHR260 cells (70,000 per ml) in DMEM medium, were aliquoted into each well of 
a Poly-D-Lysine 96-well ELISA plate, 200 µl per well. CHO-K1 cells were plated 
similarly as a negative control. The plates were incubated overnight at 37°C in a CO2 
incubator. After five washes with 400 µl of PBS, 300 µl of blocking solution (10% FCS in 
DMEM media) was added to each well in both plates and incubated at 37ºC for 1 hour. 100 
µl aliquots of M22-scFv phage (10
10
 pfu/ml) were pre-incubated for 30 min at room 
temperature with different concentrations of ID-43 scFv (2.5-40 µg/ml). The phage 
suspensions were then added to the blocked wells and incubated for 1 hour at room 
temperature. Wells were washed eight times with PBS/0.05% Tween and 100 µl of 
1:10,000 of horseradish peroxidase conjugated anti-M13 monoclonal antibody (GE 
Healthcare) in 5% skimmed milk in PBS/0.05% Tween added to each well. After 
incubation at 37ºC for 1 hour, each well was washed ten times with PBS/0.05% Tween and 
bounded phage detected by addition of 100 µl TMB peroxidase substrate (Promega). The 
reaction was stopped with 20 µl of 0.1 M H2SO4 and the absorbance readings determined 
at 450nm using an Multiskan Ascent spectrophotometer. The results are shown in Fig. 
6.21. The data were the results from three independent experiments. 
M22-scFv phage gave a significant binding signal against stable cell line 
CHO/TSHR260. Pre-incubation with purified ID-43 reduced M22 phage binding across 
the concentration range. Inhibition of M22-scFv binding was observed at the lowest 
concentration of ID-43 2.5 µg/ml. No binding was seen with control wells coated with 
CHO-K1 cells and maximal binding of M22 scFv phage was observed with no pre-
incubation with ID-43. 
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Figure 6.20Inhibition of M22-scFv-phage binding by anti-idiotypic mAb ID-43.  
Binding of M22-scFv phage was measured using a cell ELISA format. Wells were 
coated with cell line CHO/THSR260. Phage binding was inhibited by pre-
incubation of M22 phage with a range of concentrations (2.5–40 µg/ml) of purified 
anti-idiotypic antibody ID-43. Positive control wells were M22 phage without 
preincubation with ID-43. Data are the means of three independent experiments ± 
SD. 
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6.7 Discussion 
The recombinant synthesis of TSAb monoclonal M22 presented a number of novel 
opportunities for the analysis of this interest class of autoantibodies. For the first time 
we were able to produce a range of phage antibody constructs and investigate their 
binding characteristics. The difficulties we encountered with the phage selection 
experiments served to highlight the technical challenges that arise when using the 
thyrotropin receptor as an antigen binding surface. In an attempt to circumvent these 
problems we devised an alternative strategy based on the development of an anti-
idiotypic antibody that targeted the antigen binding domains of M22. A ready supply of 
recombinant M22, verified by both binding and cAMP stimulation assays, enabled the 
immunisation of a series of mice with the monoclonal TSAb. To rapidly isolate a series 
of anti-M22 monoclonals we employed a phage antibody library approach. After several 
rounds of biopanning we succeeded in isolating an enriched library and scFv antibodies 
and clones from this library were screened by ELISA against purified M22. The result 
of this approach was the characterisation of a monoclonal anti-idiotypic antibody ID-43 
that showed specific binding against M22. ID-43 was also able to neutralise the binding 
properties of M22 scFv phage against cell lines expressing TSHR260. These data 
suggest that ID-43 was reacting against the antigen binding region of M22 and so 
blocking antigen recognition, indicative of a true anti-idiotypic antibody. This is the 
first documented isolation of an anti-idiotypic reagent that targets a thyroid stimulatory 
antibody and opens the way for a series of novel experiments that will provide insights 
into the nature of this autoreactive immune response. 
The novel antibody should provide an alternative selective surface for the enrichment of 
anti-TSHR antibodies from phage libraries that is both more stable and easier to 
produce than the native receptor itself. In addition, it will selectively capture antibodies 
that share identical or similar antigen binding variable gene re-arrangements that 
recognise the thyroid stimulatory epitope of the TSHR. Aside from phage antibody 
experiments this novel reagent could also be used to label and capture circulating B 
cells from Graves’ disease patients, leading to the isolation of new examples of patient 
monoclonal TSAbs. Finally, an anti-idiotypic antibody may prove an exciting new 
departure from conventional therapeutic approaches to Graves’ disease, that is the 
221 
 
ability to specifically bind and neutralise circulating thyroid stimulating antibodies that 
are the basis of disease symptoms.  
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7 Discussion 
Together, autoimmune hypothyroidism and autoimmune hyperthyroidism, or Graves’ 
disease, represent the most common form of organ specific autoimmunity in the 
population with a frequency of approximately 1-2% (Tunbridge, Evered et al. 1977). 
Graves’ disease is particularly interesting as the condition is driven almost exclusively 
by a humoral, antibody mediated process, in contrast to many other autoimmune 
conditions in which the pathological mechanisms are dominated by cell mediated 
immunity and tissue destruction. The symptoms of Graves’ disease, chronic 
overstimulation of the thyroid gland and excess production of thyroid hormones, are 
caused by a specific sub-class of autoantibodies, TSAb, that act as agonists towards the 
thyrotropin receptor. As such they belong to a subset of autoantibodies with biological 
action separate and distinct from their role in the immune system.  
Since their discovery in 1956 (Adams 1956) these antibodies have been the subject of 
intense study. Important questions included: what was the origin of these antibodies? 
Was there a genetic basis underlying the risk of an individual developing TSAb. What 
were the target epitopes recognised by TSAb? In addition to the academic importance of 
understanding these properties, insights into the nature of these stimulatory antibodies 
may suggest novel therapeutic approaches to the treatment of Graves’ disease. Initially, 
technical limitations of available methods restricted analysis of these antibodies to the 
bulk properties of patient sera. Nonetheless it became clear that in some patients TSAb 
immunoglobulins were at least partially restricted to the lambda subclass of IgG 
(Weetman, Yateman et al. 1990), and possibly oligoclonal. With the molecular cloning 
of the human thyrotropin receptor (TSHR) cDNA in 1989 (Libert, Lefort et al. 1989; 
Nagayama, Kaufman et al. 1989) it became possible to confirm the identity of the TSH 
receptor as the target antigen for TSAb and also allowed the development of 
recombinant sources of antigen and bioassays to routinely measure the stimulatory 
activity of patient sera. With these advances it quickly became clear that TSAb, in 
contrast to other autoantibodies, were present at very low, nanogram per ml, levels in 
patient sera, a further hindrance to detailed analysis (Rapoport, Chazenbalk et al. 1998). 
With the cloning of the human TSHR attention turned to the development of 
recombinant expression of the receptor, and attempts to use this material to produce 
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animal models of Graves’ disease, the hope being that this approach would prove less 
intractable than the analysis of patient antibodies. 
For a period of some ten years following the initial publication of the TSHR sequence, a 
series of studies were reported describing immunisation of animals with recombinant 
forms of TSH receptor, and the recovery of monoclonal antibodies (Rapoport, 
Chazenbalk et al. 1998). There were repeated claims of monoclonals possessing the 
thyroid stimulatory activity observed in Graves’ disease but none could be repeated, and 
indeed on closer inspection none of the published antibodies achieved agonist activity at 
the nanogram per ml concentrations seen with true TSAb (McLachlan and Rapoport 
1996). 
What did become clear from these and other studies was that the TSH receptor itself 
was a complex and difficult antigen to manipulate experimentally. Human receptor 
antibodies failed to recognise TSHR expressed in bacteria or in other non-native forms. 
Binding of TSAb to the receptor has a strict requirement for a native confirmation 
(Rapoport, Chazenbalk et al. 1998). Expression in mammalian cells was achieved and 
stable cell lines proved useful in both bioassays and for direct binding studies, though 
the levels achieved initially did not lend themselves to high level production and 
purification (Rapoport, Chazenbalk et al. 1998). The eventual isolation of cell lines with 
high level expression was a major technical breakthrough (Stiens, Buntemeyer et al. 
2000) and for the first time allowed the development of high throughput assays for 
direct antibody binding to native TSHR that lent themselves to a degree of automation 
(Costagliola, Morgenthaler et al. 1999). 
By 2002 the development of novel immunisation strategies, including cell immunisation 
and DNA transfection (McLachlan and Rapoport 1996) lead to the first successful 
animal models of Graves’ disease, and the first recovery of TSAb monoclonals that at 
least partially fulfilled previously accepted criteria for success ie. thyroid stimulation at 
nanogram per ml levels (Costagliola and Vassart 2002; Sanders, Jeffreys et al. 2002; 
Ando, Imaizumi et al. 2003). Shortly afterwards the use of the novel high throughput 
TSHR direct binding assays contributed to the isolation of the first example of a human 
TSAb monoclonal M22 (Sanders, Evans et al. 2003). This represented a mammoth task, 
and indeed some 16,000 culture supernatants had to be screened to obtain this 
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monoclonal, an effort that would have been impossible without the use of novel binding 
assays, and testimony to the low level of circulating B cells producing TSAb in Graves’ 
patients. 
These technical breakthroughs were impressive but have not lead to an avalanche of 
further reports. Indeed, there are still only two examples of monoclonal human TSHR 
antibodies in the literature, and a handful of rodent antibodies. Thus the questions 
initially posed about the nature of patient TSAb remain to be answered. How diverse are 
they? Are they oligoclonal? Do they arise in different patients from a similar subset of 
immunoglobulin germline genes? The answers to these questions will only come from 
the analysis of further examples of clonal TSAb from a large number of patients. Given 
the efforts required to isolate the two current examples of patient TSHR antibodies, it is 
unlikely that this approach will lead to a rapid resolution of these key questions. 
Alternative approaches are required and one of these could be the use of phage display, 
a powerful technique for the expression and antigen-specific recovery of monoclonal 
antibodies (McCafferty, Griffiths et al. 1990; Burton and Barbas 1994). 
Antibody phage display techniques offer the potential for greatly facilitating the 
generation and characterization of recombinant antibodies originating from humans and 
mice (Graus, de Baets et al. 1997; Ditzel, Masaki et al. 2000). In this system the 
antibody heavy and light chain are cloned and expressed in bacteriophage, the antibody 
genes can be expressed as the scFv or Fab antibodies fragments form using suitable 
vectors and cloning systems. Recombinant antibodies are expressed on the surface of 
the phage in functional form and able to bind their corresponding antigen. Capture of 
antibodies by an antigen surface also leads to capture of the attached phage and this the 
genes used to express the antibody. Sub-culture of these selected clones and repeated 
rounds of enrichment by antigen capture allow the rapid isolation of high affinity 
monoclonal antibodies.  
Requiring only the availability of B cell RNA, the phage antibody display technique 
offers the potential for rapid enrichment of specific recombinant antibodies from cloned 
patient repertoires, and has proven particularly successful in the analysis of patient 
autoantibodies in autoimmune thyroid disease (Portolano, Chazenbalk et al. 1992; 
Hexham, Partridge et al. 1994; Jaume, Portolano et al. 1994; McIntosh and Weetman 
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1997). All these studies centered on antibodies to two major thyroid antigens: thyroid 
peroxidase and thyroglobulin. As described above the successful expression of native 
TSHR has always presented something of a technical challenge, and was thus 
unavailable as a selective binding surface until the advent of modern commerical 
binding assays. The only reported attempt to use phage display to recover TSHR 
antibodies was unsuccessful, for reasons that were unclear (Van Der Heijden, De Bruin 
et al. 1999).  
Clearly if the technical challenges for the enrichment of phage antibodies on TSHR 
could be overcome then this approach may lead to the recovery of many more examples 
of patient TSAb monoclonal and provide invaluable data regarding the nature and origin 
of this important class of autoantibodies. Accordingly this project was designed to 
investigate the potential of phage display techniques to enable the recovery of novel 
TSAb monoclonals. 
The availability of the human TSAb M22 DNA sequence provided the starting point for 
this project; the development of a positive control reagent that would allow an 
investigation of the binding conditions for TSAb in phage antibody format. In this 
project we were able to successfully synthesise and clone the immunoglobulin gene 
sequences of the human monoclonal thyroid stimulating antibody M22, and we could 
expressed and characterised the antibody. We expressed valuable quantities of the scFv 
antibody and confirm its binding and stimulating properties. The recombinant antibody 
bound to the TSHR in FACS, and more importantly it possessed agonist activity against 
the receptor. We were able to induce cAMP production in the JP09 bioassay at ng/ml 
concentrations; evidence of a true TSAb. Thyroid stimulating activity has been 
previously described for Fab fragments of M22 (Sanders, Evans et al. 2003), but this 
was the first time that stimulating activity has been documented for an scFv fragment. 
This was an important step for our project as examples of true TSAb monoclonals are 
very difficult to obtain, and are still considered commercially sensitive reagents. 
Construction of the M22-scFv phage provided for the first time a representative 
example of a TSAb in a phage display format, and could be used to investigate the 
binding properties of these antibodies, thus enabling the development of enrichment 
strategies that could be applied to recovery of other TSHR phage antibodies.  
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Initial phage binding experiments with the M22-scFv construct failed to demonstrate 
any evidence for specific binding of the recombinant antibody to tubes coated with TSH 
receptor. This result was rather surprising  because the soluble form of the antibody was 
shown to bind to the TSH receptor in FACS analysis, and stimulated cAMP production 
in the JP09 TSHR bioassay. These results showed that the antibody itself possessed the 
required specificity, but the phage-antibody fusion was unable to bind its corresponding 
epitope on the TSH receptor when it was attached to coated tubes from the commercial 
TSHR antibody assay kit (BRAHMS tubes). These observations represented a 
significant setback for the project, and what mechanism lay behind this phenomenon 
was not clear. The most likely explanation was that the phage-antibody fusion was 
behaving fundamentally different from the soluble antibody and that this different was 
the result of some unforeseen steric interaction between the phage capside and the 
receptor. 
 
In chapter 4 we sought to investigate the mechanism of phage antibody binding by 
producing a range of different phage-antibody fusions and probing the binding of each 
to the TSHR. From a purely physical standpoint it seemed likely that the relatively large 
molecular size of the phage-antibody fusion was playing a role in the antigen binding 
process. The M13 phage capsid is a relatively huge structure when compared to the 
displayed antibody. With approximate dimensions of 6 nm x 900 nm, phage particles 
are effectively a very long thin cylinder with a small antibody moiety of between 4-8 
nm attached to the end. It seems logical that this structure may prevent binding to some 
epitopes if they were partially obstructed by domains of the antigen.  
In this part of the study we synthesised a series of M22 variants in which the Fab 
version of the antibody was expressed as a phage fusion. This effectively doubled 
molecular distance of the antigen binding domains from the phage coat protein fusion 
partner. An additional construct was made in which the Fab structure was extended by a 
flexible peptide linker to be allowed to move further away from the phage capsid. The 
physical access of the antibody to the target epitope was also a consideration. The initial 
tube binding experiments depended on the commercial TSHR-coated BRAHMS tubes. 
In this system the TSH receptor is captured onto the tube surface using a specific 
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monoclonal antibody. There is at least the potential for the antigen to be coated in a 
uniform fashion in relation to its orientation. To address this possibility we extracted 
native receptor from a transfected cell line GPI-95, which expresses a high level of 
TSHR extracellular domain on the cell surface. Partitioning the GPI-anchored receptor 
using detergent (Ko and Thompson 1995) enabled the recovery of useful quantities of 
antigen, and this material was used in a series of ELISA experiments. As before only 
soluble M22 antibody was able to recognise this material, which was an important result 
as it showed that the recovered material contained receptor in native form, a prerequisite 
for the binding of TSAb. M22 in single chain form also bound the receptor extract. 
However, the M22 antibody phage fusions, including the long linker variant, failed to 
recognise the receptor in neither the BRHAMS tube format, nor in these ELISA assays. 
This effectively eliminated the hypothesis that it was the orientation of the antigen that 
was preventing antibody-phage binding, or indeed proximity to the plasma membrane. 
At this point we began to consider that the explanation may be found within the nature 
of the antigen itself. 
In chapter 5 we considered the conformation of the TSH receptor and the possibility 
that in some way the 3-dimensional shape of the receptor extracellular domain was 
preventing phage-antibody binding by some steric mechanism. By convention many 
groups had expressed the extracellular domain in a form that included the amino acid 
residues from 1 to 412. This sub-domain had been shown to be sufficient for both TSH 
and TSHR antibody binding (Rapoport, Chazenbalk et al. 1998). However, the TSHR is 
unique among glycoprotein hormone receptors in having an extra stretch of 50 amino 
acids inserted into so-called “hinge” region immediately preceding the seven 
transmembrane domains (Rapoport, Chazenbalk et al. 1998). There is no structural data 
to offer insights into the conformation of this hinge region, and it is possible that some 
residues may be positioned in the space immediately anterior to the ligand binding site 
and thus may interfere with phage-antibody binding. Evidence from studies of the 
FSHR suggested that some carboxy terminal regions of the receptor do participate in 
ligand binding and may adopt positions close to the LRR ligand binding site (Jiang, Liu 
et al. 2012). The only published crystallographic studies of the TSHR expressed a stable 
LRR domain comprising only residues 1-260, approximately half the size of the 
extracellular domain expressed in our GPI-95 cell line. Accordingly we created a new 
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GPI cell line in which expressed residues 1-260 in order that we could investigate the 
possible effect on phage antibody binding.  
Surprisingly the results showed a dramatic change in phage-antibody binding. For the 
first time we were able to demonstrate different M22 phage constructs could bind to the 
TSHR in this form. The results suggested that the hypothesis was correct and regions of 
the receptor distal to the LRR domain were in some way preventing access of phage-
antibodies to the target epitope. This was an important breakthrough and for the first 
time should allow the use of the new cell line to selectively enrich phage antibody 
libraries for TSHR antibodies. 
Chapter 6 described our efforts to pursue a radically different approach to phage-
antibody enrichment. Having encountered significant problems in our attempts to bind 
M22 phage constructs to the TSH receptor in various forms we designed an alternative 
approach that moved away from the direct use of TSH receptor as a selective surface. 
Having made recombinant M22 antibody, and verified its properties, we decided to 
exploit this resource more fully than simply using it as a control reagent. Access to the 
clonal TSAb enabled us to produce an anti-idiotypic antibody against M22 that would 
specifically recognise the antigen-binding CDR domains. We immunised a series of 
mice with recombinant M22 scFv and were able to produce a significant immune 
response. We selected scFv for this experiment rather than Fab as the variable CDR 
domains represent a greater proportion of total protein in scFv and would assist in 
restricting the murine immune response to the desired target. We synthesised a phage 
antibody library from the immunised mouse spleens and successfully enriched an anti-
idiotypic monoclonal antibody that recognised human TSAb M22. Using ELISA we 
were able to confirm the specificity of this reagent, and went on to demonstrate that the 
antibody could indeed bind the M22 CDR regions and block binding of the human 
TSAb to the TSHR. To our knowledge this is the first time and anti-idiotypic antibody 
has been raised to a human TSAb and should prove an invaluable reagent for future 
studies. 
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Future Work 
 Use the new CHO/TSHR260 cell line to selectively enrich antibody libraries 
generated from Graves’ patients and animal models of Graves’ disease and 
recover novel examples of thyroid stimulatory antibodies. 
 Investigate the use of the anti-idiotyic antibody ID-43 to stain circulating patient 
B cells and identify those producing antibodies with similar CDR regions. These 
will be recovered and studied for thyroid stimulating activity. 
 Study the ability of ID-43 to neutralise the stimulating activity of a range of 
Graves’ patient sera. This would allow us to estimate the frequency of “M22-
like” TSAb in a large number of Graves’ patients, and provide a measure of 
TSAb diversity. 
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